Document:

Form 8-K

 Exhibit 10.68 

***Text Omitted and Filed Separately 

with the Securities and Exchange Commission. 

Confidential Treatment Requested 

Under 17 C.F.R. Sections 200.80(b)(4) 

and 240.24b-2. 

COMMERCIAL SUPPLY AGREEMENT 

This Commercial Supply Agreement (this “Agreement”) is entered into as of October 16, 2008, (the
“Effective Date”) by and between Enzon Pharmaceuticals, Inc., a Delaware corporation with an address of 685 Route 202-206, Bridgewater, New Jersey 08807 (“Enzon”), and Savient Pharmaceuticals, Inc., a Delaware corporation, having
its principal place of business at One Tower Center, 14th Floor, East Brunswick, New Jersey 08816 (“Savient”). Enzon and Savient may be referred to individually as a “Party” or
collectively as “Parties.” 
 R E C I T A L S 

WHEREAS, Savient is engaged in the development and research of certain biologic products and requires manufacture of
such a product for commercial distribution; 
 WHEREAS, Enzon is a contract manufacturer that possesses the necessary
technical capabilities and operates facilities for the manufacture of pharmaceutical and biological products for commercial distribution; 

WHEREAS, Savient desires Enzon to supply to it the Product on the terms and conditions set forth herein; and 

WHEREAS, Enzon is willing to supply the Product to Savient on the terms and conditions set forth below. 

NOW, THEREFORE, in consideration of the mutual promises contained herein, and for other good and valuable
consideration, the receipt and adequacy of which each of the Parties does hereby acknowledge, the Parties, intending to be legally bound, agree as follows: 

     Section 1.    DEFINITIONS 

1.1    As used herein, the following terms shall have the following meanings: 

1.2    “Affiliate” shall mean any business entity which directly or indirectly controls, is controlled
by, or is under common control with any Party to this Agreement. A business entity shall be deemed to “control” another business entity if (i) it owns, directly or indirectly, at least fifty percent (50%) of the issued and outstanding
voting securities, capital stock, or other comparable equity or ownership interest of such business entity, or (ii) it has the de facto ability to control or direct the management of such business entity. 

1.3    “Applicable Laws” means all relevant federal, state and local laws, statutes, rules, and
regulations which are applicable to a Party’s activities hereunder, including, without limitation, the applicable regulations of the Regulatory Authority, European Medicines Agency (EMEA) and United States and European Union cGMPs. The Parties
may amend this section in writing to include additional countries. 

  
  

Commercial Supply Agreement 

Execution Copy 
 Page 1 of 44 

 1.4    “BLA” means a regulatory application filed with a
governmental agency in a the United States, the European Union, or any other country that the Parties mutually agree upon in writing (e.g. FDA and EMEA) for the purpose of lawfully marketing, selling, distributing, importing, exporting,
manufacturing, developing or using a therapeutic or prophylactic product for the treatment or prevention of a disease or physical condition. As used herein, BLA shall include, without limitation, a Marketing Authorization Application in the European
Union, a Biologics License Application in the United States. 
 1.5    “Bulk Product” shall mean the
bulk solution of [...***...] supplied by Savient to Enzon pursuant to this Agreement. 

1.6    “Commercially Reasonable Efforts” shall mean efforts in accordance with the standards of care and
diligence Enzon practices with respect to its own products. 
 1.7    “cGMPs” shall mean current good
manufacturing practices as promulgated by the FDA under the United States Food, Drug and Cosmetic Act, 21 C.F.R. Part 210 et seq., as amended from time to time, and the European Union. 

1.8    “Field Alerts” shall have the definition of field alerts used by the FDA irrespective of the
jurisdiction in which the acts or circumstances giving rise to such field alerts occur. 
 1.9    “Process
Consumables” means media, resins, raw materials, filters, membranes, product contact materials or surfaces, disposable lab supplies and similar materials used in the manufacture of Product. Provided, however, that Process Consumables shall
not include components of manufacture supplied by third parties such as labels (hereinafter referred to as “Manufacture Components”). 

1.10    “Product” means pegloticase, a PEGylated recombinant mammalian uricase formulation in final drug
product form ready for commercial sale. 
 1.11    “Quality Agreement” shall mean that certain Quality
Agreement by and between the Parties hereto, dated as of the date hereof and attached to this Agreement 

1.12    “Regulatory Authority” shall mean any governmental agency with jurisdiction over the regulation
of drug and biological agents for use in man, including, but not limited to, the United States Food and Drug Administration and any foreign equivalents thereto. 

1.13    “Savient-supplied Materials” shall mean those materials including, but not limited to Bulk
Product, supplied by Savient for use in connection with the manufacture of the Product, as set forth in the Work Plan which is attached hereto as Exhibit A or any subsequent Work Plan signed by both parties. 

1.14    “Savient Intellectual Property” shall mean (i) all valid patent claims owned or licensed by
Savient and all converted provisionals, divisions, continuations, continuations-in-part, reissues, reexaminations or extensions thereof, as well as any corresponding foreign 

  
  

					
		 	 Commercial Supply Agreement

Execution Copy
  

Page 2 of 44
	 	*** Confidential Treatment Requested

 
counterparts and equivalents thereof, whether issued or pending as of the Effective Date or thereafter; (ii) trademarks which are owned, licensed or sublicensed by Savient and which are
registered in the United States and, where applicable, foreign jurisdictions for use in association with the Product; and (iii) any Savient Know-How developed by Savient or any of its Affiliates during the Term relating to (a) the Bulk Product or
the Product (including, without limitation, its pharmaceutical utility) or (b) the Services provided hereunder 

1.15    “Savient Know-How” shall mean all technical information, data (including, without limitation,
regulatory data) patentable and unpatentable inventions, developments, discoveries, methods and processes that are, in each case, not disclosed in a published patent application or patent or otherwise publicly available, which are developed or
conceived of by Savient or any of its Affiliates or which is licensed to Savient or any of its Affiliates. 

1.16    “Service” means those services described in any Work Plan which is made a part of this Agreement
and those services described in any Quality Agreement pertaining to such services. 

1.17    “Specifications” means the written specifications for the Product and Savient-supplied Materials
attached hereto as Exhibit B, which may be amended from time to time by the mutual written agreement of the parties. 

1.18    “Work Plan” means the schedule and detailed plans used to prepare formulated Bulk Product, fill
Bulk Product into vials and package the resulting drug product thereby resulting in the ultimate deliverable which is the Product. The definition of Work Plan shall also include subsequent change orders to any Work Plan (as described in Section 3.3)
.. The first Work Plan is attached hereto as Exhibit A. 
 Section 2.    SERVICES 

2.1    Enzon shall perform the Services described in this Agreement and in the exhibits hereto, which are
made part of this Agreement, or as described in any Work Plan, the Specifications, or change order pursuant to Section 3.3. Savient shall provide such Savient-supplied Materials and make such payments as are set forth therein. The Parties mutually
acknowledge and agree that nothing contained in this Agreement or any Work Plan executed hereunder shall create an exclusive manufacture or supply arrangement between the Parties. 

2.2    To the extent necessary to enable Enzon to provide the Services, Savient hereby grants to Enzon a
royalty-free, non-exclusive license and, where appropriate, sublicense, to use the Savient Intellectual Property which pertains to the Product or the Services hereunder; provided, however, that any license, or sublicense, granted herein as the case
may be, shall be used by Enzon or any permitted sublicensee solely for the purposes of carrying out the Services and no rights or title in or to the Savient Intellectual Property shall vest in Enzon. Upon the expiration or earlier termination of
this Agreement the license or sublicense granted to Enzon to 

  
  

Commercial Supply Agreement 

Execution Copy 
 Page 3 of 44 

 
use Savient Intellectual Property shall immediately cease and Enzon shall make no further use thereof and shall cause any permitted sublicensee to make no further use thereof. 

2.3    Enzon agrees to provide the Services outlined in the Work Plan attached hereto as Exhibit A
which is incorporated and made a part of this Agreement and any other Services that may be described in any future Work Plan or change order, or Quality Agreement which addresses the Services described in this Section 2, which shall be incorporated
into this Agreement upon execution by both parties. Such Services shall be performed in accordance with Applicable Laws. Savient agrees to make payments in accordance with this Agreement and all Work Plans. In the event of a conflict between this
Agreement and any Work Plan, this Agreement shall control. 
 2.4    Enzon shall provide Savient, at no
additional charge, product support services, at Savient’s reasonable request, for the activities listed below: 
  

	 	•	 	 Meetings with Regulatory Authorities, whether in person or by phone 

	 	•	 	 Routine documentation provided to Regulatory Authorities on behalf of Savient 

	 	•	 	 Annual product reviews for commercial products, as required by Regulatory Authorities. 

	 	•	 	 All audit correspondence including Savient-requested revisions to Enzon’s audit response. 

Savient may request from Enzon other product support services at its customary rate, as set forth on Exhibit C, including but
not limited to: 
  

	 	•	 	 Preparation of documents in anticipation of a Pre-Approval Inspection. 

	 	•	 	 Letters of reference from Enzon or Enzon’s vendors that are requested by Savient (e.g., Master file reference letters, rubber or glass vendor
letters). 

	 	•	 	 Documentation provided to Regulatory Authorities on behalf of Savient, other than routine documentation. 

	 	•	 	 All time used for collecting and photocopying Savient documentation. One copy of a batch record is exempted from support charges.

	 	•	 	 Changes and revisions to artwork mandated by Regulatory Authorities or requested by Savient. 

	 	•	 	 Any additional validation work requested by Savient beyond original Work Plan or outside current validation requirements. 

	 	•	 	 Any analytical development and/or analyses beyond original Work Plan. 

For all requests under this Section 2.4, Savient shall provide Enzon a written request for product support services that describes the
required services and/or documents/work product required. Enzon shall provide Savient an estimate based on its customary rate. Upon acceptance of such estimate by Savient, Savient shall issue a purchase order to Enzon and Enzon shall perform such
services in accordance with the terms hereof. 

  
  

Commercial Supply Agreement 

Execution Copy 
 Page 4 of 44 

 2.5    Enzon shall prepare and effect the Product shipment in
accordance with explicit written instructions issued by Savient, which shall include the packaging instructions and Savient’s selected mode of transportation. All transportation costs shall be borne by Savient in accordance with the terms
contained herein. 
 Section 3.    MANAGEMENT/FORECASTING/MATERIALS 

3.1    Account Management. Each party will appoint an account manager who will be the party
responsible for overseeing the activities hereunder. 
 3.2    Content of Work Plans. Each
Work Plan shall include a reasonably detailed description of the Services to be provided, relevant Specifications, a schedule for completion of the Work Plan, a fee and payment schedule, and such other information as is necessary for Enzon to
perform the relevant Services. 
 3.3    Change Orders. In the event that Enzon is requested
to perform services that are outside the scope of agreed-upon Work Plans such changes must be mutually agreed upon by the parties in a written change order prior to the provision of said services. Each such change order constitutes an amendment to
the applicable Work Plan (which shall be explicitly referenced in such change order) and the services set forth therein shall be deemed to be part of such Work Plan. After receipt of the reasonably detailed description of the additional services
from Savient, Enzon shall provide Savient with a cost estimate for performing the changed or additional services. Each change order shall be governed by the terms and conditions of this Agreement and by such supplementary written amendments of this
Agreement or Work Plans as may be, from time to time, executed between the parties. 

3.4    Forecasting And Savient-supplied Materials 

(a)    Upon execution of this Agreement and on the first day of each [...***...] thereafter,
Savient shall deliver to Enzon’s account manager an updated rolling forecast of Product requirements (in full-batch quantities) for the [...***...] period commencing on the first day of the immediately following calendar month. Enzon
shall, within ten (10) days of receipt of a forecast from Savient, confirm its receipt thereof in writing and shall advise Savient of whether such forecast is accepted in whole or in part; in the event that any part of the forecast is not accepted
by Enzon then Enzon shall detail in writing the rationale for such non-acceptance. Within thirty (30) days of accepting each forecast, Enzon will provide Savient a projected manufacturing schedule indicating approximate dates of manufacturing which
shall conform with the delivery dates specified in the forecast supplied by Savient. The foregoing notwithstanding, once a forecast (or any portion thereof) has been accepted by Enzon it shall be binding on both parties except as otherwise may be
explicitly set forth herein; in the event that Enzon neither accepts or rejects any forecast submitted by Savient within ten (10) days of receipt from Savient then the entire forecast as submitted by Savient shall be deemed accepted by Enzon. If
accepted, the forecast for the first [...***...] of each forecast (“Firm Forecast”) shall be 100% binding on both parties and the forecast for the next [...***...] (“Planning Forecast”) shall be binding on both
parties as set forth in the 

  
  

					
		 	 Commercial Supply Agreement

Execution Copy
  

Page 5 of 44
	 	*** Confidential Treatment Requested

 
following sentence. Product requirements within the Planning Forecast shall not be increased or decreased by Savient by more than [...***...] per [...***...] period, per forecast,
provided that no month may be reduced to [...***...] batches unless the initial Planning Forecast for that particular month was initially set as [...***...] batches; for purposes of clarification only, the parties agree that the
intention of this provision is to allow Savient, in each subsequent forecast, to modify each [...***...] period of the most recently supplied Planning Forecast by [...***...] batch as follows: the [...***...] period of the most
recently provided Planning Forecast (which becomes the [...***...] period of the Firm Forecast) may be modified by [...***...], the [...***...] period of the Planning Forecast may be modified by [...***...], the
[...***...] period of the most recently provided Planning Forecast may be modified by [...***...] and the [...***...] period of the most recently provided Planning Forecast may be modified by [...***...]. Savient shall
forecast Product requirements for the [...***...] following the Planning Forecast, and the forecast for those [...***...] are non-binding (“Non-Binding Forecast”) on Savient. Savient shall place firm purchase orders for its
requirement of the Product in full-batch quantities at least [...***...] prior to the requested date of delivery. Each firm written purchase order, signed by Savient’s duly authorized representative, shall authorize Enzon to manufacture
the number of batches of the Product as are set forth therein. The number of purchase orders submitted by Savient shall not exceed [...***...] per calendar month, unless otherwise agreed to by the parties in writing. Enzon shall have completed
any and all activities which are required by the applicable Work Plan and all Applicable Laws so as to be able to deliver the Product on or before the delivery dates specified by Savient in the subject purchase order but in any event the Product
shall not be delivered by Enzon more than [...***...] in advance of any specified delivery date. Provided, however, that Enzon shall use Commercially Reasonable Efforts to minimize the amount of time elapsing between the completion of
manufacturing activities and delivery of the completed Product to Savient. 
 (b)    Starting from
inception of the manufacture of the Product, Savient shall supply to Enzon, and use Commercially Reasonable Efforts to ensure that Enzon has on hand, a sufficient stock of Savient-supplied Materials as is necessary to provide the Services. Enzon
shall have no liability for any failure to supply Product to Savient in accordance with the delivery terms contained in a Savient purchase order if sufficient quantities of Savient-supplied Materials in light of the forecasting described above have
not been supplied to Enzon at least four (4) weeks prior to the scheduled manufacture date, as communicated to Savient pursuant to Section 3.4(a). In such case, manufacture of Product may be delayed until receipt of adequate supplies of
Savient-supplied Materials and the availability of an appropriate manufacturing slot; provided, however, that Enzon shall use Commercially Reasonable Efforts to schedule the manufacture of the Product as soon as is possible subsequent to receiving
the Savient-supplied Materials. If Savient provides Enzon with insufficient Savient-supplied Materials to produce the amount of Product requested in a particular purchase order, both sides may nonetheless agree in writing to have Enzon produce a
lesser amount based on the amount of Savient-supplied Materials provided to Enzon, and all such batches shall be subject to the pricing listed in Exhibit C, including the minimum batch price, if applicable. Provided, however, that the Parties agree
that any shortfall on the part of Enzon to produce at least [...***...] vials of Product when provided with at least [...***...] of Bulk Product by Savient shall 

  
  

					
		 	 Commercial Supply Agreement

Execution Copy
  

Page 6 of 44
	 	*** Confidential Treatment Requested

 
not constitute a breach of this Agreement and that the pricing for such shortfall below [...***...] vials) shall be computed as set forth in Section 6.2(e) herein. Additionally, in the
event that any scheduled manufacture of the Product is delayed due to the unavailability of adequate stores of Savient-supplied Materials, then any Firm Forecast then in effect shall be carried forward until such a time as the manufacture and
delivery of the Product in accordance with the most recently supplied firm purchase order have been completed. Savient shall be responsible for verifying that all Savient-supplied Materials meet relevant Specifications. Title to Savient-supplied
Materials shall not be transferred to Enzon. Savient will provide a signed, abbreviated Certificate of Analysis (“CofA”) which shall, at minimum, certify that Savient-supplied Materials meet the Specifications for such Savient-supplied
Materials as defined on Exhibit B prior to the processing of Savient-supplied Materials by Enzon. Enzon shall store all Savient-supplied Materials and finished Product in accordance with instructions provided by Savient in the Quality Agreement.

 (c)    All costs associated with the selection and/or qualification of alternative suppliers for any
materials required to perform the Services shall be borne by Savient. Any such activities will be defined by Savient in writing an accompanied by an appropriate purchase order to Enzon. 

(d)    Upon execution of this Agreement and along with every [...***...] forecast, Savient shall
pay Enzon a rolling, non-refundable reservation fee equal to [...***...] (specified on Exhibit C) price for batches included in the Firm Forecast to secure manufacturing capacity slots corresponding to the forecast provided. Savient shall pay
such reservation fee to Enzon within ten (10) days of Enzon’s provision to Savient of the manufacturing schedule, as set forth in Section 3.4(a), which schedule sets forth the approximate dates of manufacturing for the Product. Such reservation
fee shall be credited towards Product produced by Enzon on a batch-by-batch basis in a prorated amount. Additionally, upon payment of the reservation fee by Savient, Enzon warrants that manufacture of the Product shall occur on or before the dates
specified in the manufacturing schedule which conforms to the Firm Forecast for which the reservation fee is paid. Upon shipment of each completed batch, Enzon will invoice Savient at a rate equivalent to the applicable unit price multiplied by the
total number of vials produced less the applicable portion of any reservation fees paid. No less than two weeks prior to each [...***...] update of the Firm Forecast, Enzon and Savient will reconcile the invoices against the above-mentioned
reservation fee. In the event that Savient cancels any batch within the Firm Forecast, Enzon will charge Savient, and Savient agrees to pay to Enzon, a cancellation fee as set forth in the following sentence. For each batch canceled by Savient,
Savient will pay Enzon an amount equal to the minimum batch price set forth on Exhibit C [...***...] representing unused Process Consumables and Manufacturing Components), which amount shall represent liquidated damages resulting from unused
manufacturing capacity. In the event that Savient postpones the manufacture of any batch scheduled during the Firm Forecast period for a period of more than thirty (30) days, then Enzon will charge Savient, and Savient agrees to pay to Enzon, a
postponement fee as set forth in the following sentence. For each batch postponed by Savient, Savient will pay Enzon an amount equal to the minimum batch price set forth on Exhibit C [...***...] representing unused Process Consumables and
Manufacturing 

  
  

					
		 	 Commercial Supply Agreement

Execution Copy
  

Page 7 of 44
	 	*** Confidential Treatment Requested

 
Components) which amount shall represent liquidated damages resulting from unused manufacturing capacity. Only with respect to batches which are postponed beyond the Firm Forecast, Savient will
remit to Enzon the amount drawn within 30 days, and that amount will be credited back to the reservation fee. Enzon will draw the cancellation and postponement fee amounts described above from the amounts previously remitted to Enzon as reservation
fees. In the event that any amounts owing to Enzon pursuant to this Section exceed the amounts previously remitted to Enzon as reservation fees, Enzon shall submit an invoice to Savient for the difference and Savient shall submit payment for such
invoiced amounts in accordance with the terms of this Agreement. 
 Section 4.    COMPENSATION AND EXPENSES 

4.1    As compensation for rendering the Services hereunder, Savient shall pay Enzon the amounts specified
in Exhibit C and any subsequent additional Work Plans executed in writing by both parties. Except as otherwise specifically provided in the attached Work Plan or any subsequent additional Work Plan, all payments by Savient shall be made within
thirty (30) days of the date of its receipt of the appropriate invoice from Enzon. Enzon will charge a late payment fee of [...***...] per month, or the maximum amount permitted by law if less than [...***...] per month, for any payment
not received within thirty (30) days of the date of Savient’s receipt of the appropriate invoice from Enzon. Failure to invoice for interest due shall not be a waiver of Enzon’s right to charge interest. Savient will pay any sales, use,
gross receipts or other taxes, licenses, or fees (excluding tax based on Enzon’s net income) required to be paid by Enzon to any state or tax jurisdiction in connection with the Services performed hereunder. 

4.2    All invoices and/or other requests for payment shall be itemized with a reasonable degree of
specificity to ensure accuracy in accounting for services and/or goods provided and invoiced for. All invoices and/or other requests for payment shall be sent to: 

Accounts Payable 

Savient Pharmaceuticals, Inc. 

One Tower Center, 14th Floor 

East Brunswick, New Jersey 08816 

4.3    Enzon will adjust prices not more often than annually, commencing on January 1, 2010, based on
normal and customary increases in costs, not greater than the pharmaceutical Producer Price Index (as published by Bureau of Labor Statistics, Industry Code 325412). Additionally, Enzon may revise the prices provided in an attached Work Plan either
upward or downward with Savient’s prior written consent, such consent not to be unreasonably withheld, if (i) any information which the parties reasonably agree is material to the performance of the Services proves to be incomplete or
inaccurate (including but not limited to a material reduction in volume or a material change in prices of Enzon’s raw materials), (ii) Savient revises Enzon’s manufacturing or packaging responsibilities, procedures, or assumptions in a way
that would impact the cost of the Services, or (iii) unforeseen circumstances, which both parties reasonably agree were unforeseeable at the time of contracting and which are not directly attributable to Enzon, affect the activities required to
complete the Work Plan. Enzon will notify Savient 

  
  

					
		 	 Commercial Supply Agreement

Execution Copy
  

Page 8 of 44
	 	*** Confidential Treatment Requested

 
immediately if the costs to complete Services materially differ, either positively or negatively, from the prices stated in the attached Work Plan. Enzon will not commence work involving charges
in excess of those stated in the attached Work Plan without Savient’s written approval unless such advance notice was not possible due to the circumstances. Savient shall be responsible for all non-cancelable costs incurred by Enzon as a direct
result of any change order or other variation in Services requested by Savient, including but not limited to, inventory rendered unusable under the Work Plan; provided, however, that Enzon shall use Commercially Reasonable Efforts to minimize any
non-cancelable costs contemplated herein including, but not limited to, by maintaining on hand only such Manufacture Components which are reasonably required to manufacture such quantities of Product as are specified in the Firm Forecast. 

4.4    Savient’s failure to pay for the amounts due under this Agreement (including but not limited
to payments under 3.4(d)) shall constitute a material breach of this Agreement. Savient shall have 45 days from Enzon’s written notice to cure such breach; provided, however, that Savient’s failure to pay any amounts otherwise owing
hereunder due to a good faith dispute relating to such amounts shall not constitute a material breach only with respect to such amounts. Upon the expiration of the stated cure period, Enzon shall have the right to suspend any Services under this
Agreement. Any batch cancellations resulting from such actions will be billed to Savient in accordance with Section 3.4(d). 
 Section
5.    CERTAIN REPRESENTATIONS, WARRANTIES, AND COVENANTS 
 OF ENZON: 

5.1    Authority. Enzon represents and warrants that it has full authority to enter into this
Agreement. 
 5.2    Material/Supplies. Enzon shall use Savient-supplied Materials only to
perform the Services hereunder. 
 5.3    Savient Intellectual Property. Enzon warrants that it
shall use Savient Intellectual Property only for the purpose of manufacturing the Product on behalf of Savient in accordance with the terms of this Agreement. 

5.4    MVP Confidential Information. Enzon hereby represents and warrants that, during the Term of
this Agreement, it has not taken any action, nor failed to take any action, which would violate or cause to be violated the terms and conditions contained in the attached Exhibit E, which is incorporated herein by reference. The warranty
contained herein shall survive the termination or expiration of the Agreement in accordance with the terms contained in the attached Exhibit E. Anything to the contrary contained in this Agreement notwithstanding, Enzon agrees that there shall be no
limitation on the amount of liability for which Enzon may be liable to either Savient or Mountain View Pharmaceuticals, Inc., for breach of this Section 5.4. 

  
  

Commercial Supply Agreement 

Execution Copy 
 Page 9 of 44 

 5.5    Books and Records. Enzon shall maintain true
and accurate books, records, test and laboratory data, reports and all other information relating to manufacture of Product as required by regulation and in accord with current good manufacturing practices (“cGMP”) and as set forth in the
Quality Agreement. 
 5.6    Regulatory Inspections. Enzon shall make its facilities and all
records relating to the Product manufacture available to the Regulatory Authorities at times agreed with such authorities and shall notify Savient if the Regulatory Authority begins or schedules an inspection of Enzon’s records, facilities, or
manufacturing processes related to the manufacture of Product and provide Savient access to any documentation related to or resulting from the inspection as described in the Quality Agreement. 

5.7    Debarment. Enzon hereby certifies it does not and shall not employ, contract with or retain
any person directly or indirectly to perform services under this Agreement if such person is debarred under 21 U.S.C. 335a (a) or (b) or other equivalent laws, rules, regulations or standards of any other relevant jurisdiction. 

5.8    Regulatory Filings. Enzon will cooperate in providing to Savient any non-confidential
information in its control relating to this Agreement or the Product that Savient may reasonably require in connection with its regulatory or governmental filings, provided that such information shall be provided in whatever form held by Enzon. If
applicable, Enzon will provide a letter permitting applicable Regulatory Authority to reference its relevant drug master file. 

5.9    Product and Process. Enzon provides services to its customers on a contractual
fee-for-service basis. Enzon warrants that it will perform the Services with due care and in accordance with agreed upon protocols and/or specifications, the terms of this Agreement and any Work Plan hereunder, generally prevailing industry
standards and Applicable Laws. Enzon warrants that its fill/finish process does not and will not infringe on the rights of any third parties. 
 OF
SAVIENT: 
 5.10    Authority. Savient represents and warrants that it has full authority
to enter into this Agreement. 
 5.11    Savient-supplied Materials. Savient represents, warrants
and covenants as follows: (i) all Savient-supplied Materials will be supplied not later than four (4) weeks prior to a scheduled manufacturing date, as communicated to Savient pursuant to Section 3.4(a), so as to enable Enzon to complete manufacture
and delivery of the Product in accordance with all forecasts and firm purchase orders submitted by Savient and accepted by Enzon; (ii) all Savient-supplied Materials shall meet all relevant specifications, (iii) Savient shall take sole and exclusive
responsibility for the quality and sufficient supply of all such Savient-supplied Materials, including responsibility for all testing and inspection of the same except to the extent (if any) that Savient and Enzon agree that Enzon shall perform any
such testing and/or inspections in any Work Plan to this Agreement, and (iv) Enzon shall have no liability for a loss of Savient-supplied Materials except as set forth in Section 11.4. 

  
  

Commercial Supply Agreement 

Execution Copy 
 Page 10 of 44 

 5.12    IP Rights. Savient represents, warrants and
covenants that Savient has all the rights necessary, including the rights to the Savient Trademarks, to permit Enzon to perform the Services hereunder without infringing the intellectual property rights of any third party. 

5.13    Debarment. Savient hereby certifies it does not and shall not employ, contract with or
retain any person directly or indirectly to perform services under this Agreement if such person is debarred under 21 U.S.C. 335a (a) or (b) or other equivalent laws, rules, regulations or standards of any other relevant jurisdiction. 

Section 6.    ADDITIONAL PRODUCT SUPPLY TERMS 

6.1    Delivery. Delivery terms shall be FCA (Incoterms 2000) Enzon’s manufacturing facility
in Indianapolis, Indiana (or such other facility as the Parties may agree upon); Product shall be delivered in accordance with the timeframe set forth in the applicable purchase order. Title to Product and Savient-supplied Materials shall remain
vested with Savient at all times. 
 6.2    Rejected Goods; Failure of Supply. 

(a)    Except as provided for in Section 11.4, Savient’s sole remedy for breach of Enzon’s
warranty in Section 5.9 shall be to require Enzon to re-perform the relevant services at Enzon’s cost. 

(b)    Concurrent with Enzon’s delivery to Savient of any Product contemplated hereunder, Enzon
shall provide to Savient a written, executed CofA demonstrating compliance of Product with all relevant Specifications; such CofA may be transmitted to Savient via facsimile or electronic mail. Promptly following receipt of Product, Savient shall
have the right but not the obligation to test such Product to determine compliance with the Specifications. Savient shall notify Enzon in writing of any rejection of Product based on any claim that the Product fails to meet Specifications within
thirty (30) days of delivery, after which point all unrejected Product shall be deemed accepted. Any rightly rejected Product that does not meet the Specifications shall, at Enzon’s sole discretion and expense, either (i) be returned to Enzon
within a reasonable period of time and relabeled or reworked as permitted in the Marketing Authorizations and Specifications, if permitted by the Applicable Laws, or (ii) be destroyed in accordance with Applicable Laws. 

(c)    In the event that Enzon believes that Product has been incorrectly rejected, Enzon may require
that Savient provide to it Product samples for testing. Enzon may retain and test the samples of Product retained by it. In the event of a discrepancy between Savient’s and Enzon’s test results such that one Party’s test results fall
within relevant Specifications and the other Party’s test results fall outside the relevant Specifications, or there exists a dispute between the Parties over the extent to which such failure is attributable to a given Party, the Parties shall
cause an independent laboratory or appropriate expert promptly to review records, test data and perform comparative tests and/or analyses on samples of the alleged defective Product. Such independent laboratory or expert shall be mutually agreed
upon by the Parties, and shall be of such national repute as to allow both Parties to reasonably agree that the independent laboratory 

  
  

Commercial Supply Agreement 

Execution Copy 
 Page 11 of 44 

 
or expert is sufficiently qualified to perform such analyses. The independent laboratory’s results shall be in writing and shall be final and binding save for manifest error. Unless
otherwise agreed to by the Parties in writing, the costs associated with such testing and review shall be borne by the Party against whom the independent laboratory rules. 

(d)    Enzon shall replace any rightly rejected Product as promptly as practicable, using Commercially
Reasonable Efforts to make available manufacturing capacity, after the notice of such rejection, and in any case as soon as reasonably possible after receiving such notice, provided that Savient shall provide to Enzon sufficient quantities of
Savient-supplied Materials at no additional cost to Enzon. However, if the failure to meet Specifications is due to defects in the Savient-supplied Materials (where such defects are not due to any failure on the part of Enzon), or any other cause
except Enzon’s failure to perform the Services in accordance with this Agreement, Savient will pay the full cost of the rejected batch. 

(e)    The Parties agree that Savient shall supply variable amounts of Bulk Product to Enzon for purposes
of allowing Enzon to provide Services to fill and finish such Bulk Product into Product; the Parties further agree that if Savient supplies to Enzon [...***...] or more of Bulk Product for a single filling run that Enzon shall produce not less
than [...***...] vials of Product; if Enzon should fail to produce at least [...***...] vials of Product as indicated herein, then Savient shall pay to Enzon an amount equal to the per-vial price indicated on the attached Exhibit C
multiplied by the actual number of vials produced. In the event that Savient supplies less than [...***...] of Bulk Product to Enzon for a single filling run, then Savient shall pay to Enzon the minimum batch price indicated on Exhibit C
attached hereto. 
 6.3    Recall; Withdrawal; Modification; Complaints. Savient shall be
responsible for the cost of and all losses associated with any recall or product withdrawal or modification; provided, however, that to the extent that any such recall or product withdrawal is due to the gross negligence or willful misconduct on the
part of Enzon, then Enzon shall reimburse Savient for all direct costs associated with such recall or withdrawal, in addition to any other rights or remedies Savient may have, but in any case only to the extent attributable to Enzon. Enzon shall
reasonably cooperate with Savient in connection with any recall, withdrawal, or modification, at the expense of Savient except as otherwise provided for herein. Savient shall share with Enzon all relevant information relating to any such recall,
withdrawal, or modification. In addition, Savient shall also promptly and fully detail for Enzon any Product complaints or Field Alerts it receives insofar as any such complaints relate to the Services rendered by Enzon hereunder. Enzon shall
cooperate with Savient to report any adverse events of which it becomes aware in accordance with the terms of the Quality Agreement. Enzon shall only be responsible for the testing and protocols set forth in the Work Plan and Exhibits A and B, as
applicable, and Savient is responsible for all other testing and protocols. 
 Section 7.    TERM AND TERMINATION 

7.1    Term. This Agreement shall commence on the Effective Date and shall remain in full force and
effect unless terminated as provided herein. 

  
  

					
		 	 Commercial Supply Agreement

Execution Copy
  

Page 12 of 44
	 	*** Confidential Treatment Requested

 7.2    Termination. Subsequent to the first (1st) anniversary of the Effective Date of this Agreement, this Agreement may be terminated by either party at any time by giving at least twenty-four (24) months prior written notice to the other party
as follows: either party may give notice to the other party thirty (30) days prior to every such anniversary date. During the 24-month period between the notice of termination and the effectiveness of such termination, the Parties shall continue to
cooperate with each other in good faith to effectuate the purpose of this Agreement; specifically, and without limitation, Savient may place, and Enzon shall accept and fulfill, forecasts and purchase orders for the manufacture of Product, all in
accordance with the terms and conditions of this Agreement. During the pendency of the effective date of the termination notice, Savient shall not reduce the final six (6) months of any previously submitted forecast to [...***...] batches
except if Enzon is the party which is terminating this Agreement. For the purposes of clarification only, the prohibition contained in the immediately preceding sentence shall not apply where the final six (6) months of the most recently supplied
forecast were identified as having [...***...] batches at the time that the notice of termination was provided. Except as provided for herein, if, at any time subsequent to the tendering of a notice of termination pursuant to the terms herein,
Savient reduces any of the final six months of the forecast to [...***...] batches, Savient shall pay Enzon a termination fee of $[...***...] per batch. Enzon shall use Commercially Reasonable Efforts to minimize the incurrence of any
additional charges, fees or expenses which will not be utilized in the manufacture of the Product on behalf of Savient prior to the effective date of termination of this Agreement. Within thirty (30) days of the effective date of the termination of
this Agreement, Enzon shall provide to Savient any case reports, analyses and other deliverables which were prepared by Enzon, if any, prior to the date of termination and Enzon shall also provide Savient with a written itemized statement of all
Services performed by it hereunder and all costs incurred or for which Enzon is obligated. In the event of termination pursuant to this Section 7.2, Enzon shall be entitled to full payment for the Services actually rendered by it hereunder and all
non-cancelable costs incurred through the date of termination. In addition to the foregoing, if Savient terminates this Agreement or any Work Plan pursuant to this Section 7.2, Savient shall pay any cancellation or postponement amounts set forth in
Section 3.4(d); provided, however, that Enzon shall use Commercially Reasonable Efforts to mitigate any such cancellation or postponement amounts by scheduling, to the extent practicable, additional third party manufacturing activities, with any
such mitigation accruing to the benefit of Savient and proportionately reducing any cancellation or postponement amounts otherwise owing. If the amount already paid by Savient to Enzon exceeds such amounts payable hereunder, Enzon shall refund such
excess to Savient and if such amounts payable are greater than the amounts already paid by Savient to Enzon, then Savient shall pay the amount of such shortfall to Enzon. 

7.3    This Agreement may also be terminated by either party upon material default in performance of the
other party, provided that any defaulting party shall be given not less than ninety (90) days’ prior written notice of default and the opportunity to cure the default during such period. In the event this Agreement is terminated pursuant to
this Section 7.3, Enzon shall be entitled to full payment for the services provided by it hereunder (as set forth in any Work Plan(s) made a part hereof) and all costs incurred through the date of termination or for which Enzon is obligated as of
the date of termination; provided, however, that if Savient terminates this Agreement pursuant to this Section 7.3 then, anything to the contrary notwithstanding, 

  
  

					
		 	 Commercial Supply Agreement

Execution Copy
  

Page 13 of 44
	 	*** Confidential Treatment Requested

 
Enzon shall be entitled only to payment for such Services which it actually rendered on behalf of Savient through the effective date of termination. In addition to the foregoing, if Enzon
terminates this Agreement or any Work Plan pursuant to this Section 7.3, Savient shall pay any applicable cancellation or postponement amounts set forth in Section 3.4(d); provided, however, that Enzon shall use Commercially Reasonable Efforts to
mitigate any such cancellation or postponement amounts by scheduling, to the extent practicable, additional third party manufacturing activities, with any such mitigation accruing to the benefit of Savient and proportionately reducing any
cancellation or postponement amounts otherwise owing. If the amount previously paid by Savient exceeds such amount payable hereunder, the excess shall be refunded to Savient and if such amounts payable are greater than the amounts already paid by
Savient to Enzon, then Savient shall pay the amount of such shortfall to Enzon. 
 7.4    In the event
that Savient’s BLA for the Product is not approved by the FDA, and where such disapproval is final or otherwise not appealed by Savient, then either Party shall have the right, but not the obligation, to terminate this Agreement upon the
provision of thirty (30) days notice to the other Party. In the event this Agreement is terminated pursuant to this Section 7.4, Savient shall pay Enzon for packaging and labeling materials, any unpaid amounts for manufactured batches, and any
reservation fees or other applicable cancellation or termination fees, provided that Enzon shall use Commercially Reasonable Efforts to mitigate such fees. 

7.5    In the event that Savient’s BLA for the Product has not been approved by April 2009, then
this Agreement shall continue in force and effect but any deliverables and obligations of the parties shall be held in abeyance for up to 18 months so as to allow Savient to address any findings in such approvable letter issued by the FDA and
resubmit the subject BLA. Savient shall pay any cancellation or postponement amounts set forth in Section 3; provided, however, that Enzon shall use Commercially Reasonable Efforts to mitigate any such postponement amounts by scheduling, to the
extent practicable, additional third party manufacturing activities, with any such mitigation accruing to the benefit of Savient and proportionately reducing any cancellation or postponement amounts otherwise owing. Savient shall provide to Enzon
notice of its receipt of an approvable letter from the FDA within five (5) business days of its receipt of same. After said 18 months lapses, Enzon shall have the right to terminate this agreement immediately and with no penalty, and Savient shall
pay all applicable cancellation and postponement amounts as set forth. 
 7.6    This Agreement may be
terminated immediately, upon written notice, upon either party’s bankruptcy (voluntary or involuntary), insolvency, or placing of either party’s business in the hands of a receiver. 

7.7    Survival. The rights and obligations of each Party which by their nature survive the
termination or expiration of this Agreement shall survive the termination or expiration of this Agreement, including Sections 4, 6, 7, 8, 9, 10, 11, 14, and 15 (to the extent relevant). In addition, Enzon hereby acknowledges that neither expiration
nor termination of this Agreement shall affect in any manner Savient’s right to manufacture and sell, or have manufactured and sold, the Product. 

  
  

Commercial Supply Agreement 

Execution Copy 
 Page 14 of 44 

 Section 8.    INTELLECTUAL PROPERTY 

8.1    Subject to Section 8.2, all Savient Intellectual Property supplied to Enzon or developed by Enzon
in the course of performing the Services hereunder are owned by Savient. All information developed by Enzon and related to the Bulk Product or the Product shall be disclosed to Savient promptly upon discovery or development by Enzon. Savient shall
have the right to make any use of such information and Enzon agrees to execute any documents which may be reasonably required to effectuate any assignment of inventorship contemplated by this provision, at Savient’s expense. Following
completion of the Services outlined in any Work Plan, Enzon will insure the return of all client data or other materials furnished to Enzon. Subject to Section 8.2, all intellectual property rights subsisting in or relating to any calculations,
data, methods, specifications, papers, documents, and any other items, material or information arising from the performance of the Services by Enzon under this Agreement are vested in and are the sole property of Savient and Enzon shall execute any
and all documents reasonably requested by Savient in order to effectuate the intent of this provision, at Savient’s expense. 

8.2    Enzon shall own all rights to any invention (whether or not patentable) relating to manufacturing
and analytical methods and processes developed by Enzon in connection with Services performed hereunder that have general use in biopharmaceutical manufacturing, to the extent not specific to Savient’s Product, and to the extent not directed to
or derived from any pre-existing Savient Intellectual Property or MVP Confidential Information (“Process Invention”); provided that the provisions of this Section 8.2 shall not apply to manufacturing and analytical methods and processes
developed by Enzon at the direction of Savient. Except as specifically prohibited with respect to MVP Confidential Information, Enzon reserves the right to use data developed during the course of performing Services hereunder to support
applications, assignments or other instruments necessary to apply for and obtain patent or other intellectual property protection with respect to Process Inventions so long as no information which Enzon is required to keep confidential under this
Agreement or any other previously executed agreement between the Parties relating to confidentiality of information is disclosed in any such application, assignment, or other instrument without the prior consent of Savient (not to be unreasonably
withheld). For Process Inventions developed by Enzon in connection with performing services hereunder, Enzon will grant to Savient a perpetual, world-wide, royalty-free, non-exclusive license for Savient to use such Process Inventions in the
development and manufacture of the Savient Products. 
 Section 9.    CONFIDENTIALITY 

9.1    For the duration of the Agreement and five (5) years thereafter with respect to Savient
Confidential Information (as defined below), or, in the case of MVP Confidential Information (as defined below), for twenty (20) years from the Effective Date of the Agreement, Enzon will not disclose, without Savient’s written permission, any
such Savient Confidential Information or MVP Confidential Information, unless such disclosure: (i) is to an Affiliate, agent, employee or consultant of Enzon that is under a similar obligation to keep such information confidential and such
disclosure is reasonably necessary for the performance of the Services contemplated herein; (ii) is or becomes publicly available through no fault of Enzon; 

  
  

Commercial Supply Agreement 

Execution Copy 
 Page 15 of 44 

 
(iii) is disclosed by a third party entitled to disclose it; (iv) is already known to Enzon as shown by its prior written records; or, (v) is required by any law, rule, regulation, order,
decision, decree, subpoena or other legal process to be disclosed or in response to a request or order from a regulatory agency. If such disclosure is requested by a regulatory agency or legal process, Enzon will make all reasonable efforts to
notify Savient of this request promptly prior to any disclosure to permit Savient to oppose such disclosure by appropriate legal action. Enzon shall use reasonable precautions to protect the confidentiality of both Savient Confidential Information
and MVP Confidential Information in a manner that is comparable to precautions taken to protect is own proprietary information. As used herein, “MVP Confidential Information” means any Confidential Information that Savient provides, or has
provided, to Enzon which is specifically identified in writing as containing Mountain View Pharmaceuticals, Inc.’s proprietary technology for the manufacture of PEGylated uricase
(Puricase®/pegloticase), specifically including the documents referenced in Schedule A of the Second Amendment to the Agreement for Services between Savient and Enzon dated October 31,
2006, which the Parties have agreed to in a letter dated September 12, 2007, as containing Confidential Information belonging to Mountain View Pharmaceuticals, Inc; “Savient Confidential Information” means any Confidential Information
provided by Savient to Enzon, with the sole exception of MVP Confidential Information, during the term of the Agreement. 

9.2    For the duration of the Agreement and five (5) years thereafter with respect to Savient
Confidential Information, or in the case of MVP Confidential Information, for twenty (20) years from the Effective Date of the Agreement, Enzon will not use such Confidential Information except in connection with the performance of Services under
the Agreement or any other Agreement between Savient and Enzon related to Savient’s PEGylated uricase (Puricase®/pegloticase) product and in particular represents and warrants that it
will not utilize such Confidential Information in the manufacturing of any other product. 
 9.3    For
twenty (20) years from the Effective Date of the Agreement, Savient will not disclose, without Enzon’s written permission, any Confidential Information belonging to Enzon which is provided to Savient by Enzon during the Term of the Agreement
(“Enzon Confidential Information”) unless such disclosure: (i) is to an affiliate, agent, employee or consultant of Savient that is under a similar obligation to keep such information confidential; (ii) is or becomes publicly available
through no fault of Savient; (iii) is disclosed by a third party entitled to disclose it; (iv) is already known to Savient as shown by its prior written records; or, (v) is required by any law, rule, regulation, order decision, decree, subpoena or
other legal process to be disclosed or in response to a request or order from a regulatory agency. If such disclosure is requested by a regulatory agency or legal process, Savient will make all reasonable efforts to notify Enzon of this request
promptly prior to any disclosure to permit Enzon to oppose such disclosure by appropriate legal action. Savient shall use reasonable precautions to protect the confidentiality of Enzon Confidential Information in a manner that is comparable to
precautions taken to protect its own proprietary information. 
 9.4    If either Party shall be obliged
to provide testimony or records pertaining to the Confidential Information provided by the other in any legal or administrative proceeding, then the Party which supplied the Confidential Information shall reimburse the other Party for its
out-

  
  

Commercial Supply Agreement 

Execution Copy 
 Page 16 of 44 

 
of-pocket costs therefore plus an hourly fee for its employees or representatives equal to the internal fully burdened costs of such employee or representative. 

9.5    For both Parties, “Confidential Information” shall mean and include, without limitation,
such types of information as: inventions, methods, plans, processes, specifications, characteristics, raw data, analyses, equipment design, trade secrets, costs, marketing, sales, and product performance information, including patents and patent
applications, grant applications, notes, and memoranda, whether in writing or presented, stored or maintained electronically, magnetically or by other means, which are disclosed by the disclosing Party to the recipient Party in writing or in other
tangible form and marked “confidential” or, if disclosed orally (or in some other non-tangible form), are identified as confidential to the recipient Party in writing within sixty (60) days of such disclosure; provided, however,
that failure to reduce any verbal disclosure to writing shall not, in and of itself, vitiate the confidential nature of such Confidential Information and provided, further, that for the purposes of this Agreement, Confidential Information shall
include any and all such information exchanged between the Parties prior to the Effective Date of this Agreement pursuant to the Confidentiality Agreement between the Parties dated July 24, 2006.” 

Section 10.    INSURANCE 

Each Party shall for the term of this Agreement and for two (2) years after the last Product is delivered, obtain and maintain
at its own cost and expense from a qualified insurance company, comprehensive general liability insurance including, but not limited to, contractual liability coverage and standard product liability coverage in an amount commensurate with industry
standards. Savient shall for the term of this Agreement and for two (2) years after the last Product is delivered, obtain and maintain at its own cost and expense from a qualified insurance Savient, insurance coverage for losses of inventory at
Enzon’s facility prior to, and following manufacture of the Product. At a Party’s request, the other Party shall provide it with proof of such coverage. 

Section 11.    INDEMNIFICATION AND LIMITS OF LIABILITY 

11.1    Without limiting Enzon’s rights under law or in equity, Savient agrees to indemnify and hold
harmless Enzon and its employees, directors and agents from and against any loss, damage, cost and expense (including without limitation attorneys’ fees and expenses) incurred in connection with any claims, proceedings or investigations arising
directly or indirectly from (a) the manufacture, promotion, marketing, distribution or sale of the Product, (b) use or exposure to Product or any material provided to Enzon by Savient, (c) use of any Savient Intellectual Property provided by Savient
to Enzon (but only in cases where Savient has provided such Savient Intellectual Property for Enzon’s use) or any infringement of the intellectual property rights of any third party related to the Product, or (d) any breach of Savient’s
representations and/or warranties, except to the extent any such claim is the result of Enzon’s [...***...]. 

  
  

					
		 	 Commercial Supply Agreement

Execution Copy
  

Page 17 of 44
	 	*** Confidential Treatment Requested

 11.2    Without limiting Savient’s rights under law or
in equity, Enzon agrees to indemnify and hold harmless Savient and its employees, directors and agents from and against any loss, damage, cost and expense (including without limitation attorneys’ fees and expenses) incurred in connection with
any claims, proceedings or investigations arising out of or in connection with (a) this Agreement and the Product produced and the Services rendered hereunder to the extent that such claim, proceeding or investigation is based on the
[...***...] of Enzon or its employees, (b) any breach of Section 9.2 of this Agreement with respect to MVP Confidential Information, (c) any breach of the representations made by Enzon in the Letter Agreement between Enzon and Savient dated
September 12, 2007, attached hereto as Exhibit E; but in any case only to the extent attributable to Enzon. 

11.3    Any party seeking indemnification pursuant to this Section 11 (the “Indemnitee”)
shall give notice within five (5) days to the party from whom indemnification is sought (the “Indemnitor”) of any claim, proceeding or investigation; provided, however, that any failure to notify the Indemnitor within such five (5)
day period shall not negate the rights of indemnification granted hereunder except to the extent that the Indemnitor is actually prejudiced by such delay in notification. The Indemnitee shall cooperate in the defense of such claim, proceeding or
investigation, subject to reimbursement by the Indemnitor for all reasonable out-of-pocket expenses. The Indemnitor shall, at its option, assume control of the defense of any such claim, proceeding or investigation. The indemnities set forth in
Sections 11.1 and 11.2 shall include amounts paid in settlement provided, however, that no such settlement shall be entered into without the Indemnitor’s consent, which consent shall not be unreasonably withheld. 

11.4    As Savient’s sole remedy, Enzon agrees to reimburse Savient up to a maximum of
$[...***...] per batch, pro-rated over the usable portion of the batch, if applicable, for any loss of Savient-supplied Materials for each batch that does not meet Specifications or was not manufactured in accordance with the Manufacturing
Process or cGMP or the requirements of this Agreement, and therefore cannot be released or otherwise utilized for its intended purpose; provided that the loss of such materials can be shown after investigation to be caused solely and directly by:
(a) the failure of Enzon to follow its SOP’s; or (b) Enzon’s negligence, gross negligence, willful misconduct, or breach of this Agreement. In addition to this payment, if due to Enzon’s gross negligence, willful misconduct, or breach
of this Agreement, Enzon will re-perform the Services as provided in Section 6.2(a) . 
 11.5    SECTION
11.4 IS SAVIENT’S SOLE AND EXCLUSIVE REMEDY FOR ANY LOSSES OF SAVIENT-SUPPLIED MATERIAL AS A RESULT OF PRODUCT THAT DOES NOT COMPLY WITH THE SPECIFICATIONS OR THE OTHER REQUIRMENTS OF THIS AGREEMENT. UNDER NO CIRCUMSTANCES SHALL ENZON BE LIABLE
TO SAVIENT OR ANY THIRD PARTY FOR ANY CONSEQUENTIAL, INDIRECT (INCLUDING LOST REVENUES OR PROFITS), SPECIAL, OR OTHER DAMAGES, AND THE WARRANTY SET FORTH IN SECTION 5.9 IS THE SOLE AND EXCLUSIVE WARRANTY AND IN LIEU OF ANY AND ALL OTHER
WARRANTIES RELATING TO THE SERVICES TO BE PERFORMED, EXPRESS OR IMPLIED, INCLUDING, WITHOUT LIMITATION, ANY IMPLIED WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, OR FOR NON-INFRINGEMENT OF INTELLECTUAL

  
  

					
		 	 Commercial Supply Agreement

Execution Copy
  

Page 18 of 44
	 	*** Confidential Treatment Requested

 
PROPERTY RIGHTS. ENZON’S MAXIMUM LIABILITY FOR DAMAGES IN CONNECTION WITH A CLAIM RELATED TO THIS AGREEMENT, REGARDLESS OF THE CAUSE OF ACTION, WILL NOT EXCEED THE SUM TOTAL OF THE AMOUNTS
PAID BY SAVIENT TO ENZON IN THE PRECEEDING TWELVE (12) MONTHS. 
 EXCEPT AS EXPRESSLY STATED HEREIN, NEITHER PARTY PROVIDES
TO THE OTHER PARTY HERETO ANY WARRANTIES, EXPRESS OR IMPLIED, WITH RESPECT TO THE SERVICES PROVIDED HEREUNDER, AND ALL SUCH WARRANTIES, EXPRESS OR IMPLIED, INCLUDING WITHOUT LIMITATION ANY IMPLIED WARRANTIES OF MERCHANTIBILITY OR FITNESS FOR A
PARTICULAR PURPOSE ARE WAIVED, OTHER THAN AGREED HEREIN. WITHOUT LIMITING THE PROVISIONS OF SECTION 5.9 AND 6.2(e), ENZON MAKES NO WARRANTIES THAT THE EXECUTION OF THIS AGREEMENT WILL RESULT IN ANY SPECIFIC QUANTITY OR QUALITY OF PRODUCT. 

Section 12.    PUBLICITY AND PUBLICATIONS 

Neither Savient nor Enzon shall make any news release or other public statement, whether to the press or otherwise, disclosing
the existence of this Agreement, the terms thereof, or of any amendment thereto without the prior written approval of the other Party, except as required by Applicable Laws including, without limitation, those regulations promulgated by the United
States Securities and Exchange Commission. 
 Section 13.    FORCE MAJEURE AND CHANGE IN CIRCUMSTANCES 

If either Party shall be delayed or hindered in or prevented from the performance of any act required hereunder by reason of
strike, lockouts, labor troubles, restrictive governmental or judicial orders or decrees, riots, insurrection, war, terrorist acts, acts of God, inclement weather, or other reason or cause reasonably beyond such Party’s control (each a
“Force Majeure”), then performance of such act shall be excused for the period of such Force Majeure. The Party affected by the Force Majeure shall provide notice to the other of the commencement and termination of the Force Majeure.
Should a Force Majeure continue for more than three (3) months, the Party unaffected by the Force Majeure may terminate this Agreement upon prior written notice to the affected Party. If the Force Majeure equally affects the ability of each Party to
perform under this Agreement, then such termination shall only be by mutual written agreement. In the event of any other type of unforeseen material change in circumstances (that does not qualify as force majeure), both parties agree to negotiate in
good faith to find a commercially reasonable solution. 
 Section 14.    NOTICES 

14.1    All administrative communications provided for in this Agreement shall be sent via first class
mail (subject to Section 14.2 below), postage prepaid, addressed to the respective parties as follows: 
  

			
	To Enzon:	  	To Savient

  
  

Commercial Supply Agreement 

Execution Copy 
 Page 19 of 44 

			
	Executive Vice President, Operations	  	Vice President, Technical Operations
	 Enzon Pharmaceuticals, Inc.
	  	 Savient Pharmaceuticals, Inc.

	 685 Route 202/206
	  	 One Tower Center, 14th Floor

	 Bridgewater, New Jersey 08807
	  	 East Brunswick, NJ 08816

	 United States of America
	  	 United States of America

	  
 With a copy to:

 
	  	
	Legal Department	  	General Counsel
	 Enzon Pharmaceuticals, Inc.
	  	 Savient Pharmaceuticals, Inc.

	 685 Route 202/206
	  	 One Tower Center, 14th Floor

	 Bridgewater, New Jersey 08807
	  	 East Brunswick, NJ 08816

	 United States of America
	  	 USA

 14.2    Original documents and other than routine correspondence required
under this Agreement shall be sent by certified mail and addressed to the respective parties at the addresses set forth in Section 14.1. All legal notices shall be in writing and sent by certified mail, return receipt requested. Such notices shall
be effective on receipt. All routine correspondence between the Parties may be sent via electronic mail, facsimile or by regular mail. 
 Section
15.    MISCELLANEOUS 
 15.1    Amendments; Assignment. This Agreement,
including any Work Plans or other attachments, may not be altered, amended or modified except by a written document signed by both Parties. Enzon will not assign this Agreement without the prior written consent of Savient and any purported
assignment in contravention of this Section shall be null and void; provided, however, that either Party may assign this Agreement in connection with the sale of all or substantially all of its assets related to this Agreement or the Services to be
provided hereunder; provided, further, that any such successor or assignee assumes and accepts in writing all obligations of the purported assigning party hereunder. 

15.2    Subcontracting. Enzon may subcontract or delegate any of its rights or obligations under
this Agreement with the prior written authorization of Savient, such authorization not to be unreasonably withheld. Enzon shall cause any subcontractor to be subject by contract to the same restrictions, exceptions, obligations, reports, termination
provisions and other provisions contained in this Agreement. 
 15.3    Successors; Assigns. This
Agreement shall be binding upon and inure to the benefit of the Parties hereto and each of their respective successors and permitted assigns. 

15.4    Severability. All agreements and covenants contained herein are severable, and in the event
any of them shall be held to be invalid by any competent court, this Agreement shall be interpreted as if such invalid agreements or covenants were not contained herein. 

  
  

Commercial Supply Agreement 

Execution Copy 
 Page 20 of 44 

 15.5    Entire Agreement. This Agreement, including
the attached Work Plans, constitutes the entire agreement between the Parties and supersedes all prior communications, representations, or agreements, either verbal or written between the Parties which are specifically related to the subject matter
contemplated herein; anything to the contrary notwithstanding, any previously executed Confidentiality and Nondisclosure Agreement shall remain valid and enforceable in accordance with its terms. Each Party confirms that it is not relying on any
representations or warranties of the other Party except as specifically set forth herein. 

15.6    Independent Contractor. This Agreement shall not be deemed to create any partnership, joint
venture, or agency relationship between the Parties. Each Party shall act hereunder as an independent contractor and its agents and employees shall have no right or authority under this Agreement to assume or create any obligation on behalf of, or
in the name of, the other Party. All persons employed by a Party shall be employees of such Party and not of the other Party, and all costs and obligations incurred by reason of any such employment shall be for the account and expense of such Party.

 15.7    Waiver. The waiver by either Party of any right hereunder shall not be deemed a waiver
of any other right hereunder. 
 15.8    Counterparts. This Agreement may be executed in two (2)
or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. 

15.9    Headings. The headings used in this Agreement are for convenience only and are not a part
of this Agreement. 
 15.10    Governing Law. This Agreement shall be construed and enforced in
accordance with the laws of the State of New Jersey, without application of its principles of conflict of laws. 

15.11    Audits. Once each calendar year during the term of this Agreement, Savient and its agents
and designees shall have the right to audit Enzon’s facilities, systems, records solely related to this Agreement or the Product. Such audits may be conducted upon reasonable notice during the term of this Agreement, so long as (i) all auditors
have entered into confidentiality agreements relating to the materials to be reviewed, (ii) no materials are removed from the premises of Enzon, provided, however, that Savient may make and retain copies of Enzon materials as may be reasonably
necessary solely for purposes of completing the contemplated audit and any such materials shall be considered confidential, and (iii) a copy of all findings is provided to Enzon. All costs for such audits shall be paid by Savient. For the avoidance
of doubt, pre-approval inspections shall be considered an audit under this Section 15.11. Anything to the contrary notwithstanding, in the event that an audit is required due to batch failures or because the Services are not rendered in accordance
with the terms of this Agreement (including any Work Plan), then such for-cause audit shall not count towards the annual audit provided for herein. 

15.12    Nonsolicitation. For the term of this Agreement, and for twelve (12) months following
termination of this Agreement, for any reason, neither Savient nor Enzon nor any of 

  
  

Commercial Supply Agreement 

Execution Copy 
 Page 21 of 44 

 
their employees or agents shall, directly or indirectly, solicit any employees of the other, who have been involved in the Services, unless otherwise approved by the other party. 

IN WITNESS WHEREOF, each of the Parties hereto has caused this Commercial Supply Agreement to be executed by its duly
authorized representative as of the date written above. 
  

									
	ENZON PHARMACEUTICALS, INC.	 		 	SAVIENT PHARMACEUTICALS, INC.
					
	By:	 	  /s/ Ralph del Campo	 		 	By:	 	  /s/ Philip K. Yachmetz
		 	 Ralph del Campo
 EVP - Operations
	 		 		 	 Philip K. Yachmetz
 EVP & Chief Business
Officer

  
  

Commercial Supply Agreement 

Execution Copy 
 Page 22 of 44 

 Exhibit A 

Work Plan 
 Enzon will
fill, inspect, package and test the Product using the components defined below and the process as outlined on the following Process Flow Diagram. 

[...***...] 

[...***...] 

  
  

					
		 	 Commercial Supply Agreement

Execution Copy
  

Page 23 of 44
	 	*** Confidential Treatment Requested

 [...***...] 

  
  

					
		 	 Commercial Supply Agreement

Execution Copy
  

Page 24 of 44
	 	*** Confidential Treatment Requested

 [...***...] 

  
  

					
		 	 Commercial Supply Agreement

Execution Copy
  

Page 25 of 44
	 	*** Confidential Treatment Requested

 Exhibit B 
  

					
	  

Final Product Release Specifications
  

	Parameter	  	Test Method	  	Specification
	 [...***...]
	  	 [...***...]
	  	 [...***...]

	 [...***...]
	  	 [...***...]
	  	 [...***...]

	 [...***...]
	  	 [...***...]

[...***...]
	  	 [...***...]

[...***...]

  

					
	  

In-Process Product Specifications
  

	Parameter	  	Test Method	  	Specification
	 [...***...]
	  	 [...***...]
	  	 [...***...]

	 [...***...]
	  	 [...***...]
	  	 [...***...]

	 [...***...]
	  	 [...***...]
	  	 [...***...]

  
  

					
		 	 Commercial Supply Agreement

Execution Copy
  

Page 26 of 44
	 	*** Confidential Treatment Requested

 Exhibit C 

Product Price 
  

			
	Commercial Manufacturing	  	Price
	 Activities
Included
 • Prepare Master Batch Records

• Materials to be packed with one vial and product insert per carton.

• Commercial Batch Prices are effective on 1 January 2008, and are effective through
31 December 2009.
 • Enzon reserves the right to increase prices pursuant to the terms of the
Supply Agreement.
 • Release testing of batches; provision of CoA

• Supply temperature recorders to Drug Substance manufacturer for shipping. Download and provide temperature
data to Savient.
  
	  	 $[...***...] per vial

 
 The minimum price per batch of $[...***...] shall
apply in accordance with the terms of Section 6.2(e) of the Agreement.

  

															
	 Puricase Final Drug
Product Stability test Schedule at [...***...]
 [...***...]

Price is per each lot tested

	Setup & initiation
Fee	 	Initial Test	 	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	  	Total Cost
	$[...***...]	 	$[...***...]	 	[...***...]	  	[...***...]	  	$[...***...]	  	$[...***...]	  	$[...***...]	  	$[...***...]
	
Puricase Final Drug Product Stability test Schedule at [...***...]

Price is per each lot tested

	Setup & initiation
Fee	 	Initial Test	 	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	  	 	  	Total Cost
	$[...***...]	 	 	 	$[...***...]	  	$[...***...]	  	$[...***...]	  	$[...***...]	  	 	  	$[...***...]

 Stability studies will be conducted on batches requested in advance by Savient. Prices will be in effect
for stability studies initiated on 2008 or 2009 and subject to review at the end of 2009. 
  

			
	Professional Services Fee Structure	  	Price
	
• One (1) man-hour
	  	
$[...***...]
 Enzon
to update prices on or about January 1 of every year

 Terms:    Purchase Orders are required for each scheduled batch. 

	 	•	 	 Invoice for vials produced will be sent upon shipment of materials. Payment due net 30 days. 

	 	•	 	 Delivery terms are FCA Enzon’s manufacturing facility in Indianapolis, IN 

	 	•	 	 Cancelled and postponed batches shall be billed in accordance with Section 3.4(d). 

  
  

					
		 	 Commercial Supply Agreement

Execution Copy
  

Page 27 of 44
	 	*** Confidential Treatment Requested

 Exhibit D 

Product Forecast 
 Savient
has provided the following forecast for the [...***...] period beginning October 2008. 
 [...***...] 

  
  

					
		 	 Commercial Supply Agreement

Execution Copy
  

Page 28 of 44
	 	*** Confidential Treatment Requested

 [...***...] 

  
  

					
		 	 Commercial Supply Agreement

Execution Copy
  

Page 29 of 44
	 	*** Confidential Treatment Requested

 Exhibit E 

Letter Agreement 
 (see
attached) 

  
  

Commercial Supply Agreement 

Execution Copy 
 Page 30 of 44 

 

 
  

			
	 September 12, 2007
	  	                         Our Ref:
pky/jmw

 Enzon Pharmaceuticals, Inc. 

Attn: Thomas J. Puskar 
 685 Route
202/206 
 Bridgewater, New Jersey 08807 
  

	 	Re:	Second Amendment to Agreement for Services (“Agreement”) between Savient Pharmaceuticals, Inc. (“Savient”) and Enzon Pharmaceuticals, Inc. (“Enzon”) dated October 31, 2006 and as
amended on June 15, 2007 

 Dear Mr. Puskar: 

Pursuant to Section 13,01 of the Agreement, Savient and Enzon hereby agree to amend the Agreement by repealing Section 4: Confidentiality and replacing it as
follows: 
 “4.01:        For the duration of the Agreement and five (5) years thereafter with
respect to Savient Confidential Information (as defined below), or, in the case of MVP Confidential Information (as defined below), for twenty (20) years from the Effective Date of the Agreement, Enzon will not disclose, without Savient’s
written permission, any such Savient Confidential Information or MVP Confidential Information, unless such disclosure: (i) is to an affiliate, agent, employee or consultant of Enzon that is under a similar obligation to keep such information
confidential and such disclosure is reasonably necessary for the performance of the Services contemplated herein; (ii) is or becomes publicly available through no fault of Enzon; (iii) is disclosed by a third party entitled to disclose it; (iv) is
already known to Enzon as shown by its prior written records; or, (v) is required by any law, rule, regulation, order decision, decree, subpoena or other legal process to be disclosed or in response to a request or order from a regulatory agency. If
such disclosure is requested by a regulatory agency or legal process, Enzon will make all reasonable efforts to notify Savient of this request promptly prior to any disclosure to permit Savient to oppose such disclosure by appropriate legal action.
Enzon shall use reasonable precautions to protect the confidentiality of both Savient Confidential Information and MVP Confidential Information in a manner that is comparable to precautions taken to protect its own proprietary information. As used
herein, “MVP Confidential Information” means any Confidential Information that Savient provides, or has provided, to Enzon which is specifically identified in writing as containing Mountain View Pharmaceuticals, Inc.’s proprietary
technology for the manufacture of PEGylated uricase 
  
 Cont.../
... 

 
(Puricase®/pegloticase), specifically including the documents referenced in the attached Schedule A, which the Parties have agreed to in a
letter dated September 12, 2007, as containing Confidential Information belonging to Mountain View Pharmaceuticals, Inc; “Savient Confidential Information” means any Confidential Information provided by Savient to Enzon, with the sole
exception of MVP Confidential Information, during the Term of the Agreement, 
 4.02        For the
duration of the Agreement and five (5) years thereafter with respect to Savient Confidential Information, or in the case of MVP Confidential Information, for twenty (20) years from the Effective Date of the Agreement, Enzon will not use such
Confidential Information except in connection with the performance of Services under the Agreement or any other Agreement between Savient and Enzon related to Savient’s PEGylated uricase
(Puricase®/pegloticase) product and in particular represents and warrants that it will not utilize such Confidential Information in the manufacturing of any other product. 

4.03        For twenty (20) years from the Effective Date of the Agreement, Savient will not disclose,
without Enzon’s written permission, any Confidential Information belonging to Enzon which is provided to Savient by Enzon during the Term of the Agreement (“Enzon Confidential Information”) unless such disclosure: (i) is to an
affiliate, agent, employee or consultant of Savient that is under a similar obligation to keep such information confidential; (ii) is or becomes publicly available through no fault of Savient; (iii) is disclosed by a third party entitled to disclose
it; (iv) is already known to Savient as shown by its prior written records; or, (v) is required by any law, rule, regulation, order decision, decree, subpoena or other legal process to be disclosed or in response to a request or order from a
regulatory agency. If such disclosure is requested by a regulatory agency or legal process, Savient will make all reasonable efforts to notify Enzon of this request promptly prior to any disclosure to permit Enzon to oppose such disclosure by
appropriate legal action. Savient shall use reasonable precautions to protect the confidentiality of Enzon Confidential Information in a manner that is comparable to precautions taken to protect its own proprietary information. 

 

	 	4.04	If either Party shall be obliged to provide testimony or records pertaining to the Confidential Information provided by the other in any legal or administrative proceeding, then the Party which supplied the Confidential
Information shall reimburse the other Party for its out-of-pocket costs therefore plus an hourly fee for its employees or representatives equal to the internal fully burdened costs of such employee or representative. 

Cont.../ ... 

  
 2 

 4.05.        For both Parties, “Confidential
Information” shall mean and include, without limitation, such types of information as: inventions, methods, plans, processes, specifications, characteristics, raw data, analyses, equipment design, trade secrets, costs, marketing, sales, and
product performance information, including patents and patent applications, grant applications, notes, and memoranda, whether in writing or presented, stored or maintained electronically, magnetically or by other means, which are disclosed by the
disclosing Party to the recipient Party in writing or in other tangible form and marked “confidential” or, if disclosed orally (or in some other non-tangible form), are identified as confidential to the recipient Party in writing within
sixty (60) days of such disclosure; provided, however, that failure to reduce any verbal disclosure to writing shall not, in and of itself, vitiate the confidential nature of such Confidential Information and provided, further, that for the purposes
of this Agreement, Confidential Information shall include any and all such information exchanged between the Parties prior to the effective date of this Agreement pursuant to the Confidentiality Agreement between the Parties dated July 24,
2006.” 
 To signify your acceptance of this Amendment, kindly countersign and return one copy to my attention. 

Should you have any questions, please do not hesitate to contact John Petrolino at (732) 565-4655. 

Very truly yours, 
 /s/ Philip K. Yachmetz

 Philip K. Yachmetz 

Executive Vice President 
 Chief
Business Officer 
 I hereby agree to the terms and conditions
 contained herein. 

Enzon Pharmaceuticals, Inc. 
  

			
		
	By:	 	      /s/ Ralph del Campo

			
		
	Name:	 	     Ralph del Campo

			
		
	Title:	 	       EVP Technical Operations

			
		
	Date:	 	       9/17/07

  
 3 

 SCHEDULE A 

List of Confidential Documents identified pursuant to 

Section 4.01 of this Agreement in the letter of September 12, 2007 

 

	1.)	 [...***...] 

	2.)	 [...***...] 

	3.)	 [...***...] 

	4.)	 [...***...] 

  

					
		 	4	 	*** Confidential Treatment Requested

 Exhibit F 

QUALITY AGREEMENT 
 Quality Technical
Agreement for: 
 PRODUCT: Puricase® (PEG-Uricase) 

DOSAGE/FORM: 8 mg/ml per vial  
 This Quality Agreement
shall be read in conjunction with a commercial Supply Agreement between ENZON and SAVIENT (“Supply Agreement”), dated as of October 16, 2008 and is incorporated into the Supply Agreement. Capitalized terms not defined herein shall
have the respective meanings set forth in the Supply Agreement. The effective date of this Quality Agreement shall be the Effective Date of the Supply Agreement. 

This Quality Agreement defines the duties of ENZON and SAVIENT for the contract pharmaceutical manufacture of Product. In particular this Quality Agreement clearly
states who is responsible for the cGMP aspects of manufacturing and specifies the way in which the Party releasing Product for sale ensures that the Product complies with the approved Product Specifications (defined below) and the Marketing
Authorizations (defined below). 
 This Quality Agreement takes the form of a detailed checklist of all the activities associated with pharmaceutical production,
analysis, release, and distribution. Responsibility for each activity is assigned to either ENZON or SAVIENT in the appropriate box in the Delegation Responsibility Checklist which follows. 

In order to provide better quality assurance, ENZON will perform the activities defined herein in accordance with its Standard Operating Procedures (defined below) to
the extent that a Standard Operating Procedure is applicable to such activity. 
 This Agreement is subject to the terms of the Supply Agreement. A breach of
this Quality Agreement shall be deemed a breach of the Supply Agreement. In the event of a conflict between this Quality Agreement and the Supply Agreement, the Supply Agreement shall control. 

This Quality Agreement is intended to comply with the guidance and directives set forth in the current versions and effective amendments of (I) FDA Guidance for
Industry, Cooperative Manufacturing Arrangements for Licensed Biologics, August 1999; (ii) 21 CFR 210 & 211 and applicable portions of 21 CFR 600 through 610; and (iii) European Commission Directive 91/356 down the principles and guidelines
of good manufacturing practice for medicinal Products for human use. This will be made accessible to relevant regulatory authorities if required by them. 

[signature page follows] 

  
  

Commercial Supply Agreement 

Execution Copy 
 Page 31 of 44 

 The Parties have caused their duly authorized representatives to executed this Quality Agreement, effective as of
October 16, 2008. 
  

			
	SAVIENT PHARMACEUTICALS, Inc.	  	ENZON PHARMACEUTICALS, Inc.
		
	     /s/ Robert Lamm
	  	     /s/ Christian W. Dreyer

	Signature	  	Signature
		
	     Robert Lamm
	  	     Christian W. Dreyer

	Printed Name	  	Printed Name
		
	     SVP, QA, RA
	  	     V.P. QOP

	Title	  	Title
		
	     10/16/08
	  	     10/21/08

	Date	  	Date

  
  

Commercial Supply Agreement 

Execution Copy 
 Page 32 of 44 

 For purposes of this Quality Agreement, the following definitions shall apply: 

 

	A.	“FDA” shall mean the United States Food and Drug Administration, and any successor entity thereto. 

  

	B.	“Marketing Application” shall mean an application for Product marketing authorization which has not yet been approved by the FDA or other regulatory authority, including, without limitation, FDA New Drug
Application, FDA Biologics License Application, and other similar marketing applications promulgated by regulatory authorities. 

  

	C.	“Marketing Authorizations” shall mean any approved application for Product marketing authorization, including, without limitation, FDA New Drug Application, FDA Biologics License Application, and other similar
marketing authorizations promulgated by international regulatory authorities. 

  

	D.	“Process” or “Processing” shall mean the sterile compounding, filling, producing and/or packaging of the raw materials into Product in accordance with the Product Specifications and the terms and
conditions set forth in the Supply Agreement and this Quality Agreement. 

  

	E.	“Product Specifications” shall mean the procedures, requirements, specifications, standards, quality control testing, other data and scope of Supply related to the Product, as set forth in the Project Plan
and/or attached hereto. ENZON shall not release Product if these parameters are not met and investigation shows the non-complying parameter to be a valid test result. 

 

	F.	“Standard Operating Procedures” or “SOPS” shall mean the standard operating procedures in effect at ENZON which have been approved by ENZON Quality Assurance department and which are applicable to
the Processing; provided that all Standard Operating Procedures applicable to the Processing or the Product shall also be approved by SAVIENT. 

  

	G.	“Bulk Product” shall mean the bulk solution of [...***...] supplied by Savient to Enzon pursuant to this agreement. 

 

	H.	“Business Day” shall mean Monday through Friday excluding government holidays. 

  

	I.	“Component” shall mean all packaging materials utilized during manufacture, including all primary and secondary packaging materials. 

 

	J.	“Deviation” shall mean any planned or unplanned event or result that is different from the expected event or result defined in existing procedures or specifications. 

  
  

					
		 	 Commercial Supply Agreement

Execution Copy
  

Page 33 of 44
	 	*** Confidential Treatment Requested

	K.	“Filled Product” shall mean in-process sterile Product that has been filled into its final primary package for further labeling and packaging. 

 

	L.	“Product” shall mean sterile Product in its final packaged and labeled form that is ready for disposition. 

  

	M.	“Manufacture” shall mean finished drug Product pooling, filling, packaging, and associated in-process and stability testing, as applicable. 

 

	N.	“Master Production Control Record (MPCR)” shall mean a master document that represents a detailed procedure and data record for the batch manufacturing process, pursuant to CFR 21 §211.186.

  

	O.	“Out of Specification (OOS)” shall mean any in-process, intermediate, or finished Product test result that is outside of acceptable ranges defined in approved specifications or analytical test methods.

  

	P.	“cGMPs’ shall mean current good manufacturing practices as promulgated by the FDA under the United States Food, Drug, and Cosmetic Act, 21 C.F.R. Part 210 et seq., as amended from time to time, and the
European Union. 

 The following Facilities shall be used by ENZON for Processing or provision of Supply (“Facilities”): 

 

	
	 Manufacturing, Packaging, Testing and Storage

	
6925 Guion Rd.
 Indianapolis, IN 46268

USA
  

 Section 16.    RESPONSIBILITY DELEGATION CHECKLIST 

 

											
	 	 	 	 	RESPONSIBILITIES	 	 	 	SAVIENT	 	ENZON
	1.	 	 	 	Regulatory Authorizations & cGMP Compliance	 	 	 	 
	 1.1
	 	 	 	 Maintain all licenses, registrations and other authorizations as are required to operate a cGMP pharmaceutical manufacturing
facility under the Applicable Laws.
	 	 	 	 	 	X
	 1.2
	 	 	 	 Maintain and operate the Facility in compliance with the cGMPs, Applicable Laws and all other Product-specific instructions and
requirements agreed to by the Parties.
	 	 	 	 	 	X

  
  

					
		 	 Commercial Supply Agreement

Execution Copy
  

Page 34 of 44
	 	

											
	 	 	 	 	RESPONSIBILITIES	 	 	 	SAVIENT	 	ENZON
	 1.3
	 	 	 	 Process the Product in accordance with the cGMPs, Applicable Laws and all other Product-specific instructions and requirements
agreed to by the Parties.
	 	 	 	 	 	X
	 1.4
	 	 	 	 Prepare, maintain and update the Marketing Authorizations in accordance with cGMPs, Applicable Laws and all other Product-specific
instructions and requirements agreed to by the Parties.
	 	 	 	X	 	 
	 1.5
	 	 	 	 Provide ENZON with copies of those portions of the Marketing Applications which are applicable to the Processing, prior to
submission of such Marketing Applications to the applicable regulatory authorities.
	 	 	 	X	 	 
	 1.6
	 	 	 	 Provide ENZON with copies of updates of those portions of the Marketing Authorizations which are applicable to the Processing,
prior to submission of such Marketing Applications to the applicable regulatory authorities.
	 	 	 	X	 	 
	 1.7
	 	 	 	 Satisfy all drug listing filing requirements for all Product and packaging configurations processed at the Facilities.
	 	 	 	 	 	X
	 1.8
	 	 	 	 Prepare and submit post-marketing annual reports to the FDA and other applicable regulatory authorities in accordance with cGMPs,
Applicable Laws and all other Product-specific instructions and requirements agreed to by the Parties.
	 	 	 	X	 	 
	 1.9
	 	 	 	 Provide SAVIENT within 30 business days of their request with the following information to be
included in the post-marketing annual reports:
  

•  Change control information for all changes implemented during the preceding year relating to the Product.

•  Applicable Product test data submitted in accordance with the requirements of the Supply Agreement, including
any non-conforming data.
	 	 	 	 	 	X
	 1.10
	 	 	 	 Conduct Annual Product Quality Review for the Product in accordance with cGMP’s, and Applicable Laws.
	 	 	 	X	 	 
	 1.11
	 	 	 	 Provide SAVIENT with the following information to be included in the Annual Product Quality
Review:
  
 •  All requested
data and information required per 21 CFR 211.180(e)
	 	 	 	 	 	X

  
  

					
		 	 Commercial Supply Agreement

Execution Copy
  

Page 35 of 44
	 	

											
	 	 	 	 	RESPONSIBILITIES	 	 	 	SAVIENT	 	ENZON
	2.	 	 	 	Regulatory Actions & Inspections	 	 	 	 	 	 
	 2.1
	 	 	 	 Promptly (within 24 hours of receiving notice) notify SAVIENT of any FDA or other regulatory authority (a) notice of inspection or
inspection of the Facilities directly relating to the Product, or (b) inspection or investigation relating to the Product; and promptly (within 3 days) notify SAVIENT of any regulatory authority request for Product samples or Product batch
records.
	 	 	 	 	 	X
	 2.2
	 	 	 	 Promptly (within 24 hours of receiving notice) notify ENZON of any FDA or other regulatory authority inspection or investigation
relating to the Product; and promptly (within 3 days) notify ENZON of any regulatory authority request for Product samples or Product batch records.
	 	 	 	X	 	 
	 2.3
	 	 	 	 Provide SAVIENT copies of any FDA Form 483’s, warning letters or the like from applicable regulatory authorities within 30
days of receipt and copies of all subsequent response(s) relating to the Product or Quality Systems.
	 	 	 	 	 	X
	 2.4
	 	 	 	 Approve inspection responses to observations relevant to Product.
	 	 	 	X	 	 
	 2.5
	 	 	 	 Other than a request(s) delivered in conjunction with an inspection, notify the other Party of any requests for information,
notices of violations or other communications from a regulatory authority relating directly to the Product produced at the Facility.
	 	 	 	X	 	 
	3.	 	 	 	Specifications & Change Control	 	 	 	 	 	 
	 3.1
	 	 	 	 Approve Product Specifications.
	 	 	 	X	 	 
	 3.2
	 	 	 	 Assume primary responsibility for ensuring that all Specifications (including Product Specifications) and batch records that
specifically relate to the manufacture and release of Product comply with relevant portions of the Marketing Applications and Marketing Authorizations, as amended from time to time.
	 	 	 	X	 	 

  
  

					
		 	 Commercial Supply Agreement

Execution Copy
  

Page 36 of 44
	 	

											
	 3.3
	 	 	 	 Assume secondary responsibility for ensuring that all Specifications (including Product
Specifications) and batch records that specifically relate to the manufacture and release of Product comply with relevant portions of the Marketing Applications and Marketing Authorizations, as amended from time to time.
	 	 	 	 	 	X
	 	 	 	 	RESPONSIBILITIES	 	 	 	SAVIENT	 	ENZON
	 3.4
	 	 	 	 Submit any proposed changes to the Specifications to SAVIENT for review and approval, prior to the implementation of such changes
by ENZON.
	 	 	 	 	 	X
	 3.5
	 	 	 	 Submit any proposed changes to the Specifications to ENZON for review and comment, prior to the submission of any such changes by
SAVIENT to the regulatory authorities.
	 	 	 	X	 	 
	 3.6
	 	 	 	 Discuss and reach agreement with SAVIENT regarding any proposed changes to the Facilities or the Processing that may impact the
Product, prior to implementation of such proposed changes.
	 	 	 	 	 	X
	 3.7
	 	 	 	 Serve as sole communicator with regulatory authorities for the approval and any revisions of Product Specifications in the Market
Applications and Marketing Authorizations.
	 	 	 	X	 	 
	4.	 	 	 	Materials	 	 	 	 	 	 
	 4.1
	 	 	 	 Maintain Bulk Product according to cGMPs and Applicable Laws
	 	 	 	X	 	 
	 4.2
	 	 	 	 Retain reference samples of Bulk Product, including samples for periodic re-tests, for 6 years beyond Product expiry
date.
	 	 	 	X	 	 
	 4.3
	 	 	 	 Provide Bulk Product meeting the Specifications and cGMPs for manufacture, as well as a certificate of analysis for Bulk
Product.
	 	 	 	X	 	 
	 4.4
	 	 	 	 Perform identification testing of Bulk Product.
	 	 	 	 	 	X
	 4.5
	 	 	 	 Source and qualify raw materials (excluding Bulk Product) used in Processing.
	 	 	 	X	 	 
	 4.6
	 	 	 	 Maintain Specifications for Components and procure, store, sample, test and release raw materials.
	 	 	 	 	 	X
	 4.7
	 	 	 	 Audit suppliers that provide Components and Process Consumables used in Processing in accordance with applicable SOPs to ensure
full compliance with cGMPs and Applicable Laws.
	 	 	 	 	 	X

  
  

					
		 	 Commercial Supply Agreement

Execution Copy
  

Page 37 of 44
	 	

											
	 4.8
	 	 	 	 Store Bulk Product and Components in accordance with the Specifications, SOPs, cGMPs and Applicable
Laws while at the Facilities.
	 	 	 	 	 	X
	 	 	 	 	RESPONSIBILITIES	 	 	 	SAVIENT	 	ENZON
	 4.9
	 	 	 	 Retain reference samples of raw materials in a quantity sufficient to perform periodic re-tests, for 1 year beyond Product expiry
date in accordance with Specifications, SOPs, cGMPs and Applicable Laws.
	 	 	 	 	 	X
	 4.10
	 	 	 	 Notify SAVIENT of intent to dispose of material retains.
	 	 	 	 	 	X
	 4.11
	 	 	 	 At SAVIENT’s option, ship material retains to SAVIENT (at SAVIENT’s expense) or destroy.
	 	 	 	 	 	X
	 4.12
	 	 	 	 Dispose of Product waste and any special waste related to the Processing of the Product in accordance with Applicable
Laws.
	 	 	 	 	 	X
	5.	 	 	 	Production, Investigations & Validations	 	 	 	 	 	 
	 5.1
	 	 	 	 Provide personnel with appropriate education, training and/or experience for manufacturing, testing and disposition of Product
that is suitable for human use, and for provision of Supply hereunder.
	 	 	 	 	 	X
	 5.2
	 	 	 	 Provide premises that are maintained and able to meet design and cleanliness requirements in accordance with Applicable Laws and
industry standards.
	 	 	 	 	 	X
	 5.3
	 	 	 	 Test and maintain utilities and environment to the appropriate compendia or environmental standard to assure appropriateness for
use in connection with Processing and the Product.
	 	 	 	 	 	X
	 5.4
	 	 	 	 Maintain, qualify and validate the Facility, equipment, utilities (air and water) and processes associated with Processing the
Product in accordance with Applicable Laws and industry standards.
	 	 	 	 	 	X
	 5.5
	 	 	 	 Manufacture and test the Product at the Facilities in accordance with the Product master Production control record, the SOPs
referenced therein, and the Specifications.
	 	 	 	 	 	X
	 5.6
	 	 	 	 Perform visual inspection of finished Product in accordance with the Product master Production control record, the SOPs referenced
therein, and the Specifications.
	 	 	 	 	 	X
	 5.7
	 	 	 	 Label Product in accordance with the Product master Production control record, the SOPs referenced therein, and the
Specifications.
	 	 	 	 	 	X

  
  

					
		 	 Commercial Supply Agreement

Execution Copy
  

Page 38 of 44
	 	

											
	 5.8
	 	 	 	 Prepare and approve all artwork, inserts, labeling and packaging in connection with the
Product.
	 	 	 	X	 	 
	 5.9
	 	 	 	 Package the Product in accordance with the Product master Production control record, the SOPs referenced therein, and the
Specifications.
	 	 	 	 	 	X
	 	 	 	 	RESPONSIBILITIES	 	 	 	SAVIENT	 	ENZON
	 5.10
	 	 	 	 Perform finished Product testing in accordance with the supply agreement and supply a certificate of analysis and a Certificate of
Compliance to SAVIENT.
	 	 	 	 	 	X
	 5.11
	 	 	 	 Final release Product in accordance with the Product Specifications.
	 	 	 	X	 	 
	 5.12
	 	 	 	 Investigate, resolve and document deviations from the Master Production Control Record and OOS test results in accordance with the
cGMPs. Investigations should be completed with 30 calendar days. Interim status reports must be provided to Savient periodically in writing for investigations remaining open beyond 30 business days.
	 	 	 	 	 	X
	 5.13
	 	 	 	 Obtain Quality Assurance approval of all investigations and corrective and preventive action plans.
	 	 	 	 	 	X
	 5.14
	 	 	 	 Provide equipment maintained and able to meet design and cleanliness requirements in accordance with Applicable Laws and industry
standards, as applicable.
	 	 	 	 	 	X
	 5.15
	 	 	 	 Establish a validation master plan and maintain the validation program in accordance with plan requirements.
	 	 	 	 	 	X
	 5.16
	 	 	 	 Prepare and execute all Product related validation protocols, and complete validation reports.
	 	 	 	 	 	X
	 5.17
	 	 	 	 Review and approve validation protocols related to Product.
	 	 	 	X	 	 
	 5.18
	 	 	 	 Provide Quality Assurance review and approval of all validation packages.
	 	 	 	 	 	X
	6.	 	 	 	Audits	 	 	 	 	 	 
	 6.1
	 	 	 	 SAVIENT will schedule and audit ENZON Facilities, records and documentation related to the Product manufactured by ENZON at a time
mutually agreed by Enzon with a minimum advanced notice of 3 months and at a frequency of not more than once every 12 months. SAVIENT may request for-cause audits as needed.
	 	 	 	X	 	 
	 6.2
	 	 	 	 Conduct internal audits of Facilities, processes and quality systems, in accordance with cGMPs and applicable SOPs.
	 	 	 	 	 	X

  
  

					
		 	 Commercial Supply Agreement

Execution Copy
  

Page 39 of 44
	 	

											
	 6.3
	 	 	 	 SAVIENT shall provide ENZON with a written audit report containing audit observations within 30
business days of the audit.
	 	 	 	X	 	 
	 6.4
	 	 	 	 ENZON will respond to Savient audit report in writing within 15 business days.
	 	 	 	 	 	X
	 6.5
	 	 	 	 SAVIENT is entitled to inspect and audit suppliers, vendors and contractors used by ENZON in connection with the Product.
	 	 	 	X	 	 
	7.	 	 	 	Lot Codes & Expiration Dating	 	 	 	 	 	 
	 7.1
	 	 	 	 Establish Product lot code.
	 	 	 	 	 	X
	 7.2
	 	 	 	 Establish Product expiry dating as per approved Product License/Marketing Authorization.
	 	 	 	X	 	 
	8.	 	 	 	Samples	 	 	 	 	 	 
	 8.1
	 	 	 	 Perform Product sampling in accordance with the Supply Agreement, cGMP’s, and as otherwise agreed to by the Parties in the
master Production control record for the Product.
	 	 	 	 	 	X
	 8.2
	 	 	 	 Retain Finished Product samples including Stability samples in accordance with cGMP’s and the Supply Agreement.
	 	 	 	 	 	X
	9.	 	 	 	Testing & Analysis	 	 	 	 	 	 
	 9.1
	 	 	 	 Perform all applicable Product testing according to the Supply Agreement.
	 	 	 	X	 	X
	 9.2
	 	 	 	 Track and investigate all deviations (including DOS’s) associated with the Product, and notify SAVIENT Quality and
Manufacturing within 24 hours of discovery of any significant deviations (those that may affect the identity, strength, quality, or purity of the Product).
	 	 	 	 	 	X
	 9.3
	 	 	 	 Notify ENZON of any Product recall that might be attributed to Processing the Product.
	 	 	 	X	 	 
	 9.4
	 	 	 	 Notify SAVIENT Quality and Manufacturing via email within the business day followed by signed documents of any confirmed failure
of the Product that might be attributed to Processing the Product.
	 	 	 	 	 	X
	10.	 	 	 	Release	 	 	 	 	 	 
	 10.1
	 	 	 	 Provide initial QA disposition of Product to SAVIENT.
	 	 	 	 	 	X
	 10.2
	 	 	 	 Provide final QA disposition of Product.
	 	 	 	X	 	 
	11.	 	 	 	Records	 	 	 	 	 	 

  
  

					
		 	 Commercial Supply Agreement

Execution Copy
  

Page 40 of 44
	 	

											
	 11.1
	 	 	 	 Review and approve the executed batch records.
	 	 	 	X	 	X
	 	 	 	 	RESPONSIBILITIES	 	 	 	SAVIENT	 	ENZON
	 11.2
	 	 	 	 Provide the released, executed batch record documentation for each batch of Product, which
shall include the following:
 •  A statement that the lot was manufactured, packaged and tested
in accordance with cGMPs, identifies the master batch Record documents, and lists any incident reports and investigations associated with the batch.

•  A certificate of analysis covering all regulatory authority and compendial tests, and a Certificate of
Compliance.
 •  The signature of the QA Representative who released the batch.

•  Copies of significant deviations (those that may materially affect the identify, strength, quality or purity
of the Product).
 •  A list of other deviations that may affect the Product.

•  A list of change control records that could impact the Product.

•  Copies of summary Quality Assurance reviewed release test records.
	 	 	 	 	 	X
	 11.3
	 	 	 	 Store the master record, batch records, manufacturing documentation and all other documentation related to the Product for the
minimum period required by all Applicable Laws.
	 	 	 	 	 	X
	 11.4
	 	 	 	 Provide copies of all documentation necessary for SAVIENT to respond to inquiries by regulatory authorities.
	 	 	 	 	 	X
	12.	 	 	 	Storage	 	 	 	 	 	 
	 12.1
	 	 	 	 Store and ship the Bulk Product in accordance with the Bulk Product Specifications, SOPs, cGMPs and Applicable Laws until
manufacture of the Product.
	 	 	 	X	 	 
	 12.2
	 	 	 	 Receive and store the Bulk Product. Intermediates, and finished Product in accordance with the Specifications, SOPs, cGMPs and
Applicable Laws pending release of the Product.
	 	 	 	 	 	X
	 12.3
	 	 	 	 Provide written instructions for shipping prior to Product release and shipment.
	 	 	 	X	 	 
	13.	 	 	 	Safety	 	 	 	 	 	 
	 13.1
	 	 	 	 Maintain safety/hazard and handling data on the Product and Bulk Product.
	 	 	 	X	 	X

  
  

					
		 	 Commercial Supply Agreement

Execution Copy
  

Page 41 of 44
	 	

											
	 	 	 	 	RESPONSIBILITIES	 	 	 	SAVIENT	 	ENZON
	 13.2
	 	 	 	 Maintain safety/hazard and handling data on the raw materials.
	 	 	 	X	 	X
	14.	 	 	 	Complaints	 	 	 	 	 	 
	 14.1
	 	 	 	 Upon request of SAVIENT, assist SAVIENT in investigating and resolving all medical, adverse events, and non-medical Product
complaints.
	 	 	 	 	 	X
	 14.2
	 	 	 	 Collect and log all information relating to Product complaints and adverse drug events.
	 	 	 	X	 	X
	 14.3
	 	 	 	 Investigate all Product complaints and adverse drug events.
	 	 	 	X	 	X
	 14.4
	 	 	 	 Issue all reports and conduct follow up corrective action relating to Product complaints and adverse drug events.
	 	 	 	X	 	X
	15.	 	 	 	Recall, Field Alerts and Product Withdrawal	 	 	 	 	 	 
	 15.1
	 	 	 	 Inform the Quality Assurance contact from the other Party within 24 hours upon knowledge of all quality issues which might
compromise the other Party’s quality requirements for Products already shipped, or about to be shipped.
	 	 	 	X	 	X
	 15.2
	 	 	 	 Issue any decision to initiate Product recall or Product withdrawal.
	 	 	 	X	 	 
	 15.3
	 	 	 	 Communicate decision to initiate Product recall to ENZON.
	 	 	 	X	 	 
	 15.4
	 	 	 	 Notify appropriate regulatory authorities of any Product recall or Product withdrawal.
	 	 	 	X	 	 
	 15.5
	 	 	 	 Manage any Product recall or Product withdrawal.
	 	 	 	X	 	 
	 15.6
	 	 	 	 Reconcile returned Product following Product recall or Product withdrawal.
	 	 	 	X	 	X
	 15.7
	 	 	 	 Issue and follow up on FDA Field Alerts (or other similar processes of other regulatory authorities).
	 	 	 	X	 	 
	 15.8
	 	 	 	 Perform mock recall and recall effectiveness checks.
	 	 	 	X	 	 
	16	 	 	 	Quality Agreement Review	 	 	 	 	 	 
	 16.1
	 	 	 	 On an as-needed basis (or once every two years), conduct a review to ensure that the Quality Agreement is in alignment with the
current scope of the Project Plan and the then- current Supply Agreement. Update by mutual agreement of the Parties (if necessary).
	 	 	 	X	 	X
	17	 	 	 	Key Contacts	 	 	 	 	 	 

  
  

					
		 	 Commercial Supply Agreement

Execution Copy
  

Page 42 of 44
	 	

											
	 17.1
	 	 	 	 Either party may change the following contact information by issuing a memo to the other
party. Each party shall attach the memo to this original signed agreement. The updated information shall be incorporated into the next controlled revision of this agreement.
	 	 	 	X	 	X

 Savient Pharmaceuticals Inc. 

For All Product Concerns: 

Savient Pharmaceutical’s Inc. 

One Tower Center 

14th Floor 

East Brunswick, New Jersey 08816 

USA 
 Enzon
Pharmaceuticals, Inc. 
 For Manufacturing, Quality Assurance and Quality Control: 

Enzon Pharmaceuticals, Inc. 

6925 Guion Road 

Indianapolis, Indiana 46268 

USA 
  

			
	 For Regulatory Affairs:
	  	For Operations, Planning & Logistics:
		
	 Enzon Pharmaceuticals, Inc.
	  	 Enzon Pharmaceuticals, Inc.

	 685 Route 202/206
	  	 685 Route 202/206

	 Bridgewater, New Jersey 08854
	  	 Bridgewater, New Jersey 08807

	 USA
	  	 USA

  

									
	Enzon Contact	  	Name/Title	  	Phone	  	Fax	  	E-mail
	 Quality Assurance
	  	 [...***...]
	  	 [...***...]
	  	 [...***...]
	  	 [...***...]

	QA –
Product
Release	  	 [...***...]
	  	 [...***...]
	  	 [...***...]
	  	 [...***...]

	 Quality
Control Lab
	  	 [...***...]
	  	 [...***...]
	  	 [...***...]
	  	
[...***...]

  
  

					
		 	 Commercial Supply Agreement

Execution Copy
  

Page 43 of 44
	 	*** Confidential Treatment Requested

									
	 Operations
	  	 Control
	  	 	  	 	  	 
	 Regulatory Affairs
	  	 [...***...]
	  	 [...***...]
	  	 [...***...]
	  	 [...***...]

	Operations – Planning	  	 [...***...]
	  	 [...***...]
	  	 [...***...]
	  	 [...***...]

  

									
	Savient
Contact	  	Name/Title	  	Phone	  	Fax	  	E-mail
	 Quality Assurance 
	  	 [...***...]
	  	 [...***...]
	  	 [...***...]
	  	 [...***...]

	Quality Assurance 	  	 [...***...]
	  	 [...***...]
	  	 [...***...]
	  	 [...***...]

	 QA — Product
Release
	  	 [...***...]
	  	 [...***...]
	  	 [...***...]
	  	 [...***...]

	 Regulatory Affairs
	  	 [...***...]
	  	 [...***...]
	  	 [...***...]
	  	 [...***...]

	 Manufacturing
	  	 [...***...]
	  	 [...***...]
	  	 [...***...]
	  	 [...***...]

	Planning and
Logistics	  	 [...***...]
	  	 [...***...]
	  	 [...***...]
	  	 [...***...]

  
  

					
		 	 Commercial Supply Agreement

Execution Copy
  

Page 44 of 44
	 	*** Confidential Treatment Requested

 AMENDMENT NO. 1 

TO 

COMMERCIAL SUPPLY AGREEMENT 

DATED OCTOBER 16, 2008 

THIS AMENDMENT, effective as of Oct. 5, 2009, is entered into by and between SAVIENT PHARMACEUTICALS, INC.
(“SAVIENT”), and ENZON PHARMACEUTICALS, INC. (“ENZON”) hereinafter collectively referred to as the “Parties.” 

WHEREAS, the Parties have entered into a certain Commercial Supply Agreement (hereinafter referred to as the
“Agreement”) with an effective date of October 16, 2008, which sets forth the terms and conditions for services performed by the Parties. 

WHEREAS, the Parties wish to amend the payment structure outlined in the Agreement. 

NOW, THEREFORE, notwithstanding anything to the contrary within the Agreement, for the duration of this Amendment set
forth below, the parties hereby agree as follows: 
  

	 	•	 	 All payments under the Agreement are to be made as follows: 

 

	 	-	 Savient shall pay the full amount for the Product upon Enzon’s receipt of Bulk Product. 

	 	-	 Payment in full due “net 15 days” from bulk receipt. Packaging will occur at Savient’s instructions; final batch cost reconciliation
will be calculated and billed at shipment (that payment also net 15 days.) Precise filling date will be confirmed by Enzon to accommodate Savient’s timelines. 

 

	 	•	 	 Upon FDA approval of a Biologics License Application for the Product, consistent with the original assumption of the Agreement, the Parties shall
repeal this Amendment by signed mutual agreement and thereby revert to the original terms of the Agreement in full. 

  

	 	•	 	 A cancellation in Purchase Order or specific Product line after the Project is initiated will not result in a refund. All payments are
considered final upon receipt. 

 Where there is any inconsistency between the provisions of the
Agreement and the Amendment, the provisions of this Amendment shall prevail. 
 All remaining terms and conditions of the
Statement shall remain unchanged and in full force and effect. 
 AGREED: 
  

													
	SAVIENT PHARMACEUTICALS, INC.	 		 	ENZON PHARMACEUTICALS, INC.
					
	By:	 	/s/Philip K. Yachmetz	 		 	By:	 	/s/Ralph del Campo
		 	 Philip K. Yachmetz
 EVP & Chief
Business Officer
	 		 		 	 Ralph del Campo
 EV, Technical
Ops

	Date:	 	10/9	 	, 2009.	 		 	Date:	 	10/5/09	 	, 2009.

 ENZON Pharmaceuticals, Inc. 

Contract Manufacturing 
 Exhibit C
to the Commercial Supply Agreement Dated October 6, 2008 
 Revision dated October 22, 2009 – supersede prior Exhibit C 

[...***...] 

  
  

 

					
		 	 Enzon Pharmaceuticals, Inc.

Commercial Supply Agreement
 Page 1
of 3
	 	  
 Exhibit C

*** Confidential Treatment Requested

 [...***...] 

  
  

 

					
		 	 Enzon Pharmaceuticals, Inc.

Commercial Supply Agreement
 Page 2
of 3
	 	  
 Exhibit C

*** Confidential Treatment Requested

 ENZON Pharmaceuticals, Inc. 

Contract Manufacturing 
 Exhibit C
to the Commercial Supply Agreement Dated October 16, 2008 
 Revision dated October 22, 2009 – supersede prior Exhibit C 

Terms: 

	 	•	 	 Terms and conditions of the Commercial Supply Agreement dated October 16, 2008 and subsequent amendments apply (October 5, 2009 –
Amendment No 1) 

	 	•	 	 Delivery terms are FCA Enzon’s Indianapolis, IN facility (Section 6.1) 

	 	•	 	 Purchase orders are required for all scheduled work 

	 	•	 	 Canceled or postponed batches will be billed in full. All payment are considered final 

The Parties have caused their duly authorized representatives to execute this supplemental Exhibit C to the Commercial Manufacturing
Agreement. 
  

					
	SAVIENT PHARMACEUTICALS, Inc.	 		 	ENZON PHARMACEUTICALS, Inc.
			
	/s/ Philip K. Yachmetz	 		 	/s/ Ralph del Campo
	 Signature
	 		 	 Signature

			
	 Philip K. Yachmetz
	 		 	 Ralph del Campo

	 Printed Name
	 		 	
			
	 SVP & General Counsel
	 		 	 EVP – Tech Ops

	 Title
	 		 	 Title

			
	 10-26-09
	 		 	 10/26/09

	 Date
	 		 	 Date

  
  

 

					
		 	 Enzon Pharmaceuticals, Inc.

Commercial Supply Agreement
 Page 1
of 3
	 	  
 Exhibit C

 AMENDMENT TO COMMERCIAL SUPPLY AGREEMENT 

This Amendment (“Amendment”) is entered into as of July 29, 2014 (the “Effective Date”), by and between
Sigma Tau PharmaSource, Inc., with its principal executive offices located at 6925 Guion Road, Indianapolis, IN, 46268 (“STPS”) and Crealta Pharmaceuticals LLC with its principal executive offices located at 500 W. Silver Spring Drive,
Suite K-200, Glendale, WI 53217 (“Crealta”). 
 WHEREAS, STPS and Crealta are parties to a certain Commercial Supply
Agreement dated October 16, 2008, (the “Agreement”); 
 The parties desire to amend the Agreement to expand the scope
of the Agreement. In consideration of the promises and of the mutual covenants and agreements set forth, the parties agree as follows: 
  

	 	1.	 Recitals. The following two recitals are hereby added to the RECITALS section of the Agreement: 

 

	 	    	 WHEREAS, on or about January 29, 2010, Enzon Pharmaceuticals, Inc. assigned its rights under this Agreement to Sigma-Tau PharmaSource,
Inc. (“STPS”); 

 WHEREAS, on or about January 9, 2014, Savient Pharmaceuticals, Inc.
assigned its rights under the Agreement to Crealta; and 
  

	 	2.	 Terms and Conditions. Except as herein amended, all other terms and conditions of Agreement shall remain unchanged and in full
force and effect. All defined terms used and not otherwise defined in this Amendment have the meanings ascribed to such terms in the Agreement. This Amendment may only be modified by a written document, signed by both parties. This
Amendment may be executed in counterparts, each of which is an original, but all of which together constitute one and the same instrument. The terms and conditions of this Amendment and any Exhibits are incorporated into and made a part of the
Agreement. 

  

	 	3.	 Section 2.4 of the Agreement is deleted in its entirety and replaced with the following: 

 

	 	    	 STPS shall provide Crealta, at no additional charge, product support services, at Crealta’s reasonable request, for the activities listed
below: 

  

	 	•	 	 Meetings with Regulatory Authorities, whether in person or by phone 

 

	 	•	 	 Routine documentation provided to Regulatory Authorities on behalf of Crealta 

 

	 	•	 	 Routine validation activities to support commercial production (e.g. Media fills, annual sterilization validations, or vial washing
requalifications). 

  

	 	•	 	 Annual product reviews for commercial products, as required by Regulatory Authorities. 

 

	 	•	 	 All audit correspondence including Crealta-requested revisions to STPS’s audit response. 

 

	 	•	 	 Preparation of documents in anticipation of a Pre-Approval Inspection. 

 

	 	•	 	 Letters of reference from STPS or STPS’s vendors that are requested by Crealta (e.g., Master file reference letters, rubber or glass
vendor letters). 

  

	 	•	 	 Documentation provided to Regulatory Authorities on behalf of Crealta, other than routine documentation. 

 

	 	•	 	 All time used for collecting and photocopying Crealta documentation. 

 

	 	•	 	 Changes and revisions to artwork mandated by Regulatory Authorities or requested by Crealta. 

 

	 	•	 	 Batch storage. 

  
 Page 1 

	 	    	 Crealta may request from STPS other product support services at its customary rate, as set forth on Exhibit C, including but not limited to:

  

	 	•	 	 Any additional validation work requested by Crealta beyond original Work Plan or outside current validation requirements. 

 

	 	•	 	 Any analytical development and/or analyses beyond original Work Plan. 

 

	 	    	 For all requests under this Section 2.4, Crealta shall provide STPS a written request for product support services that describes the required
services and/or documents/work product required. STPS shall provide Crealta an estimate based on its customary rate. Upon acceptance of such estimate by Crealta, Crealta shall issue a purchase order to STPS and STPS shall perform such
services in accordance with the terms hereof. 

  

	 	4.	 The first 2 sentences of Section 7.2 shall be deleted in their entirety and replaced with the following: 

 

	 	    	 Subsequent to the first (1st) anniversary of the Effective Date of this Agreement, this Agreement may be terminated by either party at any time by
giving at least thirty-six (36) months prior written notice to the other party as follows: either party may give notice to the other party thirty (30) days prior to every such anniversary date. During the 36-month period between the notice of
termination and the effectiveness of such termination, the Parties shall continue to cooperate with each other in good faith to effectuate the purpose of this Agreement; specifically, and without limitation, Crealta may place, and STPS shall accept
and fulfill, forecasts and purchase orders for the manufacture of Product, all in accordance with the terms and conditions of this Agreement. 

  

	 	5.	 Section 14.1 is deleted in its entirety and replaced with the following: 

 

	 	    	 All administrative communications provided for in this Agreement shall be sent via first class mail (subject to Section 14.2 below), postage
prepaid, addressed to the respective parties as follows: 

  

			
	 To STPS:
	  	 To Crealta:

		
	 Sigma-Tau PharmaSource, Inc.
	  	 Crealta Pharmaceuticals LLC

		
	 6925 Guion Rd.
	  	 Attn: Richard Crowley

		
	 Indianapolis, IN 46268
	  	 150 S. Saunders Rd., Suite 130

		  	 Lake Forest, IL 60045

		
	 With a Copy to:
	  	 With a Copy to:

		
	 Sigma-Tau Pharmaceuticals, Inc.
	  	 Crealta Pharmaceuticals LLC

		
	 Attn: Legal Dept.
	  	 Attn: Edward Donovan

		
	 9841 Washingtonian Blvd., Suite 500
	  	 150 S. Saunders Rd., Suite 130

		
	 Gaithersburg, MD 20878
	  	 Lake Forest, IL 60045

  

	 	6.	 Exhibit C of the Agreement is deleted in its entirety and replaced with Attachment 1 of this Amendment. 

 

	 	7.	 Exhibit F is deleted in its entirety and incorporates by reference with the Quality Agreement between the Parties dated October 16, 2008. Such
new version is the new Exhibit F, which supersedes all prior versions of such Quality Agreement. 

  
 Page 2 

	 	8.	 The parties acknowledge that the revised pricing reflected herein is reasonable as of the Effective Date of this Amendment and that current
business conditions, as of the Effective Date, with respect thereto do not warrant any adjustment to the prices set forth herein pursuant to the second sentence of Section 4.3. Notwithstanding the foregoing, nothing in this Section 8 of this
Amendment shall alter, modify, diminish, or otherwise affect any of the Parties’ rights under Section 4.3 of the Agreement. 

The parties have executed this Amendment to be effective as of the Effective Date. 

 

									
	Sigma-Tau PharmaSource, Inc.	 		 	Crealta Pharmaceuticals LLC
					
	By:	 	/s/ Dave Lemus	 		 	By:	 	/s/ Richard Crowley
					
	Name:	 	Dave Lemus	 		 	Name:	 	Richard Crowley
					
	Title:	 	President	 		 	Title:	 	Senior VP, Operations & QA
					
	Date:	 	9-22-14	 		 	Date:	 	September 9, 2014

  
 Page 3 

 ATTACHMENT 1 

Exhibit C 

Product Price 

[...***...] 

  

					
		 	Page 4	 	*** Confidential Treatment Requested

 [...***...] 

Terms: Purchase Orders are required for each scheduled batch. 

 

	 	•	 	 Invoice for vials produced will be sent upon shipment of materials. Payment due Net 30 days. 

 

	 	•	 	 Delivery terms are FCA STPS’s manufacturing facility in Indianapolis, IN 

 

	 	•	 	 Cancelled and postponed batches shall be billed in accordance with Section 3.4(d) 

STPS and Crealta agree that the total price (costs, fees, and incentives, if any) for all work provided for under the Agreement, including the
work authorized under this Amendment, shall not exceed the new total contract price. All invoices must be presented to Company no later than 120 days after the completion of services. 

  

					
		 	Page 5	 	*** Confidential Treatment RequestedEX-10.1

 Exhibit 10.1 

COHERUS BIOSCIENCES, INC., 
 as
Issuer, 
 the Guarantors from time to time party hereto, 

as Guarantors 
 AND 

HealthCare Royalty Partners III, L.P., 

MX II Associates LLC, 
 KMG Capital
Partners, LLC 
 AND 
 KKR
Biosimilar L.P., 
 each as an Investor 
  

 
 Senior
Convertible Note Purchase Agreement 
 Dated as of February 29, 2016 

 
  

8.2% Convertible Senior Notes due 2022 

 TABLE OF CONTENTS 

 

							
	 	 	 	  	Page	 
	ARTICLE 1.	  
	DEFINITIONS AND OTHER PROVISIONS OF GENERAL APPLICATION	  
			
	 Section 1.01
	 	 Definitions
	  	 	1	  
	 Section 1.02
	 	 Acts of Holder; Record Dates
	  	 	11	  
	 Section 1.03
	 	 Effect of Headings and Table of Contents
	  	 	11	  
	 Section 1.04
	 	 Successors and Assigns
	  	 	11	  
	 Section 1.05
	 	 Severability Clause
	  	 	11	  
	 Section 1.06
	 	 Benefits of Agreement
	  	 	11	  
	
	ARTICLE 2.	  
	PURCHASE AND ISSUANCE OF NOTES	  
			
	 Section 2.01
	 	 Purchase and Sale
	  	 	11	  
	 Section 2.02
	 	 Form of Notes
	  	 	12	  
	
	ARTICLE 3.	  
	THE SECURITIES	  
			
	 Section 3.01
	 	 Title and Terms; Payments
	  	 	12	  
	 Section 3.02
	 	 Ranking
	  	 	12	  
	 Section 3.03
	 	 Denominations
	  	 	12	  
	 Section 3.04
	 	 Execution, Delivery and Dating
	  	 	12	  
	 Section 3.05
	 	 Registration; Registration of Transfer and Exchange
	  	 	13	  
	 Section 3.06
	 	 Transfer Restrictions
	  	 	13	  
	 Section 3.07
	 	 Mutilated, Destroyed, Lost and Stolen Notes
	  	 	14	  
	 Section 3.08
	 	 Persons Deemed Owners
	  	 	14	  
	 Section 3.09
	 	 Transfer and Exchange
	  	 	14	  
	 Section 3.10
	 	 Cancellation
	  	 	15	  
	 Section 3.11
	 	 Outstanding Notes.
	  	 	15	  
	
	ARTICLE 4.	  
	PARTICULAR COVENANTS OF THE COMPANY	  
			
	 Section 4.01
	 	 Payment of Principal and Interest
	  	 	16	  
	 Section 4.02
	 	 Maintenance of Office or Agency
	  	 	16	  
	 Section 4.03
	 	 Reports
	  	 	16	  
	 Section 4.04
	 	 Offer to Repurchase upon Fundamental Change
	  	 	17	  
	 Section 4.05
	 	 Existence
	  	 	19	  
	 Section 4.06
	 	 Limitation on Additional Indebtedness
	  	 	19	  
	 Section 4.07
	 	 Limitation on Dividends
	  	 	20	  
	 Section 4.08
	 	 Default Notices
	  	 	20	  
	 Section 4.09
	 	 Payment of Taxes
	  	 	20	  
	
	ARTICLE 5.	  
	REDEMPTION	  
			
	 Section 5.01
	 	 No Right to Redeem Before March 31, 2020
	  	 	20	  
	 Section 5.02
	 	 Right to Redeem the Notes on or After March 31, 2020
	  	 	20	  
	 Section 5.03
	 	 Redemption Prohibited in Certain Circumstances
	  	 	20	  
	 Section 5.04
	 	 Redemption Date
	  	 	20	  
	 Section 5.05
	 	 Redemption Price
	  	 	20	  
	 Section 5.06
	 	 Redemption Notice
	  	 	20	  
	 Section 5.07
	 	 AHYDO Saver
	  	 	21	  

  
 -i- 

							
	 	 	 	  	Page	 
	ARTICLE 6.	  
	CONDITIONS	  
			
	 Section 6.01
	 	 Closing Date Conditions
	  	 	21	  
	
	ARTICLE 7.	  
	CONVERSION	  
			
	 Section 7.01
	 	 Right to Convert
	  	 	22	  
	 Section 7.02
	 	 Conversion Procedure
	  	 	22	  
	 Section 7.03
	 	 Settlement upon Conversion Into Common Stock
	  	 	23	  
	 Section 7.04
	 	 Adjustment of Conversion Rate
	  	 	23	  
	 Section 7.05
	 	 Effect of Reclassification, Consolidation, Merger, Sale, Etc.
	  	 	29	  
	 Section 7.06
	 	 Adjustments of Prices
	  	 	30	  
	 Section 7.07
	 	 Increased Conversion Rate Applicable to Certain Notes Surrendered in Connection with Make-Whole Fundamental Changes
	  	 	30	  
	 Section 7.08
	 	 Taxes on Shares Issued
	  	 	32	  
	 Section 7.09
	 	 Reservation of Shares; Listing
	  	 	32	  
	 Section 7.10
	 	 Shareholder Rights Plan
	  	 	32	  
	 Section 7.11
	 	 Company Determination Final
	  	 	32	  
	 Section 7.12
	 	 Exchange in Lieu of Conversion
	  	 	32	  
	
	ARTICLE 8.	  
	REPRESENTATIONS, WARRANTIES AND COVENANTS	  
			
	 Section 8.01
	 	 Representations and Warranties of Investors
	  	 	33	  
	 Section 8.02
	 	 Representations and Warranties of the Credit Parties
	  	 	34	  
	 Section 8.03
	 	 HSR Act Matters
	  	 	36	  
	 Section 8.04
	 	 Agreement Not to Tender in Certain Fundamental Changes
	  	 	36	  
	
	ARTICLE 9.	  
	EVENTS OF DEFAULT; REMEDIES	  
			
	 Section 9.01
	 	 Events of Default
	  	 	37	  
	 Section 9.02
	 	 Reporting Defaults
	  	 	38	  
	 Section 9.03
	 	 Acceleration of Maturity; Waiver of Past Defaults and Rescission
	  	 	38	  
	 Section 9.04
	 	 Unconditional Right of Holders to Receive Payment and Convert
	  	 	39	  
	 Section 9.05
	 	 Restoration of Rights and Remedies
	  	 	39	  
	 Section 9.06
	 	 Rights and Remedies Cumulative
	  	 	39	  
	 Section 9.07
	 	 Delay or Omission Not Waiver
	  	 	40	  
	 Section 9.08
	 	 Control by Holders
	  	 	40	  
	 Section 9.09
	 	 Undertaking for Costs
	  	 	40	  
	
	ARTICLE 10.	  
	MERGER, CONSOLIDATION OR SALE OF ASSETS	  
			
	 Section 10.01
	 	 Company May Consolidate, etc., only on Certain Terms
	  	 	40	  
	 Section 10.02
	 	 Successor Substituted
	  	 	40	  

  
 -ii- 

							
	 	 	 	  	Page	 
	ARTICLE 11.	  
	REGISTRATION RIGHTS	  
			
	 Section 11.01
	 	 Demand Registrations
	  	 	41	  
	 Section 11.02
	 	 Piggyback Registration.
	  	 	41	  
	 Section 11.03
	 	 Obligations of the Company
	  	 	42	  
	 Section 11.04
	 	 Black-Out Periods
	  	 	44	  
	 Section 11.05
	 	 Effect of Failure to File and Obtain and Maintain Effectiveness of Registration Statement or Failure to Timely Convert
	  	 	44	  
	 Section 11.06
	 	 Obligations of Holders
	  	 	45	  
	 Section 11.07
	 	 Indemnification
	  	 	45	  
	 Section 11.08
	 	 Effectiveness; Termination; Survival
	  	 	47	  
	
	ARTICLE 12.	  
	GUARANTEES	  
			
	 Section 12.01
	 	 Guarantee
	  	 	47	  
	 Section 12.02
	 	 Execution and Delivery of Guarantee
	  	 	48	  
	 Section 12.03
	 	 Limitation of Guarantors’ Liability; Certain Bankruptcy Events
	  	 	48	  
	 Section 12.04
	 	 Releases
	  	 	48	  
	
	ARTICLE 13.	  
	AMENDMENTS	  
			
	 Section 13.01
	 	 Amendments
	  	 	49	  
	
	ARTICLE 14.	  
	MISCELLANEOUS	  
			
	 Section 14.01
	 	 Notices
	  	 	49	  
	 Section 14.02
	 	 Confidentiality
	  	 	50	  
	 Section 14.03
	 	 When Notes Are Disregarded
	  	 	52	  
	 Section 14.04
	 	 Deferral of Payments When Payment Date is Not a Business Day
	  	 	52	  
	 Section 14.05
	 	 Governing Law
	  	 	52	  
	 Section 14.06
	 	 No Recourse against Others
	  	 	52	  
	 Section 14.07
	 	 Successors
	  	 	52	  
	 Section 14.08
	 	 Multiple Originals
	  	 	52	  
	 Section 14.09
	 	 Indemnification
	  	 	52	  
	 Section 14.10
	 	 Waiver of Consequential and Punitive Damages
	  	 	52	  
	 Section 14.11
	 	 Table of Contents; Headings
	  	 	53	  
	 Section 14.12
	 	 Severability Clause
	  	 	53	  
	 Section 14.13
	 	 Calculations
	  	 	53	  
	 Section 14.14
	 	 Waiver of Jury Trial
	  	 	53	  
	 Section 14.15
	 	 Consent to Jurisdiction
	  	 	53	  
	 Section 14.16
	 	 Tax Forms
	  	 	53	  
			
	 Exhibits
	 		  			
			
	 Exhibit A
	 	 Form of Note
	  			
	 Exhibit B
	 	 Form of Restricted Stock Legend
	  			
	 Exhibit C
	 	 Form of Closing Date Certificate
	  			

  
 -iii- 

 SENIOR CONVERTIBLE NOTE PURCHASE AGREEMENT (this “Agreement”), dated as of
February 29, 2016 (the “Closing Date”) among Coherus BioSciences, Inc., a Delaware corporation, as Issuer (the “Company”), InteKrin Therapeutics Inc., a Delaware corporation, and Coherus Intermediate Corp., a
Delaware corporation, as the Guarantors (as defined below), and HealthCare Royalty Partners III, L.P., MX II Associates LLC, KMG Capital Partners, LLC and KKR Biosimilar L.P. (each, an “Investor,” and, collectively, the
“Investors”). 
 RECITALS OF THE COMPANY 

WHEREAS, the Company has duly authorized the issuance of its 8.2% Senior Convertible Notes due 2022 (each a “Note” and,
collectively, the “Notes”), representing its unsecured and general, senior unsubordinated obligations, and guaranteed by the Guarantors in the manner hereinafter set forth, and to provide therefor, the Company has duly authorized
the execution and delivery of this Agreement; and 
 WHEREAS, the Company has agreed to issue the Notes to the Investors in exchange for the
payment by the Investors to the Company of the Purchase Price (as defined below) and subject to the other terms set forth herein. 
 NOW,
THEREFORE, THIS AGREEMENT WITNESSETH, for and in consideration of the premises and the purchases of the Notes by the respective Investors thereof, it is mutually agreed, for the benefit of the Company and the ratable benefit of such Investors (and
any subsequent Holder (as defined below)), as follows: 
 ARTICLE 1. 

DEFINITIONS AND OTHER PROVISIONS OF GENERAL APPLICATION 

Section 1.01 Definitions. For all purposes of this Agreement, except as otherwise expressly provided or unless the context
otherwise requires: 
 (i) the terms defined in this Article 1 have the meanings assigned to them in this Article and include
the plural as well as the singular; 
 (ii) “or” is not exclusive; 

(iii) references to “dollars” or “$” refer to U.S. dollars; 

(iv) references to “interest” that accrues on any Note includes Stated Interest and, if applicable, Additional
Interest and Special Interest; 
 (v) all accounting terms not otherwise defined herein have the meanings assigned to them in
accordance with GAAP; and 
 (vi) the words “herein,” “hereof” and “hereunder” and other words
of similar import refer to this Agreement as a whole and not to any particular Article, Section or other subdivision of this Agreement. 

“Additional Interest” means any interest that accrues on any Note pursuant to Section 11.05. 

“Affiliate” means any Person that directly, or indirectly through one or more intermediaries, controls, is controlled by, or
is under common control with another Person. For the purposes of this definition, “control,” when used with respect to any specified Person means the power to direct or cause the direction of the management and policies of such Person,
directly or indirectly, whether through ownership of voting securities, by contract or otherwise; and the terms “controlling” and “controlled” have meanings correlative to the foregoing. For purposes of Section 8.01(j) only,
the term “Affiliate” shall not include Cowen Group, Inc. and its subsidiaries other than HealthCare Royalty Management and the investment vehicles managed by it. 

 “Agreement” means this Senior Convertible Note Purchase Agreement as originally
executed or as it may from time to time be supplemented or amended by one or more agreements supplemental hereto entered into pursuant to the applicable provisions hereof. 

“Allowable Black-Out Period” has the meaning specified in Section 11.04. 

“Average Life” means, as of any date, with respect to any Indebtedness, an amount equal to (a) the sum of the product of
(x) the number of years (rounded to the nearest one-twelfth (1/12th) of one year) from such date to the dates of each successive scheduled principal payment of such Indebtedness or mandatory redemption; and (y) the amount of such
payment, divided by (b) the sum of all such payments. 
 “Bankruptcy Code” means Title 11 of the United States
Code entitled “Bankruptcy,” as now or hereinafter in effect, or any successor statute. 
 “Benefited Party” has
the meaning specified in Section 12.01(a). 
 “Black-Out Period” has the meaning specified in Section 11.04. 

“Board of Directors” means the board of directors of the Company or any committee thereof duly authorized to act on behalf of
such board. 
 “Business Day” means any day other than a Saturday, a Sunday or a day on which the Federal Reserve Bank of
New York is authorized or required by law or executive order to close or be closed. 
 “Capital Stock” means, with respect
to any Person, any and all shares, interests, rights to purchase, warrants, options, participations or other equivalents, including membership interests (however designated, whether voting or nonvoting), of equity of such Person, including, if such
Person is a partnership, partnership interests (whether general or limited) and any other interest or participation that confers on a Person the right to receive a share of the profits and losses of, or distributions of property of, such
partnership, whether outstanding on the date hereof or issued after the Closing Date; provided, however, that Capital Stock will not include any Indebtedness that is convertible into or exchangeable for (x) any such equity or
(y) any combination of such equity and cash based on the value of such equity. 
 “Close of Business” means 5:00 p.m.
New York City time. 
 “Closing Date” has the meaning specified in the preamble of this Agreement. 

“Commission” means the Securities and Exchange Commission, as from time to time constituted or created under the Exchange
Act. 
 “Common Equity” means the Capital Stock of any Person that is generally entitled (a) to vote in the election
of the directors of such Person or (b) if such Person is not a corporation, to vote or otherwise participate in the selection of the governing body, partners, managers or others that will control the management and policies of such Person. 

“Common Stock” means the shares of common stock, $0.0001 par value per share, of the Company as they exist on the date of
this Agreement, subject to the provisions of Section 7.05. 
 “Common Stock Change Event” has the meaning specified in
Section 7.05. 
 “Company” means the Person named as the “Company” in the preamble of this Agreement until a
successor Person shall have become such pursuant to the applicable provisions of this Agreement, and thereafter “Company” shall mean such successor Person. 

  
 -2- 

 “Confidential Information” means any and all information, whether communicated
orally or in any physical form, including, without limitation, financial and all other information which Disclosing Party or its authorized Representatives provide to the Recipient, together with such portions of analyses, compilations, studies or
other documents, prepared by or for the Recipient and its Representatives, which contain or are derived from information provided by Disclosing Party or its authorized Representative. Without limiting the foregoing, information shall be deemed to be
provided by the Disclosing Party or its authorized Representative to the extent it is learned or derived by the Recipient or its Representatives (a) from any inspection, examination or other review of books, records, contracts, other
documentation or operations of the Disclosing Party or its authorized Representative, (b) from communications with the Disclosing Party or it Representatives or (c) created, developed, gathered, prepared or otherwise derived by the
Recipient or its Representatives while in discussions with the Disclosing Party or its Representatives. However, Confidential Information does not include any information which the Recipient can demonstrate (i) is or becomes part of the public
domain through no fault of Recipient or its Representatives, (ii) was known by the Recipient on a non-confidential basis prior to disclosure by the Disclosing Party or its Representatives, or (iii) was independently developed by Persons
who were not given access to the Confidential Information disclosed to Recipient by the Disclosing Party or its Representatives. For purposes of this Agreement, the party disclosing the Confidential Information shall be referred to as
“Disclosing Party” and the party receiving the Confidential Information shall be referred to as the “Recipient.” 

“Conversion Date” has the meaning specified in Section 7.02(a). 

“Conversion Price” means, as of any time, an amount equal to (a) one thousand dollars ($1,000) divided by
(b) the Conversion Rate in effect at such time. 
 “Conversion Rate” means initially 44.7387 shares of Common Stock
per $1,000 Principal Amount of Notes, subject to adjustment as set forth herein. Whenever this Agreement refers to the Conversion Rate as of a particular date without setting forth a particular time on such date, such reference will be deemed to be
to the Conversion Rate as of the Close of Business on such date. 
 “Credit Parties” means the Company and the Guarantors.

 “Default” means any event that is or with the passage of time or the giving of notice or both would become an Event of
Default. 
 “Default Interest” has the meaning specified in Section 4.01. 

“Delay Payments” has the meaning specified in Section 11.04. 

“Demand” has the meaning specified in Section 11.01. 

“Designated Counsel” has the meaning specified in Section 11.03(k). 

“Disclosing Party” has the meaning specified in the definition of “Confidential Information.” 

“Disqualified Capital Stock” of any Person means any class of Capital Stock of such Person that, by its terms, or by the
terms of any related agreement or of any security into which it is convertible or exchangeable, is, or upon the happening of any event (other than a Fundamental Change or similar event) or the passage of time would be, required to be redeemed by
such Person, at the option of the holder thereof, or matures or is mandatorily redeemable, pursuant to a sinking fund obligation or otherwise, in whole or in part, on or prior to the date which is 91 days after the Maturity Date; provided,
however, that any class of Capital Stock of such Person that, by its terms, authorizes such Person to satisfy in full its obligations with respect to the payment of dividends or upon maturity, redemption (pursuant to a sinking fund or
otherwise) or repurchase thereof or otherwise by the delivery of Capital Stock that is not Disqualified Capital Stock, and that is not convertible or exchangeable for Disqualified Capital Stock or Indebtedness, will not be deemed to be Disqualified
Capital Stock so long as such Person satisfies such obligations solely by the delivery of Capital Stock that is not Disqualified Capital Stock. 

  
 -3- 

 “Distributed Property” has the meaning specified in Section 7.04(c). 

“Effective Date” means, for any Registration Statement, the date that such Registration Statement has become effective under
the Securities Act. 
 “Effectiveness Failure” has the meaning specified in Section 11.04. 

“Eligible Market” means the New York Stock Exchange, The NASDAQ Global Market or The NASDAQ Global Select Market (or any of
their respective successors). 
 “Equity Interest” means, with respect to any Person, the Capital Stock of such Person and
all warrants, options or other rights to acquire the Capital Stock of such Person; provided, however, that Equity Interests will not include any Indebtedness that is convertible into or exchangeable for (x) any such Capital Stock
or (y) any combination of such Capital Stock and cash based on the value of such Capital Stock. 
 “Event of Default”
has the meaning specified in Section 9.01. 
 “Ex-Dividend Date” means, with respect to a issuance, dividend or
distribution on the Common Stock, the first date on which the shares of Common Stock trade on the applicable exchange or in the applicable market, regular way, without the right to receive such issuance, dividend or distribution in question, from
the Company or, if applicable, from the seller of the shares of Common Stock on such exchange or market (in the form of due bills or otherwise) as determined by such exchange or market. For the avoidance of doubt, any alternative trading convention
on the applicable exchange or market in respect of the Common Stock under a separate ticker symbol or CUSIP number will not be considered “regular way” for this purpose. 

“Exchange Act” means the U.S. Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated
thereunder. 
 “Expiration Date” has the meaning specified in Section 7.04(e). 

“Expiration Time” has the meaning specified in Section 7.04(e). 

“FCPA” means the Foreign Corrupt Practices Act of 1977, as amended, and the rules and regulations thereunder. 

“FDA” means the United States Food and Drug Administration. 

“Foreign Subsidiary” means a Subsidiary of the Company that is organized under the laws of a jurisdiction other than the
United States or any state thereof of the District of Columbia. 
 “Fundamental Change” means: 

(a) any “person” or “group” (within the meaning of Sections 13(d)(3) or 14(d)(2) of the Exchange Act),
other than the Company or its Wholly Owned Subsidiaries, or their respective employee benefit plans, files any report with the Commission indicating that such person or group is or has become the direct or indirect “beneficial owner” (as
defined in Rule 13d-3 under the Exchange Act) of more than fifty percent (50%) of the voting power of the Company’s Common Equity then outstanding; 

(b) the consummation of (i) any recapitalization, reclassification or change of the Common Stock (other than changes
resulting from a subdivision, combination or change in par value) as a result of which the Common Stock would be converted into, or exchanged for, stock, other securities or other property or assets; (ii) any share exchange, consolidation or
merger of the Company pursuant to which the Common Stock will be converted into cash, securities or other property or assets; or (iii) any sale, lease or other transfer, in one transaction or a series of transactions, of all or substantially
all of the consolidated assets of the Company and its Subsidiaries, taken as a whole, to any Person other than one of the 

  
 -4- 

 
Company’s direct or indirect Wholly Owned Subsidiaries; provided, however, that a transaction described in clause (ii) in which the holders of all classes of the
Company’s Common Equity immediately prior to such transaction own, directly or indirectly, more than fifty percent (50%) of all classes of Common Equity of the continuing or surviving corporation or transferee or the parent thereof
immediately after such transaction in substantially the same proportions (relative to each other) as such ownership immediately prior to such transaction shall not be a Fundamental Change pursuant to this clause (b); 

(c) the stockholders of the Company approve any plan or proposal for the liquidation or dissolution of the Company (other than
in connection with a transaction described in clause (b) above); or 
 (d) the Common Stock (or other common stock, if
any, then underlying the Notes) ceases to be listed or quoted on an Eligible Market and are not promptly re-listed or re-quoted on an Eligible Market. 

A transaction or transactions described in clause (a) or clause (b) above will not constitute a Fundamental Change, however, if at
least ninety percent (90%) of the consideration received or to be received by the holders of the Company’s Common Equity, excluding cash payments for fractional shares or pursuant to statutory appraisal rates, in connection with such
transaction or transactions consist of shares of common stock, depositary receipts representing Common Equity or other certificates representing Common Equity, in each case, that are listed or quoted on any Eligible Market or will be so listed or
quoted when issued or exchanged in connection with such transaction or transactions and, as a result of such transaction or transactions, the Notes become convertible into such consideration, excluding cash payments for fractional shares or pursuant
to statutory appraisal rights. 
 “Fundamental Change Company Notice” has the meaning specified in Section 4.04(c).

 “Fundamental Change Repurchase Date” has the meaning specified in Section 4.04(a). 

“Fundamental Change Repurchase Notice” has the meaning specified in Section 4.04(b)(i). 

“Fundamental Change Repurchase Price” has the meaning specified in Section 4.04(a). 

“GAAP” means generally accepted accounting principles set forth in the opinions and pronouncements of the Accounting
Principles Board of the American Institute of Certified Public Accountants and statements and pronouncements of the Financial Accounting Standards Board or in such other statements by such other entity as have been approved by a significant segment
of the accounting profession, which are in effect from time to time. 
 “Governmental Authority” means any nation or
government, any state or other political subdivision thereof, and any entity exercising executive, legislative, judicial, regulatory or administrative functions of, or pertaining to, government. 

The term “guarantee” means a guarantee (other than by endorsement of negotiable instruments for collection in the ordinary
course of business), direct or indirect, in any manner, including, without limitation, by way of a pledge of assets or through letters of credit or reimbursement agreements in respect thereof, of all or any part of any Indebtedness (whether arising
by virtue of partnership arrangements or by agreements to keep-well, to purchase assets, goods, securities or services, to take or pay or to maintain financial statement conditions or otherwise). 

“Guarantee” means the full and unconditional guarantee provided by the Guarantors in respect of the Notes as made applicable
to the Notes in accordance with the provisions of Section 12.01. 
 “Guarantee Obligations” has the meaning specified
in Section 12.01. 
 “Guarantor” means the Persons named as such in the first paragraph of this Agreement, each other
Person that becomes a Guarantor by executing an amendment or supplement to this Agreement pursuant to Section 12.01(c), and the successors and assigns of the foregoing. 

“HCR Investor” means HealthCare Royalty Partners III, L.P. 

  
 -5- 

 “Hedging and Short Sales” means all “short sales” as defined in Rule
200 of Regulation SHO under the Exchange Act and all types of forward sale contracts, options, puts, calls, short sales, swaps, derivatives and similar arrangements (including on a total return basis). 

“Holder” means a person in whose name a Note is registered on the Register; provided, however, that, solely for
purposes of Article 11, Holder means a person in whose name any Registrable Security is registered on the books of the Company or its transfer agent. 

“HSR Act” means the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended. 

“Indebtedness” with respect to any Person means any amount (absolute or contingent) payable by such Person as debtor,
borrower, issuer, guarantor or otherwise (a) pursuant to an agreement or instrument involving or evidencing money borrowed, the advance of credit, a conditional sale or a transfer with recourse or with an obligation to repurchase or evidenced
by a promissory note, bond, debenture or similar instrument, (b) pursuant to a capital lease with substantially the same economic effect as any such agreement or instrument, (c) any obligations of the issuer thereof with respect to
Disqualified Capital Stock, (d) pursuant to indebtedness of a third party secured by (or for which the holder of such indebtedness has an existing right, contingent or otherwise, to be secured by) any Lien on assets owned or acquired by such
Person, whether or not the indebtedness secured thereby has been assumed, (e) pursuant to an interest rate protection agreement, foreign currency exchange agreement or other hedging arrangement, (f) pursuant to a letter of credit issued
for the account of such Person, or (g) all guarantees by such Person with respect to Indebtedness of the types specified in clauses (a) through (f) above of another Person. For the avoidance of doubt, the Indebtedness of any Person
shall include the Indebtedness of any other entity to the extent such Person is directly liable therefor as a result of such Person’s ownership interest in or other relationship with such entity, except to the extent the terms of such
Indebtedness provide that such Person is not liable therefor. 
 “Indemnified Liabilities” means, collectively, any and all
liabilities, obligations, losses, damages, penalties, claims, costs, expenses and disbursements of any kind or nature whatsoever (including the reasonable fees and disbursements of counsel of each Indemnified Party in connection with any
investigative, administrative or judicial proceeding commenced or threatened by any Person, whether or not any such Indemnified Party shall be designated as a party or a potential party thereto, and any fees or expenses actually incurred by any such
Indemnified Party in enforcing the indemnity provided herein), whether direct, indirect or consequential and whether based on any federal, state or foreign laws, statutes, rules or regulations (including securities and commercial laws, statutes,
rules or regulations), on common law or equitable cause or on contract or otherwise, imposed on, incurred by, or asserted against any such Indemnified Party, in any manner relating to or arising out of this Agreement or the Note Documents or the
transactions contemplated hereby or thereby (including any enforcement of any of the Note Documents). 
 “Indemnified
Party” means each Investor and its Affiliates. 
 “Initial Notes” has the meaning specified in Section 3.01.

 “Interest Payment Date” means, with respect to each Note, each of
March 31, June 30, September 30 and December 31 of each year, commencing on the date set forth in the certificate representing such Note. 

“Investor” and “Investors” have the meaning specified in the preamble of this Agreement. 

“Last Reported Sale Price” of the Common Stock for any Trading Day means the closing sale price per share (or, if no closing
sale price is reported, the average of the last bid price and the last ask price per share or, if more than one in either case, the average of the average last bid prices and the average last ask prices per share) of Common Stock on such Trading Day
as reported in composite transactions for the principal U.S. national or regional securities exchange on which the Common Stock is then listed. If the Common Stock is not listed on a U.S. national or regional securities exchange on such Trading Day,
then the Last Reported Sale Price will be the last quoted bid price per share of Common Stock on such Trading Day in the over-the-counter market as reported by OTC Markets Group Inc. or a similar organization. If the Common Stock is not so quoted on
such Trading Day, then the Last Reported Sale Price will be the average of the mid-point of the last bid price and the last ask price per share of Common Stock on such Trading Day from an investment banking firm selected by the Company. 

  
 -6- 

 “Lien” means any mortgage or deed of trust, pledge, hypothecation, lien, charge,
attachment, setoff, encumbrance or other security interest in the nature thereof (including any conditional sale agreement, equipment trust agreement or other title retention agreement, a lease with substantially the same economic effect as any such
agreement) or other encumbrance of a similar nature. 
 “Maintenance Failure” has the meaning specified in
Section 11.04. 
 “Make-Whole Fundamental Change” means any transaction or event that constitutes a Fundamental Change
(as defined above and determined after giving effect to any exceptions to or exclusions from such definition, but without regard to the proviso in clause (b) of the definition thereof). 

“Make-Whole Fundamental Change Period” has the meaning specified in Section 7.07(a). 

“Market Disruption Event” means, with respect to any date, the occurrence or existence, during the one-half hour period
ending at the scheduled close of trading on such date on the principal U.S. national or regional securities exchange or other market on which the Common Stock is listed for trading or trades, of any material suspension or limitation imposed on
trading (by reason of movements in price exceeding limits permitted by the relevant exchange or otherwise) in the Common Stock or in any options, contracts or future contracts relating to the Common Stock. 

“Material Adverse Effect” means (a) a material adverse change in the business, operations, prospects, properties,
liabilities, results of operations or condition (financial or other) of the Company and the other Credit Parties, taken as a whole; (b) a material adverse effect on the validity or enforceability of the Note Documents or an adverse effect on
the validity or enforceability of any material provision thereof; (c) a material adverse effect on the ability of the Company or any other Credit Party to consummate the transactions contemplated by the Note Documents or on the ability of the
Company or any of the other Credit Parties to perform its obligations under the Note Documents; (d) a material adverse effect on the rights or remedies of the Holder under any of Note Documents; and (e) a material adverse effect on the
right of the Holders to receive the interest or any other payment due under the Note Documents. 
 “Material Contract”
means any agreement, contract or other instrument pursuant to which the Company or any of its Subsidiaries is a party or any of the respective assets or properties of the Company or any of its Subsidiaries are bound or committed and for which any
breach, violation, nonperformance or early cancellation could reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect. 

“Material Domestic Subsidiary” of any Person means any Subsidiary of such Person that is organized and existing under the
laws of the United States of America, any State thereof or the District of Columbia and has gross assets of at least two million five hundred thousand dollars ($2,500,000). 

“Maturity Date” means March 31, 2022. 

“Notes” has the meaning specified in the first paragraph of the Recitals hereof, and includes any Note or Notes, as the case
may be, delivered under this Agreement. 
 “Note Documents” means this Agreement and the Notes. 

“Notice of Default” means written notice provided to the Company by the Holders of a Default by the Company, which notice
must specify the Default, demand that it be remedied and expressly state that such notice is a “Notice of Default.” 

“Open of Business” means 9:00 a.m., New York City time. 

  
 -7- 

 “Other Connection Taxes” means, with respect to any person, Taxes imposed as a
result of a present or former connection between such person and the jurisdiction imposing such Tax (other than connections arising from such person having executed, delivered, become a party to, performed its obligations under, received payments
under, received or perfected a security interest under, engaged in any other transaction pursuant to or enforced this Agreement or any Note, or sold or assigned an interest in this Agreement or any Note). 

“Party” means the Company, any Guarantor or any Holder; and “Parties” means the Company, the Guarantors and
the Holders. 
 “Payment Default” has the meaning specified in Section 4.01. 

“Permitted Refinancing Indebtedness” means any Indebtedness that Refinances any other Indebtedness, including any successive
Refinancings, so long as (a) such Refinancing Indebtedness is an aggregate principal amount (or if incurred with original issue discount, an aggregate issue price) not in excess of the sum of (x) the aggregate principal amount (or if
incurred with original issue discount, the aggregate accreted value) then outstanding of the Indebtedness being Refinanced; and (y) an amount necessary to pay any fees and expenses, including premiums and defeasance costs, related to such
Refinancing(s); (b) the Average Life of such Refinancing Indebtedness is equal to or greater than the Average Life of the Indebtedness being Refinanced; (c) the Stated Maturity of such Refinancing Indebtedness is no earlier than the Stated
Maturity of the Indebtedness being Refinanced; and (d) such Refinancing Indebtedness is not senior in right of payment to the Indebtedness that is being Refinanced. 

“Person” means any individual, corporation, partnership, joint venture, association, joint-stock company, trust,
unincorporated organization, limited liability company or government or other entity. 
 “Principal Amount” of a Note means
the principal amount as set forth on the face of the Note. 
 “Purchase Price” has the meaning specified in
Section 2.01(b). 
 “Recipient” has the meaning specified in the definition of “Confidential Information.”

 “Record Date” means, with respect to any dividend, distribution or other transaction or event in which the holders of
the Common Stock have the right to receive any cash, securities or other property or in which the Common Stock is exchanged for or converted into cash, securities or other property, the date fixed for determination of holders of the Common Stock
entitled to receive such cash, securities or other property (whether such date is fixed by the Board of Directors, statute or contract or otherwise). 

“Redemption” means the repurchase of any Note by the Company pursuant to Article 5. 

“Redemption Date” means the date fixed for the repurchase of any Notes by the Company pursuant to a Redemption. 

“Redemption Notice” has the meaning set forth in Section 5.06. 

“Redemption Notice Date” means, with respect to a Redemption, the date on which the Company sends the Redemption Notice for
such Redemption pursuant to Section 5.06. 
 “Redemption Price” means the cash price payable by the Company to redeem
any Note upon its Redemption, calculated pursuant to Section 5.05. 
 “Reference Property” has the meaning specified
in Section 7.05. 
 “Reference Property Unit” has the meaning specified in Section 7.05. 

  
 -8- 

 “Refinance” means, with respect to any specified Indebtedness, to refinance,
extend, renew, refund or repay or to issue other Indebtedness in exchange or replacement for such specified Indebtedness. “Refinanced” and “Refinancing” have meanings correlative to the foregoing. 

“Register” has the meaning specified in Section 3.05. 

“Registrable Securities” means, shares of Common Stock actually issued upon conversion of the Notes, which shares of Common
Stock are both held by, and proposed to be sold in a registered offering by, the converting Holder. Registrable Securities will continue to be Registrable Securities until the first time at which they (a) are sold pursuant to an effective
registration statement under the Securities Act, (b) are sold pursuant to Rule 144, or (c) they have otherwise been transferred and new securities not subject to transfer restrictions under any federal securities laws and not bearing any
legend substantially similar to a Restricted Stock Legend will have been delivered by the Company. 
 “Registration
Statement” means a Registration Statement of the Company required to be filed pursuant to Section 11.01 under the Securities Act covering the Registrable Securities. 

“Regular Record Date” means, with respect to any Interest Payment Date, the
March 15, June 15, September 15 or December 15, as the case may be, immediately preceding such Interest Payment Date. 

“Reimbursable Investor Expenses” means the actual, documented, out-of-pocket fees and expenses of the HCR Investor or KKR
Biosimilar L.P., as applicable (including, without limitation, legal fees and expenses incurred in connection with such Investor’s due diligence investigation), in connection with the negotiation, preparation and execution of this Agreement, in
each case incurred on or prior to the Closing Date. 
 “Repayment Premium” means, as of any date on which the Company is
obligated hereunder to repurchase any Notes or any Notes otherwise become due and payable (including, without limitation, on the Maturity Date), other than solely upon the conversion of such Notes, a premium equal to nine percent (9%) of the
Principal Amount thereof. 
 “Reporting Event of Default” has the meaning specified in Section 9.02(a). 

“Representative” means, with respect to any Person, any stockholder, member, partner, manager, director, officer, employee,
agent, advisor or other representative of such Person. 
 “Requesting Holder” has the meaning specified in
Section 11.01. 
 “Restricted Note” has the meaning specified in Section 3.06(a)(i). 

“Restricted Notes Legend” means a legend substantially in the form of Note set forth in Section 2.02. 

“Restricted Payment” means any dividend or other distribution (whether in cash, securities or other property) with respect to
any Equity Interest in the Company or its Subsidiaries, or any payment (whether in cash, securities or other property), including any sinking fund or similar deposit, on account of the purchase, redemption, retirement, acquisition, cancellation or
termination of any such Equity Interest of the Company or its Subsidiaries; provided, however, that the following will not constitute a Restricted Payment: (a) a dividend, distribution or payment consisting solely of, or made
solely with the net cash proceeds of a substantially concurrent sale of, Equity Interests of the Company (other than Disqualified Capital Stock); (b) the repurchase of any Equity Interests deemed to occur upon the exercise of stock options or
similar instruments to the extent such Equity Interests represent a portion of the exercise price of such stock options or interests; (c) the payment of cash in lieu of issuing or delivering any fractional share of Common Stock or other Equity
Interest; (d) any Dividend or distribution by a Subsidiary of the Company on its Equity Interests; and (e) any other dividend, distribution or payment that does not exceed fifteen million dollars ($15,000,000) in the aggregate since the
date of this Agreement. 
 “Restricted Stock” has the meaning specified in Section 3.06(b)(i). 

  
 -9- 

 “Restricted Stock Legend” means a legend substantially in the form set forth in
Exhibit B hereto. 
 “Rule 144” means Rule 144 under the Securities Act (including any successor rule thereto), as
the same may be amended from time to time. 
 “Securities Act” means the U.S. Securities Act of 1933, as amended, and the
rules and regulations of the Commission promulgated thereunder. 
 “Selling Expenses” shall mean all underwriting
discounts, selling commissions and stock transfer taxes applicable to the sale of Registrable Securities and all fees and disbursements of counsel for any Holder (other than the reasonable fees and disbursements of Designated Counsel to be paid by
the Company pursuant to Section 11.03(k)) (which shall, in any event, be paid by such Holder). 
 “Shelf Offering” has
the meaning specified in Section 11.01. 
 “Significant Subsidiary” has the meaning specified in Rule 1-02(w) of
Regulation S-X under the Securities Act. 
 “Special Interest” means any interest that accrues on any Note pursuant to
Section 9.02. 
 “Spin-Off” has the meaning specified in Section 7.04(c). 

“Spin-Off Valuation Period” has the meaning set forth in 0. 

“Stated Interest” has the meaning specified in Section 4.01. 

“Stated Maturity” means, with respect to any installment of interest or principal on any series of Indebtedness, the date on
which the payment of interest or principal was scheduled to be paid in the documentation governing such Indebtedness, and will not include any contingent obligations to repay, redeem or repurchase any such interest or principal prior to the date
originally scheduled for the payment thereof. 
 “Stock Price” has the meaning specified in Section 7.07(c). 

“Subsidiary” means, with respect to any Person: 

(a) any corporation, association or other business entity of which more than 50% of the total voting power of shares of Capital
Stock entitled (without regard to the occurrence of any contingency and after giving effect to any voting agreement or stockholders’ agreement that effectively transfers voting power) to vote in the election of directors, managers or trustees
of the corporation, association or other business entity is at the time owned or controlled, directly or indirectly, by such Person or one or more of the other Subsidiaries of such Person (or a combination thereof); and 

(b) any partnership or limited liability company of which (i) more than 50% of the capital accounts, distribution rights,
total equity and voting interests or general and limited partnership interests, as applicable, are owned or controlled, directly or indirectly, by such Person or one or more of the other Subsidiaries of such Person or a combination thereof, whether
in the form of membership, general, special or limited partnership interests or otherwise, and (ii) such Person or any Subsidiary of such Person is a controlling general partner or otherwise controls such entity. 

“Successor Company” has the meaning specified in Section 10.01(a). 

“Tax Return” shall mean all original, amended or estimated returns, statements, filings, attachments and other documents or
certifications filed or required to be filed in respect of Taxes. 

  
 -10- 

 “Taxes” shall mean all present or future taxes, levies, imposts, duties,
deductions, withholdings, assessments, fees or other charges imposed by any Governmental Authority, including any interest, additions to tax or penalties applicable thereto. 

“Tender/Exchange Offer Valuation Period” has the meaning specified in Section 7.04(e). 

“Trading Day” means any day on which (i) trading in the Common Stock generally occurs on the principal U.S. national or
regional securities exchange on which the Common Stock is then listed or, if the Common Stock is not then listed on a U.S. national or regional securities exchange, on the principal other market on which the Common Stock is then traded, and
(ii) there is no Market Disruption Event. If the Common Stock is not so listed or traded, then “Trading Day” means a Business Day. 

“U.S.” means the United States of America. 

“Underwritten Offering” has the meaning specified in Section 11.01. 

“Wholly Owned Subsidiary” means, with respect to a Person, a Subsidiary of such Person all of the outstanding Capital Stock
or other ownership interests of which (other than directors’ qualifying shares) are owned by such Person or by one or more Wholly Owned Subsidiaries of such Person. 

Section 1.02 Acts of Holder; Record Dates. Any request, demand, authorization, direction, notice, consent, waiver or other
act of the Holder of any Note shall bind every future Holder of the same Note and the Holder of every Note issued upon the registration of transfer thereof or in exchange therefor or in lieu thereof in respect of anything done, omitted or suffered
to be done by the Company in reliance thereon, whether or not notation of such action is made upon such Note. 
 Section 1.03 Effect
of Headings and Table of Contents. The Article and Section headings herein and the Table of Contents are for convenience only and shall not affect the construction hereof, and all Article and Section references are to Articles and
Sections, respectively, of this Agreement unless otherwise expressly stated. 
 Section 1.04 Successors and Assigns. All
covenants and agreements in this Agreement by the Company or the Holders, as applicable, shall bind its successors and assigns, whether so expressed or not. 

Section 1.05 Severability Clause. In case any provision in this Agreement or in the Notes shall be invalid, illegal or
unenforceable, the validity, legality and enforceability of the remaining provisions shall not in any way be affected or impaired thereby. 

Section 1.06 Benefits of Agreement. Nothing in this Agreement or in the Notes, express or implied, shall give to any
Person, other than the parties hereto, their respective successors hereunder, any Holder and the persons, entities specifically referenced in Section 11.07 any benefit or any legal or equitable right, remedy or claim under this Agreement;
provided, however, that no right of any Investor, as such, hereunder, will inure to the benefit of any Holder, as such, that is not an Investor. 

ARTICLE 2. 
 PURCHASE AND ISSUANCE
OF NOTES 
 Section 2.01 Purchase and Sale. 

(a) Upon the terms and subject to the conditions of this Agreement, on the basis of the representations and warranties hereby contained, the
Company agrees to issue and sell to each Investor, and each Investor, severally and not jointly, agrees to purchase from the Company upon the satisfaction of the conditions set forth in Section 6.01, a Note having the Principal Amount, and at
the cash Purchase Price, payable immediately available funds, in an amount, set forth in Section 2.01(b) below, in each case on the Closing Date. 

  
 -11- 

 (b) The purchase price (the “Purchase Price”) payable by each Holder on the
Closing Date and the aggregate Principal Amount of Notes issuable by the Company on the Closing Date to such Holder, in each case upon the terms and subject to the conditions of this Agreement, are set forth below: 

(i) for HCR Investor, (x) the Purchase Price is seventy five million dollars ($75,000,000) less Reimbursable Investor
Expenses of three hundred and twenty nine thousand three hundred and sixty one dollars ($329,361) for such Investor, and (y) the Principal Amount is seventy five million dollars ($75,000,000); 

(ii) for MX II Associates LLC, (x) the Purchase Price is four million dollars ($4,000,000), and (y) the Principal
Amount is four million dollars ($4,000,000); 
 (iii) for KMG Capital Partners, LLC, (x) the Purchase Price is one
million dollars ($1,000,000), and (y) the Principal Amount is one million dollars ($1,000,000); 
 (iv) for KKR
Biosimilar L.P., (x) the Purchase Price is twenty million dollars ($20,000,000) less Reimbursable Investor Expenses of twenty four thousand seven hundred and fifty dollars ($24,750) for such Investor, and (y) the Principal Amount is twenty
million dollars ($20,000,000). 
 (c) The Notes shall initially be issued in the form of permanent Notes in registered form in substantially
the form set forth in this Article. 
 Section 2.02 Form of Notes. The Notes shall be substantially in the form set forth
in Exhibit A, the terms and provisions of which shall constitute, and are hereby expressly incorporated in and made, a part of this Agreement. 

ARTICLE 3. 
 THE SECURITIES 

Section 3.01 Title and Terms; Payments. The aggregate Principal Amount of Notes that may be executed and delivered under this
Agreement is initially limited to $100,000,000 (the “Initial Notes”), except for Notes delivered upon registration or transfer of, or in exchange for, or in lieu of, other Notes pursuant to Sections 3.05, 3.07 or 3.09. 

The Notes shall be known and designated as the “8.2% Senior Convertible Notes due 2022” of the Company. The Principal Amount plus
the Repayment Premium of each outstanding Note shall be payable on the Maturity Date. 
 The principal of, and interest and premium on, the
Notes will be paid by wire transfer of immediately available funds to such Holder’s account within the United States, as designated by such Holder to the Company in writing at least five (5) calendar days prior to the applicable payment
date. 
 Any Notes repurchased by the Company will be retired and no longer outstanding hereunder. 

Section 3.02 Ranking. The Notes constitute general, senior unsubordinated obligations of the Company and are guaranteed by the
Guarantors to the extent provided in Article 12. 
 Section 3.03 Denominations. The Notes shall be issuable only in registered
form without coupons and in denominations of $1,000 and any integral multiple of $1,000 in excess thereof. 
 Section 3.04
Execution, Delivery and Dating. The Notes shall be executed on behalf of the Company by its Chief Executive Officer, its President or its Chief Financial Officer. 

  
 -12- 

 Notes bearing the manual or facsimile signatures of individuals who were, at the time of the
execution of such Notes, the proper officers of the Company shall bind the Company, notwithstanding that such individuals or any of them have thereafter ceased to hold such offices. 

Each Note shall be dated the date of its issuance. 

Section 3.05 Registration; Registration of Transfer and Exchange. The Company shall maintain a register (the
“Register”) in which, subject to such reasonable regulations as it may prescribe, the Company shall provide for the registration of Notes and of transfers of Notes. 

Subject to Section 3.06 and the other provisions of this Section 3.05, upon surrender for registration of transfer of any Note at an
office or agency of the Company designated pursuant to Section 4.02 for such purpose, the Company shall execute one or more new Notes of any authorized denominations and of a like aggregate Principal Amount and tenor, each such Note bearing
such restrictive legends as may be required by this Agreement. 
 All Notes issued upon any registration of transfer or exchange of Notes
shall be the valid obligations of the Company, evidencing the same debt, and entitled to the same benefits under this Agreement, as the Notes surrendered upon such registration of transfer or exchange. 

Every Note presented or surrendered for registration of transfer or for exchange shall (if so required by the Company) be duly endorsed, or be
accompanied by a written instrument of transfer in form satisfactory to the Company duly executed by the Holder thereof or his attorney duly authorized in writing. As a condition to the registration of transfer of any Notes, the Company may require
evidence satisfactory to them as to the compliance with the restrictions set forth in the legend on such Notes. 
 Section 3.06
Transfer Restrictions. 
 (a) Restricted Notes. 

(i) Every Note (and all securities issued in exchange therefor or substitution thereof) that bears, or that is required under
this Section 3.06 to bear, the Restricted Notes Legend will be deemed to be a “Restricted Note.” Each Restricted Note will be subject to the restrictions on transfer set forth in the Restricted Notes Legend unless such
restrictions on transfer are eliminated or otherwise waived by written consent of the Company, and each Holder of a Restricted Note, by such Holder’s acceptance of such Restricted Note, will be deemed to be bound by such restrictions on
transfer. 
 (ii) Any Note (or any security issued in exchange therefor or substitution thereof, except any shares of Common
Stock issued upon the conversion thereof) will bear the Restricted Notes Legend unless the Company reasonably determines that the Restricted Notes Legend may be removed from such Note. 

(b) Restricted Stock. 

(i) Every share of Common Stock that bears, or that is required under this Section 3.06 to bear, the Restricted Stock
Legend will be deemed to be “Restricted Stock.” Each share of Restricted Stock will be subject to the restrictions on transfer set forth in the Restricted Stock Legend unless such restrictions on transfer are eliminated or waived by
written consent of the Company, and each Holder of Restricted Stock, by such Holder’s acceptance of Restricted Stock, will be deemed to be bound by such restrictions on transfer. 

(ii) Any share of Common Stock issued upon the conversion of a Note will be issued in book entry form with the applicable
transfer agent, subject to the Restricted Stock Legend unless (A) covered by an effective registration statement under the Securities Act and a current prospectus naming as a selling stockholder the person to whom such share is issued or
(B) the Company reasonably determines that such share of Common Stock need not bear the Restricted Stock Legend or need not be issued in such format. 

  
 -13- 

 (c) As used in this Section 3.06, the term “transfer” means any sale,
pledge, hedging transaction, transfer, loan, hypothecation or other disposition whatsoever of any Restricted Note or Restricted Stock or any interest therein. 

Section 3.07 Mutilated, Destroyed, Lost and Stolen Notes. If any mutilated Note is surrendered to the Company, the Company shall
execute and deliver in exchange therefor a new Note of like tenor and Principal Amount and bearing an identification number not contemporaneously outstanding. 

If there shall be delivered to the Company (a) evidence to its satisfaction of the destruction, loss or theft of any Note and
(b) such security or indemnity as may be required by its to save it and any of its agents harmless, then, in the absence of notice to the Company that such Note has been acquired by a bona fide purchaser, the Company shall execute, in lieu of
any such destroyed, lost or stolen Note, a new Note of like tenor and Principal Amount and bearing an identification number not contemporaneously outstanding. 

In case any such mutilated, destroyed, lost or stolen Note has become or is about to become due and payable, the Company in its discretion
may, instead of issuing a new Note, pay such Note. 
 Upon the issuance of any new Note under this Section 3.07, the Company may
require payment by the relevant Holder of a sum sufficient to cover any tax or other governmental charge that may be imposed in relation thereto and any other expenses connected therewith. 

Every new Note issued pursuant to this Section 3.07 in lieu of any destroyed, lost or stolen Note shall constitute an original additional
contractual obligation of the Company, whether or not the destroyed, lost or stolen Note shall be at any time enforceable by anyone, and shall be entitled to all the benefits of this Agreement equally and proportionately with any and all other Notes
duly issued hereunder. 
 The provisions of this Section are exclusive and shall preclude (to the extent lawful) all other rights and
remedies with respect to the replacement or payment of mutilated, destroyed, lost or stolen Notes. 
 Section 3.08 Persons Deemed
Owners. Prior to due presentment of a Note for registration of transfer to the Company or any agent of the Company, the Company or such agent shall treat the Person in whose name such Note is registered as the owner of such Note for the purpose
of receiving payment of the principal of such Note and for all other purposes whatsoever, whether or not such Note be overdue, and neither the Company nor any agent of the Company shall be affected by notice to the contrary. 

Section 3.09 Transfer and Exchange. 

(a) Provisions Applicable to All Transfers and Exchanges. 

(i) Subject to the restrictions set forth in this Section 3.09 and elsewhere in this Agreement, Notes may be transferred
or exchanged from time to time as desired, and each such transfer or exchange will be noted by the Company in the Register. 

(ii) All Notes issued upon any registration of transfer or exchange in accordance with this Agreement will be the valid
obligations of the Company, evidencing the same debt, and entitled to the same benefits under this Agreement, as the Notes surrendered upon such registration of transfer or exchange. 

(iii) No service charge will be imposed on any Holder of a Note for any exchange or registration of transfer, but the Company
may require such Holder to pay a sum sufficient to cover any transfer tax that are Other Connection Taxes, assessment or other governmental charge imposed in connection with such registration of transfer or exchange to a person other than the
Company or its affiliates. 
 (iv) Unless the Company specifies otherwise, the Company will not be required to exchange or
register a transfer of any Note that has been surrendered for conversion or for which a Fundamental Change Repurchase Notice has been delivered or that is subject to Redemption, except to the extent any portion of such Note is not subject to the
foregoing. 

  
 -14- 

 (v) Notwithstanding anything to the contrary herein, no transfer or exchange of
any Note will be permitted without the prior written consent of the Company (not to be unreasonably withheld, conditioned or delayed). 

(b) Transfer and Exchange of Notes. 

(i) If a transfer of a Note is otherwise permitted hereunder, a Holder may transfer such Note by: (A) surrendering such
Note for registration of transfer to the Company, together with any endorsements or instruments of transfer required by the Company; (B) delivering any documentation that the Company requires to ensure that such transfer complies with
Section 3.05, Section 3.06 and any applicable securities laws; and (C) satisfying all other requirements for such transfer set forth in this Section 3.09 and in Section 3.05 and Section 3.06. Upon the satisfaction of
conditions (A), (B) and (C) above, the Company, in accordance with Section 3.04, will promptly execute and deliver, in the name of the designated transferee or transferees, one or more new Notes, of any authorized denominations,
having like aggregate Principal Amount and bearing any restrictive legends required by Section 3.06. 
 (ii) A Holder
may exchange a Note for other Notes of any authorized denominations and aggregate Principal Amount equal to the aggregate Principal Amount of the Notes to be exchanged by surrendering such Notes, together with any endorsements or instruments of
transfer required by the Company at any office or agency maintained by the Company for such purposes pursuant to Section 4.02. Whenever a Holder surrenders Notes for exchange, the Company, in accordance with Section 3.04, will promptly
execute and deliver the Notes that such Holder is entitled to receive, bearing identification numbers not contemporaneously outstanding and any restrictive legends that such Notes are to bear under Section 3.06. 

Section 3.10 Cancellation. The Company at any time may cancel any Notes previously delivered hereunder that the Company may have
acquired in any manner whatsoever. All Notes surrendered for registration of transfer, exchange, payment, purchase, repurchase, conversion (pursuant to Article 7) or cancellation will be subject to immediate cancellation by the Company. If the
Company shall acquire any of the Notes, such acquisition shall not operate as a redemption or satisfaction of the Indebtedness represented by such Notes unless and until the same are cancelled. The Notes so acquired, while held by or on behalf of
the Company or any of its Subsidiaries, shall not entitle the Holder thereof to convert the Notes. The Company may not issue new Notes to replace Notes it has paid in full or cancelled. 

Section 3.11 Outstanding Notes. 

(a) Generally. The Notes that are outstanding at any time will be deemed to be those Notes that, at such time, have been duly executed
and delivered, excluding those Notes (or portions thereof) that have theretofore been (i) delivered to the Company for cancellation in accordance with Section 3.10; (ii) paid in full in accordance herewith; or (iii) deemed to
cease to be outstanding to the extent provided in, and subject to, subsection (b), (c) or (d) of this Section 3.11. 
 (b)
Replaced Notes. If a Note is replaced pursuant to Section 3.07, then such Note will cease to be outstanding at the time of its replacement, unless the Company receives proof reasonably satisfactory to it that such Note is held by a bona
fide purchaser under applicable law. 
 (c) Maturing Notes and Notes Subject to Redemption or Repurchase. If the Company has caused
any Note to be (or portion thereof) repaid in full as provided herein, whether a Fundamental Change Repurchase Date, a Redemption Date, the Maturity Date or otherwise, then (i) such Notes (or portion thereof) will be deemed, as of the date of
such payment, to cease to be outstanding, and (ii) the rights of the Holders of such Notes (or such portion thereof), as such, will terminate with respect to such Notes (or such portion thereof), in each case subject to the right of Holders as
of the Close of Business on a Regular Record Date to receive interest as provided in Section 5.05 or Section 4.04(a), if applicable. 

  
 -15- 

 (d) Notes to Be Converted. At the Close of Business on the Conversion Date for any Note
(or any portion thereof) to be converted, such Note (or such portion) will (unless there occurs a Default in the delivery of the consideration due upon conversion or interest due upon such conversion) be deemed to cease to be outstanding, subject to
Section 7.03(d). 
 (e) Cessation of Accrual of Interest. Except as provided in Section 4.04(a) or 7.03(d), interest will
cease to accrue on each Note from, and including, the date that such Note is deemed, pursuant to this Section 3.11, to cease to be outstanding, unless there occurs a default in the payment or delivery of any cash or other property due on such
Note. 
 ARTICLE 4. 
 PARTICULAR
COVENANTS OF THE COMPANY 
 Section 4.01 Payment of Principal and Interest. The Company covenants and agrees that it shall duly
and punctually pay or cause to be paid the principal of, interest and premium on each of the Notes to the applicable Holder of the Notes at the places, at the respective times and in the manner provided herein and in the Notes. Each Note will accrue
interest at a rate per annum equal to 8.2% (the “Stated Interest”), plus any Special Interest, Additional Interest or Default Interest that may accrue pursuant to Section 9.02, Section 11.05 or this Section 4.01,
respectively. Stated Interest on each Note will (a) accrue from, and including, the most recent date to which Stated Interest has been paid or duly provided for (or, if no Stated Interest has theretofore been paid or duly provided for, the date
set forth in the certificate representing such Note as the date from, and including, which Stated Interest will begin to accrue in such circumstance) to, but excluding, the date of payment of such Stated Interest; and (b) be, except as
otherwise provided in this Agreement, payable quarterly in arrears on each Interest Payment Date, beginning on the first Interest Payment Date set forth in the certificate representing such Note, to the Holder of such Note as of the Close of
Business on the immediately preceding Regular Record Date. Interest on the Notes will be computed on the basis of a 360-day year comprised of twelve 30-day months. If the Maturity Date of a Note is not an Interest Payment Date, then the accrued and
unpaid interest on such Note to, but excluding, the Maturity Date will be paid, on the Maturity Date, to the Person to whom the Principal Amount and Repayment Premium of such Note is paid. Special Interest, Additional Interest and Default Interest,
if any, will accrue and be paid in the manner set forth in Section 9.02, Section 11.05 and this Section 4.01, respectively. 

To the extent that the payment of such interest shall be legally enforceable, upon the occurrence of and during the continuation of a Default
or Event of Default under Section 9.01(a) (a “Payment Default”), any principal of, or premium or installment of interest on, the Notes which is overdue shall bear interest at the rate of, in each case, five percent
(5.0%) per annum (“Default Interest”) in excess of the rate of interest then borne by the Notes from the date of such Payment Default until cured or waived, and such Default Interest shall be payable in cash on each succeeding
Interest Payment Date. 
 Section 4.02 Maintenance of Office or Agency. The Company shall maintain an office or agency in the
United States, where the Notes may be surrendered for registration of transfer or exchange or for presentation for payment or for conversion and where notices and demands to or upon the Company in respect of the Notes and this Agreement may be
served. The initial location of such office and agency is the Company’s address set forth in Section 14.01, and the Company shall give prompt written notice to each Holder of any change in the location of such office or agency. 

The Company may also from time to time designate co-registrars and one or more offices or agencies where the Notes may be presented or
surrendered for any or all such purposes and may from time to time rescind such designations. The Company will give prompt written notice of any such designation or rescission and of any change in the location of any such other office or agency.

 Section 4.03 Reports. The Company shall furnish to the Holders, on or before the fifth (5th) day after the date that the
Company is required to file the same (after giving effect to all applicable grace periods under the Exchange Act), all reports that the Company is required to file with the Commission pursuant to Section 13(a) or 15(d) of the Exchange Act;
provided, however, that the Company need not send to any Holder any material for 

  
 -16- 

 
which the Company has received, or is seeking in good faith and has not been denied, confidential treatment by the Commission. Any report that the Company files with the Commission through the
EDGAR system (or any successor thereto) will be deemed to be sent to the Holders at the time such report is so filed. 
 Section 4.04
Offer to Repurchase upon Fundamental Change. 
 (a) If a Fundamental Change occurs at any time prior to the Maturity Date, each Holder
shall have the right, at such Holder’s option, to require the Company to repurchase for cash all of such Holder’s Notes, or any portion thereof that is equal to $1,000 or an integral multiple of $1,000 in excess thereof, on the date (the
“Fundamental Change Repurchase Date”) specified by the Company that is not less than twenty (20) Business Days or more than thirty (30) Business Days following the date of the Fundamental Change Company Notice at a
repurchase price equal to one hundred and nine percent (109%) of the Principal Amount thereof, plus accrued and unpaid interest, if any, thereon to, but excluding, the Fundamental Change Repurchase Date (the “Fundamental Change
Repurchase Price”), unless the Fundamental Change Repurchase Date for any Note to be so repurchased falls after a Regular Record Date but on or prior to the Interest Payment Date to which such Regular Record Date relates, in which case the
Company shall instead pay, on such Interest Payment Date, pay to the Holder of record of such Note as of the Close of Business on such Regular Record Date, the amount of interest that would have accrued on such Note to such Interest Payment Date,
and the Fundamental Change Repurchase Price of such Note shall be equal to one hundred and nine percent (109%) of the Principal Amount of such Notes. 

(b) Repurchases of Notes under this Section 4.04 shall be made, at the option of the Holder thereof. To exercise such right, such Holder
must deliver, prior to the Close of Business on the Business Day immediately preceding the Fundamental Change Repurchase Date, to the Company: 

(i) a duly completed notice (the “Fundamental Change Repurchase Notice”) to the Company; and 

(ii) the Notes to be repurchased. 

The Fundamental Change Repurchase Notice in respect of any Notes to be repurchased shall state: 

(i) the certificate numbers of the Notes to be delivered for repurchase; 

(ii) the portion of the principal amount of Notes to be repurchased, which must be $1,000 or an integral multiple in excess thereof; and 

(iii) that the Notes are to be repurchased by the Company pursuant to the applicable provisions of the Notes and this Agreement. 

Notwithstanding anything herein to the contrary, any Holder delivering to the Company the Fundamental Change Repurchase Notice contemplated by this
Section 4.04 shall have the right to withdraw, in whole or in part, such Fundamental Change Repurchase Notice by at any time prior to the close of business on the Business Day immediately preceding the Fundamental Change Repurchase Date by
delivery of a written notice of withdrawal to the Company in accordance with Section 4.04(e). 
 (c) On or before the 20th Business Day
after the occurrence of a Fundamental Change, the Company shall provide to all Holders of Notes a written notice (the “Fundamental Change Company Notice”) of the occurrence of the Fundamental Change and of the repurchase right at
the option of the Holders arising as a result thereof. Each Fundamental Change Company Notice shall specify: 
 (i) the
events causing the Fundamental Change; 
 (ii) the date of the Fundamental Change; 

  
 -17- 

 (iii) the last date on which a Holder may exercise the repurchase right pursuant
to this Section 4.04; 
 (iv) the Fundamental Change Repurchase Price; 

(v) the Fundamental Change Repurchase Date; 

(vi) if applicable, the Conversion Rate and any adjustments to the Conversion Rate resulting from the Fundamental Change; 

(vii) that the Notes with respect to which a Fundamental Change Repurchase Notice has been delivered by a Holder may be
converted only if the Holder withdraws the Fundamental Change Repurchase Notice in accordance with the terms of this Agreement; and 

(viii) the procedures that Holders must follow to require the Company to repurchase their Notes. 

No failure of the Company to give the foregoing notices and no defect therein shall limit the Holders’ repurchase rights or affect the validity of the
proceedings for the repurchase of the Notes pursuant to this Section 4.04. 
 (d) Notwithstanding the foregoing, no Notes may be
repurchased by the Company on any date at the option of the Holders upon a Fundamental Change if the principal amount of the Notes has been accelerated, and such acceleration has not been rescinded, on or prior to such date (except in the case of an
acceleration resulting from a Default by the Company in the payment of the Fundamental Change Repurchase Price with respect to such Notes). 

(e) A Fundamental Change Repurchase Notice may be withdrawn (in whole or in part) by means of a written notice of withdrawal delivered to the
Company at any time prior to the Close of Business on the Business Day immediately preceding the Fundamental Change Repurchase Date, specifying: 

(i) the principal amount of the Notes with respect to which such notice of withdrawal is being submitted, which must be $1,000
or an integral multiple of $1,000 in excess thereof; 
 (ii) the certificate number of the Note in respect of which such
notice of withdrawal is being submitted; and 
 (iii) the principal amount, if any, of such Note that remains subject to the
original Fundamental Change Repurchase Notice, which portion must be in principal amounts of $1,000 or an integral multiple of $1,000 in excess thereof. 

(f) The Company shall not be required to repurchase or make an offer to repurchase the Notes upon a Fundamental Change if a third party makes
such an offer in the same manner, at the same time and otherwise in compliance with the requirements made for an offer made by the Company as set forth in this Section 4.04 and such third party purchases all Notes properly surrendered and not
validly withdrawn under its offer in the same manner, at the same time and otherwise in compliance with the requirements for an offer made by the Company as set forth in this Section 4.04. 

(g) Notwithstanding anything to the contrary in this Section 4.04, the Company will not be required to send a Fundamental Change Company
Notice, or offer to repurchase or repurchase any Notes pursuant to this Section 4.04, in connection with a Fundamental Change occurring pursuant to clause (b)(i) or (b)(ii) of the definition thereof, if (i) such Fundamental Change
constitutes a Common Stock Change Event whose Reference Property consists solely of cash in U.S. dollars; (ii) immediately after such Fundamental Change, the Notes become convertible, pursuant to Section 7.05 and, if applicable,
Section 7.07, into solely cash in U.S. dollars in an amount per Note that equals or exceeds the Fundamental Change Repurchase Price per Note (calculated assuming that the same includes accrued interest to, but excluding, the latest possible
Fundamental Change Repurchase Date for such Fundamental Change); and (iii) the Company notifies Holders of the occurrence of such Fundamental Change and that, pursuant to this Section 4.04(g), the Company is not required to offer to
repurchase the Notes in connection therewith. 

  
 -18- 

 Section 4.05 Existence. Subject to Article 10, the Company will do or cause to be
done and will cause its Subsidiaries to do all things necessary to preserve and keep in full force and effect their respective existence and material rights (charter and statutory); provided, however, that the Company need not preserve
or keep in full force and effect any such existence or right if the Board of Directors determines that (a) the preservation thereof is no longer desirable in the conduct of the business of the Company and its Subsidiaries, taken as a whole; and
(b) the loss thereof is not, individually or in the aggregate, materially adverse to the Holders. 
 Section 4.06 Limitation on
Additional Indebtedness. Neither the Company nor any of its Subsidiaries shall, directly or indirectly, create, incur, assume or suffer to exist (collectively, “incur”) any Indebtedness for borrowed money that is
(a) unsecured Indebtedness, (b) Indebtedness, or preferred stock, that is convertible into Common Stock, if, in the case of clause (a) or (b) above, such Indebtedness or securities have a final maturity date, principal
amortization or mandatory redemption date (other than pursuant to which such Indebtedness or securities are paid solely by, or repurchased, redeemed, exchanged or otherwise retired solely for, Equity Interests that do not constitute Disqualified
Capital Stock) that is earlier than twelve (12) months after the Maturity Date, or (c) secured Indebtedness that is senior in right of payment to the Notes unless, in the case of this clause (c), (i) such Indebtedness is incurred
after the first bona fide commercial sale of at least one of the Company’s products and (ii) the outstanding aggregate principal amount of such Indebtedness shall not at any time exceed one hundred million dollars ($100,000,000);
provided, however, that this Section 4.06 will not prohibit the Company or any of its Subsidiaries from incurring any of the following: 

(i) any Indebtedness of the Company and its Subsidiaries in existence on the date of this Agreement; 

(ii) Indebtedness under the Initial Notes or under this Agreement with respect to the Initial Notes; 

(iii) the incurrence by the Company or any of its Subsidiaries of intercompany Indebtedness between or among the Company and
any of its Subsidiaries; provided, however, that: 
 (A) if the Company or any Guarantor is the obligor on such
Indebtedness and the payee is not the Company or a Guarantor, such Indebtedness must be unsecured and expressly subordinated to the prior payment in full in cash of all obligations then due with respect to the Notes, in the case of the Company, or
the applicable Guarantee, in the case of a Guarantor; and 
 (B) (x) any subsequent issuance or transfer of Equity Interests
that results in any such Indebtedness being held by a Person other than the Company or a Subsidiary of the Company and (y) any sale or other transfer of any such Indebtedness to a Person that is not either the Company or a Subsidiary of the
Company, will be deemed, in each case, to constitute an incurrence of such Indebtedness by the Company or such Subsidiary, as the case may be, that was not permitted by this clause (iii); 

(iv) the incurrence by the Company or any of its Subsidiaries of Permitted Refinancing Indebtedness in exchange for, or the net
proceeds of which are used to renew, refund, refinance, replace, defease or discharge any Indebtedness (other than intercompany Indebtedness) that was permitted by this Agreement to be incurred under clauses (i), (ii), (iv) and (v) of this
Section 4.06; and 
 (v) any (a) unsecured Indebtedness or (b) secured Indebtedness incurred to finance the
acquisition, construction or improvement of any fixed or capital asset constituting purchase money Indebtedness provided that such Indebtedness is incurred within ninety (90) days after such acquisition or the completion of such construction or
improvement, not to exceed, in the case of both (a) and (b) together, in the aggregate at any time fifteen million dollars ($15,000,000). 

  
 -19- 

 Section 4.07 Limitation on Dividends. Neither the Company nor any of its
Subsidiaries, directly or indirectly, will declare or make, or agree to declare or make, any Restricted Payment or incur any obligation (contingent or otherwise) to do so. 

Section 4.08 Default Notices. The Company shall promptly give written notice to each of the Holders of each Default or Event of
Default. 
 Section 4.09 Payment of Taxes. Each Credit Party shall pay and discharge promptly when due all Taxes, imposed
upon it or upon its income or profits or in respect of its property, before the same shall become delinquent or in default (including in its capacity of a withholding agent); provided that such payment and discharge shall not be required with
respect to any such Tax, so long as (i) the validity or amount thereof shall be contested in good faith by appropriate proceedings timely instituted and diligently conducted and the applicable Credit Party shall have set aside on its books
adequate reserves or other appropriate provisions with respect thereto in accordance with GAAP and such contest operates to suspend collection of the contested Taxes or (ii) the failure to pay could not reasonably be expected, individually or
in the aggregate, to result in a Material Adverse Effect. 
 ARTICLE 5. 

REDEMPTION 
 Section 5.01
No Right to Redeem Before March 31, 2020. The Company may not redeem the Notes at its option at any time before March 31, 2020. 

Section 5.02 Right to Redeem the Notes on or After March 31, 2020. Subject to the terms of this Article 5, the Company has
the right, at its election, to redeem all, and not less than all, of the Notes not previously converted, at any time, on a Redemption Date on or after March 31, 2020, for a cash purchase price equal to the Redemption Price, but only if the Last
Reported Sale Price per share of Common Stock exceeds one hundred and sixty percent (160%) of the Conversion Price on each of at least twenty (20) Trading Days (whether or not consecutive) during the thirty (30) consecutive Trading
Days ending on, and including, the Trading Day immediately before the Redemption Notice Date for such Redemption. 
 Section 5.03
Redemption Prohibited in Certain Circumstances. Notwithstanding the foregoing, no Notes may be redeemed by the Company pursuant to this Article 5 on any date if the principal amount of the Notes has been accelerated, and such acceleration has
not been rescinded, on or prior to such date (except in the case of an acceleration resulting from a Default by the Company in the payment of the Redemption Price with respect to such Notes). 

Section 5.04 Redemption Date. The Redemption Date for any Redemption will be a Business Day of the Company’s choosing that is
on or after March 31, 2020 and is no more than eighty (80), nor less than twenty (20), calendar days after the Redemption Notice Date for such Redemption. 

Section 5.05 Redemption Price. The Redemption Price for any Note called for Redemption is an amount in cash equal to one hundred
and nine percent (109%) of the Principal Amount of such Note plus accrued and unpaid interest on such Note to, but excluding, the Redemption Date for such Redemption; provided, however, that if such Redemption Date is after a
Regular Record Date and on or before the next Interest Payment Date, then (a) the Holder of such Note at the Close of Business on such Regular Record Date will be entitled, notwithstanding such Redemption, to receive, on such Interest Payment
Date, the unpaid interest that would have accrued on such Note to, but excluding, such Interest Payment Date (assuming, solely for these purposes, that such Note remained outstanding through such Interest Payment Date, if such Redemption Date is
before such Interest Payment Date); and (b) the Redemption Price will not include accrued and unpaid interest on such Note to, but excluding, such Redemption Date. 

Section 5.06 Redemption Notice. To call any Notes for Redemption, the Company must send to each Holder a written notice of such
Redemption (a “Redemption Notice”) stating (a) that the Notes have been called for Redemption, briefly describing the Company’s Redemption right under this Agreement; (b) the Redemption Date for such Redemption;
(c) the Redemption Price for such Redemption; and (d) the place or places where Notes are to be 

  
 -20- 

 
surrendered for payment of the Redemption Price. Once a Redemption Notice is given, the Notes shall, on the Redemption Date, become due and payable at the Redemption Price, and upon surrender of
any Note for Redemption in accordance with such Redemption Notice, such Note shall be paid by the Company at the Redemption Price. 

Section 5.07 AHYDO Saver. Notwithstanding anything to the contrary, if the Note would otherwise constitute an “applicable
high-yield discount obligation” within the meaning of Section 163(i) of the Internal Revenue Code or any successor provisions, on each Interest Payment Date ending on or after the date that is five years after the Closing Date, the Company
shall make a payment in an amount necessary (if any) to ensure that the Note shall not be considered an applicable high yield discount obligation; provided, however, that, any payment made pursuant to this Section 5.07 shall
reduce the amount of any subsequent Repayment Premium required to be paid by the Company and shall not reduce the Principal Amount. 

ARTICLE 6. 
 CONDITIONS 

Section 6.01 Closing Date Conditions. The obligation of each Investor to purchase the Notes hereunder shall be subject to the
satisfaction on the Closing Date of the conditions precedent set forth below: 
 (a) The Company shall have delivered to the
Investors the Notes and this Agreement, each dated the Closing Date. 
 (b) The Company shall have delivered to the Investors
an executed copy of: 
 (i) a certificate of the Company, dated the Closing Date, substantially in the form set forth in
Exhibit C hereto together with the attachments specified therein; and 
 (ii) an opinion of counsel to the Company,
dated the Closing Date, in form and substance reasonably acceptable to the Investors. 
 (c) The Company shall have delivered
to the Investors (i) a certificate, dated the Closing Date, of a senior officer of each Credit Party (the statements made in which to have been true and correct on and as of the Closing Date): (x) attaching copies, certified by such
officer as true and complete, of such Credit Party’s certificate of incorporation and bylaws (together with any and all amendments thereto); (y) attaching copies, certified by such officer as true and complete, of resolutions of the board
of directors (or other governing body) of such Credit Party authorizing and approving the execution, delivery and performance by such Credit Party of this Agreement and the other Note Documents and the transactions contemplated herein and therein;
and (x) setting forth the incumbency of the officer or officers of such Credit Party who executed and delivered this Agreement and the other Note Documents including therein a signature specimen of each such officer or officers; and
(ii) certificates of the appropriate Governmental Authority of the jurisdiction of formation of such Credit Party and its Subsidiaries, stating that such Credit Party and its Subsidiaries were in good standing under the laws of such
jurisdiction as of the Closing Date (or such earlier date as shall be reasonably acceptable to the Investors). 
 (d) No
event shall have occurred and be continuing that (i) constitutes a Default or an Event of Default or (ii) could reasonably be expected to constitute a Material Adverse Effect. 

(e) All necessary governmental and third-party approvals, consents and filings required for the issuance of the Notes and entry
into the other Note Documents shall have been obtained or made and shall remain in full force and effect. 

  
 -21- 

 ARTICLE 7. 

CONVERSION 
 Section 7.01
Right to Convert. Subject to and upon compliance with the provisions of this Agreement, each Holder shall have the right, at such Holder’s option, at any time prior to the Close of Business on the Business Day immediately preceding the
Maturity Date, to convert the Principal Amount of such Holder’s Notes, or any portion of such Principal Amount that is $1,000 and any integral multiple of $1,000 in excess thereof, into shares of Common Stock (and, if applicable, cash in lieu
of any fractional share of Common Stock). Notwithstanding anything to the contrary: 
 (a) Notes may be surrendered for conversion only
after the Open of Business and before the Close of Business on a day that is a Business Day; 
 (b) in no event may any Note be converted
after the Close of Business on the Business Day immediately preceding the Maturity Date; 
 (c) if the Company calls any Note for Redemption
pursuant to Article 5, then the Holder of such Note may not convert such Note after the Close of Business on the Business Day immediately before the applicable Redemption Date, except to the extent the Company fails to pay the Redemption Price for
such Note in accordance with this Indenture; 
 (d) if a Fundamental Change Repurchase Notice is validly delivered pursuant to
Section 4.04(b) with respect to any Note, then such Note may not be converted, except to the extent (i) such Note is not subject to such notice; (ii) such notice is withdrawn in accordance with Section 4.04(e); or (iii) the
Company fails to pay the Fundamental Change Repurchase Price for such Note in accordance with this Agreement; and 
 (e) in no event will
any Note be converted unless and until all applicable waiting periods (and any extension thereof) prescribed by the HSR Act, if any, have expired or been terminated. 

Section 7.02 Conversion Procedure. 

(a) In order to exercise the conversion right with respect to any Notes, the Holder of any such Notes to be converted, in whole or in part,
shall: 
 (i) complete and manually sign the conversion notice provided on the back of the Note (or a facsimile of such
conversion notice) and deliver the same to the Company; 
 (ii) surrender the Note to the Company; 

(iii) if required, furnish appropriate endorsements and transfer documents, 

(iv) if required pursuant to Section 7.08, pay any transfer taxes or duties; and 

(v) if required, pay funds equal to interest payable on the next Interest Payment Date as required by Section 7.03(d).

 The date on which the Holder satisfies all of the applicable requirements set forth above is the “Conversion Date.” 

(b) In case any Note having a Principal Amount greater than $1,000 shall be surrendered for partial conversion, the Company shall execute and
deliver to the Holder of such Note, without charge to such Holder, new Notes in authorized denominations in an aggregate Principal Amount equal to the unconverted portion of such Note. 

Each conversion shall be deemed to have been effected as to any such Notes (or portion thereof) on the Conversion Date for such conversion,
and the Person in whose name the shares of Common Stock shall be issuable upon such conversion shall be deemed to have become the holder of record of such shares as of the Close of Business on such the Conversion Date for such conversion. 

  
 -22- 

 (c) Each share of Common Stock issued upon conversion of any Notes that are Restricted Notes
shall be subject to the Restricted Stock Legend as set forth in Section 3.06. 
 Section 7.03 Settlement upon Conversion Into
Common Stock. 
 (a) The type and amount of consideration due in respect of each $1,000 principal amount of a Note to be converted will
be a number of shares of Common Stock equal to the Conversion Rate in effect on the Conversion Date for such conversion; provided, however, that, subject to Section 7.03(e), in lieu of issuing or delivering any fraction of any
share of Common Stock, the Company will instead either, at the Company’s option, (I) pay cash in an amount equal to the product of (x) such fraction and (y) the Last Reported Sale Price per share of Common Stock on such
Conversion Date; or (II) deliver an additional whole share of Common Stock. 
 (b) Subject to Section 7.05, the Company will deliver
the consideration due upon conversion of any Note on or before the third (3rd) Business Day after the Conversion Date for such conversion. 

(c) Subject to Section 7.03(d), upon conversion, Holders shall not receive any separate cash payment for accrued and unpaid interest.

 (d) If the Conversion Date for any Note is after a Regular Record Date and before the next Interest Payment Date, then (i) the
Holder(s) of such Note at the Close of Business on such Regular Record Date will receive, on such Interest Payment Date, the interest that would have accrued on such Note to, and been payable on, such Interest Payment Date notwithstanding the
conversion; and (ii) such Note, when surrendered for conversion, must be accompanied by funds equal to the amount of such interest; provided, however, that no such payment need be made (x) for conversions whose Conversion
Date occurs following the Regular Record Date immediately preceding the Maturity Date, (y) for conversions whose Conversion Date occurs following a Regular Record Date immediately preceding a Redemption Date, or (z) to the extent of any
overdue interest, if any overdue interest exists at the time of conversion with respect to such Note. 
 (e) If multiple Notes shall be
surrendered for conversion with the same Conversion Date by the same Holder, the number of full shares which shall be issuable upon such conversion (and the number of fractional shares, if any, for which cash shall be delivered) shall be computed on
the basis of the aggregate Principal Amount of such Notes to be so converted. 
 (f) By delivery to the Holder of the consideration due upon
conversion of any Note, the Company will be deemed to satisfy in full its obligation to pay the Principal Amount of the Notes and all accrued and unpaid interest to, but excluding, the Conversion Date. Upon conversion of the Notes, all accrued and
unpaid interest to, but excluding, the Conversion Date will be deemed to be paid in full rather than canceled, extinguished or forfeited, subject to Section 7.03(d). 

(g) Shares of Common Stock issued upon a conversion shall be delivered pursuant to a book entry with the transfer agent for the Common Stock,
and in no event shall paper certificates be issued or delivered, except with the consent of the Holder receiving the same. 

Section 7.04 Adjustment of Conversion Rate. The Conversion Rate shall be adjusted from time to time by the Company if any of the
following events occurs as described below, except that the Company will not make any adjustment to the Conversion Rate if Holders of Notes participate, at the same time and on the same terms as holders of shares of Common Stock, solely as a result
of holding the Notes, in any of the transactions described in this Section 7.04, without having to convert their Notes, as if each Holder held, on the applicable Record Date or effective date, a number of shares of Common Stock equal to the
Conversion Rate in effect on such Record Date or effective date, multiplied by the Principal Amount of Notes held by such Holder, divided by $1,000. 

  
 -23- 

 (a) If the Company issues solely shares of Common Stock as a dividend or distribution on all or
substantially all of the shares of the Common Stock, or the Company effects a share split or share combination applicable to all shares of the Common Stock (in each case excluding an issuance solely pursuant to a Common Stock Change Event, as to
which the provisions set forth in Section 7.05 will apply), the Conversion Rate will be adjusted based on the following formula: 
  

							
		  	 CR1 = CR0 ×
	 	 OS1
	  	
		  	 	OS0	  	

 where, 
  

					
	CR0	 	=	  	the Conversion Rate in effect immediately prior to the Close of Business on the Record Date of such dividend or distribution, or immediately prior to the Open of Business on the effective date of such share split or share
combination, as applicable;
			
	CR1	 	=	  	the Conversion Rate in effect immediately after the Close of Business on such Record Date or effective date, as applicable;
			
	OS0	 	=	  	the number of shares of Common Stock outstanding immediately prior to the Close of Business on such Record Date or effective date, as applicable; and
			
	OS1	 	=	  	the number of shares of Common Stock outstanding immediately after giving effect to such dividend, distribution, share split or share combination.

 If any dividend, distribution, share split or share combination of the type described in this
Section 7.04(a) is declared but not so paid or made, the Conversion Rate shall be immediately readjusted, effective as of the date the Board of Directors determines not to pay such dividend or distribution or to effect such share split or share
combination, to the Conversion Rate that would then be in effect if such dividend, distribution, share split or share combination had not been declared or announced. 

(b) If the Company distributes, to all or substantially all holders of shares of Common Stock, any rights, options or warrants entitling such
holders for a period of not more than sixty (60) calendar days after the Record Date of such distribution to subscribe for or purchase shares of Common Stock, at a price per share less than the average of the Last Reported Sale Prices per share
of Common Stock over the ten (10) consecutive Trading Days ending on, and including, the Trading Day immediately preceding the date of announcement of such distribution, the Conversion Rate will be increased based on the following formula: 

 

							
		 	CR1 = CR0 ×	 	 OS + X
	  	
		 	 	OS + Y	  	

 where, 
  

					
	CR0	 	=	  	the Conversion Rate in effect immediately prior to the Close of Business on the Record Date for such distribution;
			
	CR1	 	=	  	the Conversion Rate in effect immediately after the Close of Business on such Record Date;
			
	OS	 	=	  	the number of shares of Common Stock outstanding immediately prior to the Close of Business on such Record Date;
			
	X	 	=	  	the total number of shares of Common Stock issuable pursuant to such rights, options or warrants; and
			
	Y	 	=	  	the number of shares of Common Stock equal to the aggregate price payable to exercise such rights, options or warrants divided by the average of the Last Reported Sale Prices per share of Common Stock over the ten (10)
consecutive Trading Days ending on, and including, the Trading Day immediately preceding such date of announcement.

  
 -24- 

 The foregoing increase in the Conversion Rate shall be successively made whenever any such
rights, options or warrants are distributed. If such rights, options or warrants are not so distributed, the Conversion Rate will be immediately readjusted to the Conversion Rate that would then be in effect if such Record Date for such distribution
had not been fixed. In addition, to the extent that shares of Common Stock are not delivered after the expiration of such rights, options or warrants (including as a result of such rights, options or warrants not being exercised), the Conversion
Rate shall be immediately readjusted to the Conversion Rate that would then be in effect had the increase to the Conversion Rate made for the distribution of such rights, options or warrants been made on the basis of delivery of only the number of
shares of Common Stock actually delivered upon exercise of such rights, option or warrants. 
 In determining whether any rights, options or
warrants entitle the holders of shares of Common Stock to subscribe for or purchase shares of Common Stock at less than such average of the Last Reported Sale Prices, and in determining the aggregate price payable to exercise such rights, options or
warrants, there shall be taken into account any consideration received by the Company for such rights, options or warrants and any amount payable upon exercise or conversion thereof, the value of such consideration, if other than cash, to be
determined by the Board of Directors. 
 (c) 

(i) If the Company distributes shares of its Capital Stock, evidences of its Indebtedness, other assets or property of the
Company or rights, options or warrants to acquire the Company’s Capital Stock or other securities (the “Distributed Property”), to all or substantially all holders of shares of Common Stock, excluding: 

(A) dividends, distributions, rights, options or warrants for which an adjustment is required (or would be required without
regard to Section 7.04(h)) pursuant to Section 7.04(a) or Section 7.04(b); 
 (B) dividends or distributions
paid exclusively in cash for which an adjustment is required (or would be required without regard to Section 7.04(h)) pursuant to Section 7.04(d); 

(C) rights issued or otherwise distributed pursuant to a stockholder rights plan, except to the extent provided in
Section 7.10; 
 (D) Spin-Offs for which an adjustment is required (or would be required without regard to
Section 7.04(h)) pursuant to Section 7.04(c)(ii); and 
 (E) a distribution solely pursuant to a Common Stock
Change Event, as to which the provisions set forth in Section 7.05 will apply, 
 then the Conversion Rate will be increased based on
the following formula: 
  

							
		  	CR1 = CR0 ×	  	 SP
	  	
		  	  	SP – FMV	  	

  

					
		 		  	where,
			
	CR0	 	=	  	the Conversion Rate in effect immediately prior to the Close of Business on the Record Date for such distribution;
			
	CR1	 	=	  	the Conversion Rate in effect immediately after the Close of Business on such Record Date;

  
 -25- 

					
	SP	 	=	  	the average of the Last Reported Sale Prices per share of Common Stock over the ten (10) consecutive Trading Days ending on, and including, the Trading Day immediately preceding the Ex-Dividend Date for such distribution;
and
			
	FMV	 	=	  	the fair market value (as determined by the Board of Directors), as of such Record Date, of such Distributed Property distributed per share of Common Stock pursuant to such distribution.

 No adjustment pursuant to the above formula shall result in a decrease of the Conversion Rate.
If such distribution is not so paid or made, or such rights, options or warrants are not exercised before their expiration (including as a result of being redeemed or terminated), the Conversion Rate shall be readjusted to be the Conversion Rate
that would then be in effect had the adjustment been made on the basis of only the distribution, if any, actually made or paid or on the basis of the distribution of only such rights, options or warrants, if any, that were actually exercised, if at
all. Notwithstanding the foregoing, if “FMV” (as defined above) is equal to or greater than “SP” (as defined above), then, in lieu of the foregoing increase, each Holder shall receive, in respect of each $1,000 principal amount
of Notes that it held on the Record Date for such distribution, at the same time and upon the same terms as holders of the Common Stock receive the Distributed Property, without having to convert its Notes, the amount and kind of Distributed
Property such Holder would have received if such Holder owned, on such Record Date, a number of shares of Common Stock equal to the Conversion Rate in effect on such Record Date. If the Board of Directors determines the “FMV” (as defined
above) of any distribution for purposes of this Section 7.04(c)(i) by reference to the actual or when-issued trading market for any securities, it shall in doing so consider the prices in such market over the same period used in computing the
average Last Reported Sale Prices per share of Common Stock referred to above. 
 (ii) With respect to an adjustment pursuant
to this Section 7.04(c) where there has been a payment of a dividend or other distribution on all or substantially all shares of the Common Stock of shares of Capital Stock of any class or series, or similar equity interest, of or relating to a
Subsidiary, or other business unit or Affiliate, of the Company, where such Capital Stock or similar equity interest is listed or quoted (or will be listed or quoted upon consummation of the transaction) on a U.S. or non-U.S. securities exchange (as
determined by the Company) (a “Spin-Off”), the Conversion Rate will be increased based on the following formula: 
  

							
		 	CR1 = CR0 ×	  	 FMV + MP
	  	
		 	  	MP	  	

  

					
		 		  	where,
			
	CR0	 	=	  	the Conversion Rate in effect immediately before the Close of Business on the Record Date for such Spin-Off;
			
	CR1	 	=	  	the Conversion Rate in effect immediately after the Close of Business on such Record Date;
			
	FMV	 	=	  	the average of the Last Reported Sale Prices per share of Capital Stock or similar equity interest distributed per share of Common Stock in such Spin-Off (determined for purposes of the definition of “Last Reported Sale
Price” as if references therein to Common Stock were instead references to such Capital Stock or similar equity interest) over the ten (10) consecutive Trading Days beginning on, and including, the Ex-Dividend Date of the Spin-Off (the
“Spin-Off Valuation Period”); and
			
	MP	 	=	  	the average of the Last Reported Sale Prices per share of Common Stock over the Spin-Off Valuation Period.

 The adjustment to the Conversion Rate pursuant to this Section 7.04(d) will be calculated as of the Close
of Business on the last Trading Day of the Spin-Off Valuation Period but will be given effect immediately after the Close of Business on the Record Date for the Spin-Off, with retroactive effect. If a Note is converted and the

  
 -26- 

 
Conversion Date occurs during the Spin-Off Valuation Period, then, notwithstanding anything to the contrary, the Company will, if necessary, delay the settlement of such conversion until the
third (3rd) Business Day after the last day of the Spin-Off Valuation Period. To the extent any dividend or distribution that constitutes a Spin-Off is declared but not paid or made, the Conversion Rate shall be immediately readjusted to the
Conversion Rate that would then be in effect had the adjustment been made on the basis of only the dividend or distribution, if any, actually made or paid. 

(d) If any cash dividend or distribution is paid or made to all or substantially all holders of shares of Common Stock, the Conversion Rate
shall be increased based on the following formula: 
  

							
		  	CR1 = CR0 ×	 	 SP
	  	
		  	 	SP – C	  	

 where, 
  

					
	CR0	 	=	  	the Conversion Rate in effect immediately prior to the Close of Business on the Record Date for such dividend or distribution;
			
	CR1	 	=	  	the Conversion Rate in effect immediately after the Close of Business on such Record Date;
			
	SP	 	=	  	the Last Reported Sale Price per share of Common Stock on the Trading Day immediately prior to such Ex-Dividend Date; and
			
	C	 	=	  	the amount in cash per share of Common Stock in such dividend or distribution.

 No adjustment pursuant to the above formula shall result in a decrease of the Conversion Rate. To the extent
such dividend or distribution is declared but not made or paid, the Conversion Rate will be readjusted to the Conversion Rate that would then be in effect had the adjustment been made on the basis of only the dividend or distribution, if any,
actually made or paid. Notwithstanding the foregoing, if “C” (as defined above) is equal to or greater than “SP” (as defined above), then, in lieu of the foregoing increase, each Holder shall receive, for each $1,000 principal
amount of Notes that it held on the Record Date for such distribution, at the same time and upon the same terms as holders of shares of the Common Stock, without having to convert its Notes, the amount of cash that such Holder would have received if
such Holder owned, on such Record Date, a number of shares of Common Stock equal to the Conversion Rate on such Record Date. 
 (e) If the
Company or any of its Subsidiaries makes a payment in respect of a tender offer or exchange offer for shares of Common Stock, to the extent that the value (determined as of the Expiration Time by the Board of Directors) of the cash and any other
consideration paid per share of Common Stock in such tender or exchange offer exceeds the Last Reported Sale Prices per share of Common Stock on the Trading Day immediately after the last date (the “Expiration Date”) on which
tenders or exchanges may be made pursuant to such tender or exchange offer (as it may be amended), then the Conversion Rate will be increased based on the following formula: 
  

							
		  	CR1 = CR0 ×	  	 AC + (SP × OS1)
	  	
		  	  	OS0 × SP	  	

 where, 
  

					
	CR0	 	=	  	the Conversion Rate in effect immediately prior to the time (the “Expiration Time”) such tender or exchange offer expires;
			
	CR1	 	=	  	the Conversion Rate in effect immediately after the Expiration Time;

  
 -27- 

					
	AC	 	=	  	the aggregate value (determined as of the Expiration Time by the Board of Directors) of all cash and other consideration paid for shares of Common Stock purchased in such tender or exchange offer;
			
	OS0	 	=	  	the number of shares of Common Stock outstanding immediately prior to the Expiration Time (prior to giving effect to the purchase of shares of Common Stock accepted for purchase or exchange in such tender or exchange
offer);
			
	OS1	 	=	  	the number of shares of Common Stock outstanding immediately after the Expiration Time (after giving effect to the purchase of shares of Common Stock accepted for purchase or exchange in such tender or exchange offer); and
			
	SP	 	=	  	the average of the Last Reported Sale Prices per share of Common Stock over the ten (10) consecutive Trading Day period (the “Tender/Exchange Offer Valuation Period”) beginning on, and including, on the Trading Day
next succeeding the Expiration Date.

 The adjustment to the Conversion Rate pursuant to this Section 7.04(e) will be calculated as of the Close
of Business on the last Trading Day of the Tender/Exchange Offer Valuation Period but will be given effect immediately after the Expiration Time, with retroactive effect. If a Note is converted and the Conversion Date occurs during the
Tender/Exchange Offer Valuation Period, then, notwithstanding anything to the contrary, the Company will, if necessary, delay the settlement of such conversion until the third (3rd) Business Day after the last day of the Tender/Exchange Offer
Valuation Period. No adjustment pursuant to the above formula shall result in a decrease of the Conversion Rate. 
 If the Company is
obligated to purchase shares of Common Stock pursuant to any such tender or exchange offer, but the Company is ultimately prevented by applicable law from effecting all or any portion of such purchases or all such purchases are rescinded, the
Conversion Rate shall immediately be readjusted to the Conversion Rate that would then be in effect if such tender or exchange offer had not been made or had been made only in respect of the purchases that had been effected. 

(f) In addition to those Conversion Rate adjustments required by Sections 7.04(a), 7.04(b), 7.04(c), 7.04(d) and 7.04(e), and to the extent
permitted by applicable law and subject to the applicable rules of The NASDAQ Global Market (including Market Rule 5635) and, if applicable, any securities exchange on which the Company’s securities are then listed, the Company from time to
time may (but is not required to) (i) increase the Conversion Rate by any amount for a period of at least twenty (20) Business Days if the Board of Directors determines that such increase would be in the Company’s best interest and
(ii) increase the Conversion Rate to avoid or diminish any income tax to holders of shares of Common Stock or rights to purchase shares of Common Stock in connection with any dividend or distribution of shares of Common Stock (or rights to
acquire shares of Common Stock) or similar event. 
 (g) Notwithstanding anything to the contrary, the Conversion Rate will not be adjusted:

 (i) the sale of shares of Common Stock for a purchase price that is less than the market price per share of Common Stock
or less than the Conversion Price; 
 (ii) upon the issuance of any shares of Common Stock pursuant to any present or future
plan providing for the reinvestment of dividends or interest payable on the Company’s securities and the investment of additional optional amounts in shares of Common Stock under any plan; 

(iii) upon the entry into any share repurchase program by the Company, including any accelerated share repurchase transaction
or other share repurchase transaction effected through the use of derivatives; 

  
 -28- 

 (iv) upon the issuance of any shares of Common Stock or options or rights to
purchase those shares pursuant to any present or future employee, director or consultant benefit plan or program of (or assumed by) the Company or any its Subsidiaries; 

(v) upon the issuance of any shares of Common Stock pursuant to any option, warrant, right or exercisable, exchangeable or
convertible security not described in clause (iv) above and outstanding as of the date the Notes were first issued, except as set forth in Section 7.10; 

(vi) for a change in the par value of the Common Stock; or 

(vii) for accrued and unpaid interest, if any, on the Notes. 

(h) Adjustments to the Conversion Rate under this Article 7 shall be calculated to the nearest cent or to the nearest one-ten thousandth
(1/10,000th) of a share of Common Stock. Notwithstanding anything to the contrary in Section 7.04, no adjustment shall be made to the Conversion Rate unless such adjustment would require a change of at least one percent (1%) in the
Conversion Rate, and any adjustment that would otherwise be required to be made shall be carried forward and taken into account in any future adjustment; provided, however, that upon any conversion of the Notes, the Company shall give
effect to all adjustments that Company otherwise has deferred pursuant to this sentence, and those adjustments will no longer be carried forward and taken into account in any future adjustment. 

(i) After any adjustment to the Conversion Rate pursuant hereto, the Company shall prepare and send to Holders, within 20 days of the
effective date of such adjustment, a notice of such adjustment setting forth the adjusted Conversion Rate and the date on which each adjustment became effective. Failure to deliver such notice shall not affect the legality or validity of any such
adjustment. 
 (j) For purposes of this Section 7.04, the number of shares of Common Stock at any time outstanding shall not include
shares held in the treasury of the Company, so long as the Company does not pay any dividend or make any distribution on such shares, but shall include shares issuable in respect of scrip certificates issued in lieu of fractions of shares of Common
Stock. 
 Section 7.05 Effect of Reclassification, Consolidation, Merger, Sale, Etc. In the case of (i) any
recapitalization, reclassification or change of the Common Stock (other than changes resulting from a subdivision or combination, any stock dividends or any change in par value or from a par value to no par value or from no par value to a par
value), (ii) any consolidation, merger or combination involving the Company, (iii) any sale, lease or other transfer to a third party of all or substantially all of the consolidated assets of the Company and its Subsidiaries, taken as a
whole, or (iv) any statutory share exchange, in each case, as a result of which the Common Stock would be converted into, or exchanged for, or represent solely the right to receive, stock, other securities or other property or assets (including
cash or any combination thereof) (any such event, a “Common Stock Change Event,” and such stock, securities, property or assets, the “Reference Property,” and the amount and kind of Reference Property that a holder
of one (1) share of Common Stock would be entitled to receive on account of such Common Stock Change Event (without giving effect to any arrangement not to issue fractional shares of securities or other property), a “Reference Property
Unit”), then, notwithstanding anything to the contrary, 
 (a) at the effective time of such Common Stock Change Event,
(1) the consideration due upon conversion of any Note will be determined in the same manner as if each reference to any number of shares of Common Stock in this Article 7 (or in any related definitions) were instead a reference to the same
number of Reference Property Units; and for (2) purposes of the definition of “Fundamental Change” and “Make-Whole Fundamental Change,” the term “Common Stock” will be deemed to mean the Common Equity, if any,
forming part of such Reference Property; 
 (b) if such Reference Property Unit consists entirely of cash, then, in respect of all
conversions whose Conversion Date occurs on or after the effective date of such Common Stock Change Event, the Company will pay the cash due upon such conversions no later than the third (3rd) Business Day after the relevant Conversion Date;

  
 -29- 

 (c) for these purposes, the Last Reported Sale Price of any Reference Property Unit or portion
thereof that does not consist of a class of securities will be the fair value of such Reference Property Unit or portion thereof, as applicable, determined in good faith by the Company (or, in the case of cash denominated in U.S. dollars, the face
amount thereof); 
 (d) the Company shall promptly execute, and the Holders shall counter-sign, a supplemental agreement pursuant to Article
13 that (1) will provide for subsequent conversions of Notes in the manner set forth in this Section 7.05; (2) will provide for subsequent adjustments to the Conversion Rate pursuant to Section 7.04(a), 7.04(b), 7.04(c), 7.04(d),
7.04(e) and 7.07 in a manner consistent with this Section 7.05; and (3) may contain such other provisions as (i) the Company in good faith determines are appropriate to preserve the economic interests of the Holders and to give effect
to the provisions of this Section 7.05 and (ii) to which Holders of at least a majority of the aggregate principal amount of Notes then outstanding reasonably agree. 

If such Common Stock Change Event causes the Common Stock to be converted into, or exchanged for, or represent solely the right to receive,
more than a single type of consideration (determined based in part upon any form of shareholder election), the composition of the Reference Property Unit will be deemed to be the weighted average of the types and amounts of consideration received by
the holders of Common Stock that affirmatively make such an election. The Company shall notify Holders of the Notes of such weighted average as soon as practicable after such determination is made. 

The Company shall not become a party to any Common Stock Change Event unless its terms are consistent with this Section 7.05. None of the
foregoing provisions shall affect the right of a Holder of Notes to convert its Notes as set forth in Section 7.01 and Section 7.02 prior to the effective date of such Common Stock Change Event. 

Section 7.06 Adjustments of Prices. Whenever any provision of this Agreement requires a calculation of the Last Reported Sale
Prices, or a function thereof, over a span of multiple days, the Company may make adjustments determined by the Company or its agents to account for any adjustment to the Conversion Rate that becomes effective, or any event requiring an adjustment
to the Conversion Rate where the Ex-Dividend Date, Record Date, effective date or Expiration Date, as the case may be, of the event occurs, at any time during the period during which such calculations are based. 

Section 7.07 Increased Conversion Rate Applicable to Certain Notes Surrendered in Connection with Make-Whole Fundamental Changes.

 (a) If a Make-Whole Fundamental Change occurs or becomes effective prior to the Maturity Date and a Holder elects to convert any of its
Notes in connection with such Make-Whole Fundamental Change, the Company shall, under the circumstances described below, increase the Conversion Rate for such Notes by a number of additional shares of Common Stock (the “Additional
Shares”), as set forth below. A conversion of Notes shall be deemed for these purposes to be “in connection with” such Make-Whole Fundamental Change if the Conversion Date for such conversion occurs on or after the effective date
of the Make-Whole Fundamental Change and on or before the Business Day immediately prior to the related Fundamental Change Repurchase Date (or, if such Make-Whole Fundamental Change is not a Fundamental Change, on or before the 35th Trading Day
immediately following the Effective Date of such Make-Whole Fundamental Change) (such period, the “Make-Whole Fundamental Change Period”). Notwithstanding anything to the contrary, in no event will the Conversion Rate applicable to
the conversion of any Note in connection with a Make-Whole Fundamental Change be increased pursuant to this Section 7.07 if such Make-Whole Fundamental Change constitutes a Fundamental Change pursuant to clause (a) of the definition of
such term where the “person” or “group” referred to in such clause is, or includes, the Holder or beneficial owner of such Note or any Affiliate thereof. 

(b) If a Make-Whole Fundamental Change described in clause (b) of the definition of Fundamental Change, constitutes a Common Stock Change
Event for which the Reference Property is composed entirely of cash, then, for any conversion of Notes with a Conversion Date following the effective date of such Make-Whole Fundamental Change, the consideration due upon such shall be deemed to be
an amount of cash per $1,000 principal amount of converted Notes equal to the applicable Conversion Rate (including any adjustment for Additional Shares), multiplied by such Stock Price. The Company shall notify the Holders of Notes of the
effective date of any Make-Whole Fundamental Change no later than five (5) Business Days after such effective date. 

  
 -30- 

 (c) The number of Additional Shares, if any, by which the Conversion Rate shall be increased
shall be determined by reference to the table in Section 7.07(e), based on the date on which the Make-Whole Fundamental Change occurs or becomes effective and the price (the “Stock Price”) paid (or deemed to be paid) per share
of the Common Stock in the Make-Whole Fundamental Change. If the holders of the Common Stock receive in exchange for their Common Stock only cash in a Make-Whole Fundamental Change described in clause (b) of the definition of Fundamental
Change, the Stock Price shall be the cash amount paid per share. Otherwise, the Stock Price shall be the average of the Last Reported Sale Prices per share of Common Stock over the five (5) Trading Days ending on, and including, the Trading Day
immediately preceding the Effective Date of the Make-Whole Fundamental Change. 
 (d) The Stock Prices set forth in the column headings of
the table in Section 7.07(e) shall be adjusted in the same manner as, and at the same time and for the same events for which, the Conversion Rate is adjusted pursuant to Section 7.04(a), 7.04(b), 7.04(c), 7.04(d) or 7.04(e). The adjusted
Stock Prices shall equal the Stock Prices applicable immediately prior to such adjustment, multiplied by a fraction, the numerator of which is the Conversion Rate immediately prior to such adjustment giving rise to the Stock Price adjustment
and the denominator of which is the Conversion Rate as so adjusted. The number of Additional Shares set forth in the table below shall be adjusted in the same manner as, and at the same time and for the same events for which, the Conversion Rate is
adjusted pursuant to Section 7.04(a), 7.04(b), 7.04(c), 7.04(d) or 7.04(e). 
 (e) The following table sets forth the number of
Additional Shares of Common Stock by which the Conversion Rate shall be increased per $1,000 principal amount of Notes pursuant to this Section 7.07 for each Stock Price and effective date set forth below: 

 

																																													
	 	 	Stock Price	 
	 Effective Date
	 	$13.97	 	 	$17.00	 	 	$20.00	 	 	$22.35	 	 	$30.00	 	 	$35.76	 	 	$40.00	 	 	$45.00	 	 	$55.00	 	 	$65.00	 	 	$75.00	 
	 February 29, 2016
	 	 	26.8433	  	 	 	20.2953	  	 	 	16.0710	  	 	 	13.6944	  	 	 	8.9603	  	 	 	6.9600	  	 	 	5.9230	  	 	 	4.9949	  	 	 	3.7175	  	 	 	2.8774	  	 	 	2.2789	  
	 March 31, 2017
	 	 	26.8433	  	 	 	19.1159	  	 	 	14.8280	  	 	 	12.4492	  	 	 	7.8320	  	 	 	5.9597	  	 	 	5.0173	  	 	 	4.1936	  	 	 	3.0951	  	 	 	2.3957	  	 	 	1.9069	  
	 March 31, 2018
	 	 	26.8433	  	 	 	17.9029	  	 	 	13.4685	  	 	 	11.0403	  	 	 	6.4653	  	 	 	4.7148	  	 	 	3.8755	  	 	 	3.1738	  	 	 	2.2936	  	 	 	1.7683	  	 	 	1.4151	  
	 March 31, 2019
	 	 	26.8433	  	 	 	16.7765	  	 	 	12.0940	  	 	 	9.5459	  	 	 	4.8273	  	 	 	3.1390	  	 	 	2.4035	  	 	 	1.8518	  	 	 	1.2631	  	 	 	0.9649	  	 	 	0.7796	  
	 March 31, 2020
	 	 	26.8433	  	 	 	15.7959	  	 	 	10.8685	  	 	 	8.2362	  	 	 	3.2290	  	 	 	1.0825	  	 	 	0.0370	  	 	 	0.0000	  	 	 	0.0000	  	 	 	0.0000	  	 	 	0.0000	  
	 March 31, 2021
	 	 	26.8433	  	 	 	14.4600	  	 	 	9.0065	  	 	 	6.3669	  	 	 	2.2413	  	 	 	0.7640	  	 	 	0.0370	  	 	 	0.0000	  	 	 	0.0000	  	 	 	0.0000	  	 	 	0.0000	  
	 March 31, 2022
	 	 	26.8433	  	 	 	14.0847	  	 	 	5.2615	  	 	 	0.0040	  	 	 	0.0000	  	 	 	0.0000	  	 	 	0.0000	  	 	 	0.0000	  	 	 	0.0000	  	 	 	0.0000	  	 	 	0.0000	  

 If such effective date or Stock Price are not set forth in the table above, then: 

(i) if such Stock Price is between two Stock Prices in the table above or the effective date is between two effective dates in
the table above, then the number of Additional Shares will be determined by a straight-line interpolation between the numbers of Additional Shares set forth for the higher and lower Stock Prices in the table and the earlier and later effective dates
in the table above, as applicable, based on a 365- or 366-day year, as applicable; 
 (ii) if the Stock Price is greater than
$75.00 per share (subject to adjustment in the same manner as the Stock Prices set forth in the column headings of the table above are adjusted pursuant to Section 7.07(d)), then no Additional Shares will be added to the Conversion Rate; and

 (iii) if the Stock Price is less than $13.97 per share (subject to adjustment in the same manner as the Stock Prices set
forth in the column headings of the table above are adjusted pursuant to Section 7.07(d)), then no Additional Shares will be added to the Conversion Rate. 

Notwithstanding anything to the contrary, in no event will the Conversion Rate be increased pursuant to this Section 7.07 to an amount
that exceeds 69.3000 shares of Common Stock per $1,000 principal amount of Notes, which amount is subject to adjustment in the same manner as, and at the same time and for the same events for which, the Conversion Rate is required to be adjusted
pursuant to Section 7.04(a), 7.04(b), 7.04(c), 7.04(d) or 7.04(e). 

  
 -31- 

 Section 7.08 Taxes on Shares Issued. Any issue of shares of Common Stock upon the
conversion of Notes shall be made without charge to the converting Holder for any documentary, transfer, stamp or any similar tax in respect of the issue thereof, and the Company shall pay any and all documentary, stamp or similar issue or transfer
taxes or duties that may be payable in respect of the issue or delivery of shares of Common Stock, if any, upon conversion of Notes pursuant hereto. The Company shall not, however, be required to pay any such tax which may be payable in respect of
any transfer involved in the issue and delivery of shares in any name other than that of the Holder of any Notes converted, and, in addition to any other requirements or conditions set forth herein, the Company shall not be required to issue or
deliver any such shares unless and until the Person or Persons requesting the issue thereof shall have paid to the Company the amount of such tax or shall have established to the satisfaction of the Company that such tax has been paid. 

Section 7.09 Reservation of Shares; Listing. The Company shall at all times provide, out of its authorized but unissued shares or
shares held in treasury, sufficient shares of Common Stock to provide for the conversion of the Notes from time to time as such Notes are presented for conversion (assuming that, at the time of the computation of such number of shares, all such
Notes would be held by a single Holder). The Company will use its best efforts to cause all shares of Common Stock issued upon conversion of the Notes to be listed on any U.S. securities exchange upon which the Common Stock is then listed. 

Section 7.10 Shareholder Rights Plan. Each share of Common Stock, if any, issued upon conversion of Notes pursuant to this Article
7 shall be entitled to receive the appropriate number of rights, if any, and the certificates, if any, representing such shares shall bear such legends, if any, in each case as may be provided by the terms of any then-effective shareholder rights
agreement adopted by the Company, as any such agreement may be amended from time to time. Notwithstanding the foregoing, if, prior to any conversion of any Notes, such rights have separated from the Common Stock in accordance with the provisions of
the applicable shareholder rights agreement, then the Conversion Rate shall be adjusted at the time of separation as if the Company had distributed, to all holders of the Common Stock, Distributed Property as described in Section 7.04(c),
subject to readjustment in the event of the expiration, termination or redemption of such rights. Unless and until such rights have so separated, no adjustment to the Conversion Rate will be made pursuant to Section 7.04(c) on account of such
rights. 
 Section 7.11 Company Determination Final. Any determination that the Board of Directors contemplated pursuant to this
Article 7 shall be conclusive if made in good faith and in accordance with the provisions of this Article 7, absent manifest error. 

Section 7.12 Exchange in Lieu of Conversion. Notwithstanding anything to the contrary in this Article 7, and subject to the terms
of this Section 7.12, if a Note is to be converted, the Company may elect to arrange to have such Note exchanged in lieu of conversion by a financial institution designated by the Company. To make such election, the Company must provide written
notice of such election to the Holder of such Note before the Close of Business on the Business Day immediately after the Conversion Date for such Note. If the Company has made such election, then: 

(a) no later than the Business Day immediately after such Conversion Date, the Company must deliver such Note, together with delivery
instructions for the consideration due upon such conversion, to a financial institution designated by the Company that has agreed to deliver such consideration in the manner and at the time the Company would have had to deliver the same pursuant to
this Article 7; and 
 (b) such Note will not cease to be outstanding by reason of such exchange in lieu of conversion; 

provided, however, that if such financial institution does not accept such Note or fails to timely deliver such consideration, then the Company
will be responsible for delivering such consideration in the manner and at the time provided in this Article 7 as if the Company had not elected to make an exchange in lieu of conversion. 

  
 -32- 

 ARTICLE 8. 

REPRESENTATIONS, WARRANTIES AND COVENANTS 

Section 8.01 Representations and Warranties of Investors. Each Investor, severally and not jointly, hereby represents and
warrants, as of the Closing Date, as follows: 
 (a) It is an “accredited investor” as that term is defined in
Regulation D as promulgated under the Securities Act. It is purchasing the Notes and the shares of Common Stock, if any, issuable upon conversion thereof for its own account solely for investment purposes and not with a view to the resale or
distribution of the Notes or such shares of Common Stock. It has not been formed for the specific purpose of acquiring the Notes or such shares of Common Stock. 

(b) It has such knowledge and experience in financial and business matters as to be capable of evaluating the merits and risks
of investing in the Notes and shares of Common Stock, if any, issuable upon conversion thereof, and it is experienced in investing in capital markets and is able to bear the economic risk of investing in the Notes and such shares of Common Stock,
including a complete loss of such investment. 
 (c) It is aware that an investment in the Notes and shares of Common Stock,
if any, issuable upon conversion thereof involves a high degree of risk, and such securities are, therefore, a speculative investment. 

(d) The Company has not given any investment advice or rendered any opinion to it as to whether an investment in the Notes or
shares of Common Stock, if any, issuable upon conversion thereof is prudent or suitable. 
 (e) It acknowledges that it has
(i) had the opportunity to ask questions and receive answers from the Company, (ii) been furnished with all other materials that it considers relevant to an investment in the Notes and shares of Common Stock, if any, issuable upon a
conversion thereof and (iii) been given the opportunity fully to perform its own due diligence, in each case, to the extent it has determined adequate to invest in the Notes and shares of Common Stock, if any, issuable upon conversion thereof.

 (f) It has consulted its own legal, accounting, financial and tax advisors to extent it deems appropriate. 

(g) It has not engaged the services of a broker, investment banker or finder to contact any potential investor nor has it
agreed to pay any commission, fee or other remuneration to any third party to solicit or contact any potential investor. 

(h) It understands that the offer and sale of the Notes and shares of Common Stock, if any, issuable upon conversion thereof
have not been registered under the Securities Act, are “restricted securities” (within the meaning of Rule 144 under the Securities Act) and it is purchasing the Notes and shares of Common Stock, if any, issuable upon conversion thereof in
accordance with a valid exemption from the registration requirements under the Securities Act. It acknowledges that it will receive the Notes and (in certain circumstances) shares of Common Stock, if any, issuable upon conversion thereof with a
restrictive legend imprinted upon them. It will not offer, sell, pledge, hedge or otherwise transfer any Notes or shares of Common Stock, if any, issuable upon conversion thereof except in a transaction that complies with the Securities Act and
other applicable securities laws. 
 (i) It has not been solicited by any Person to purchase any Notes or share of Common
Stock issuable upon conversion of the Notes by means of any general solicitation or advertising within the meaning of the Securities Act. 

  
 -33- 

 (j) Neither it nor any of its Affiliates has, in connection with the transactions
contemplated by this Agreement, directly or indirectly, engaged in any Hedging and Short Sales in connection with the Notes or the shares of Common Stock issuable upon conversion of the Notes. 

Section 8.02 Representations and Warranties of the Credit Parties. Each Credit Party hereby represents and warrants to the
Investors and their respective Affiliates that, as of the Closing Date (except for any representations and warranties which speak as to a specific date, which representations and warranties shall be made as of the date specified): 

(a) Existence. The Company and each of its Subsidiaries (i) is a corporation duly incorporated, validly existing
and in good standing under the laws of its jurisdiction of incorporation; (ii) has all necessary powers, licenses, authorizations, consents and approvals required to carry on its business as now conducted and to own and lease its properties;
and (iii) is duly qualified to do business as a foreign corporation, and is in good standing, in every jurisdiction in which its business or properties require such qualification, except, in the case of clause (ii) or (iii), to the extent
that the failure to have such powers, licenses, authorizations, consents or approvals or to be so qualified and in good standing could not reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect. 

(b) Authorization. Such Credit Party has all necessary power and authority to enter into, execute and deliver this
Agreement and the other Note Documents and to perform all of the obligations to be performed by it hereunder and thereunder and to consummate the transactions contemplated hereby and thereby. 

(c) Enforceability. This Agreement has been duly authorized, executed and delivered by such Credit Party and
constitutes, and each of the other Note Documents have been duly authorized by such Credit Party and, when executed and delivered by such Credit Party, will constitute, valid and binding obligations of such Credit Party, enforceable against such
Credit Party in accordance with their terms, assuming the due authorization, execution and delivery by the other parties hereto and thereto (if applicable) and subject to laws of general application relating to bankruptcy, insolvency,
reorganization, moratorium or similar laws affecting creditors’ rights generally or general equitable principles (regardless of whether enforcement is sought in equity or at law) and rules of law governing specific performance, injunctive
relief and other equitable remedies. 
 (d) Governmental Authorization. None of the execution and delivery by such
Credit Party of Note Documents, the performance by such Credit Party of any of the obligations to be performed by them hereunder or thereunder, or the consummation by such Credit Party of any of the transactions contemplated hereby or thereby, will
require any notice to, action, approval or consent by, or in respect of, or filing or registration with any Governmental Authority or other Person, except (i) filings required to be made with the Commission and NASDAQ and (ii) in
connection with the conversion of any Note, any required approval, or the expiration of the applicable waiting period, under the HSR Act. 

(e) No Conflicts. Except as could not reasonably be expected to have, individually or in the aggregate, a Material
Adverse Effect, no consent or approval of, or notice to, any Person is required by the terms of any Material Contract for the execution or delivery of, or the performance of the obligations of such Credit Party under, this Agreement and the other
Note Documents to which such Credit Party is party or the consummation of the transactions contemplated hereby or thereby, and such execution, delivery, performance and consummation will not result in any breach or violation of, or constitute a
default under any Material Contract or any law applicable to such Credit Party, any of its Subsidiaries or any of its or their assets. 

(f) No Material Adverse Effect. Since December 31, 2014, there has been no change, effect, event, state of facts,
development, condition or circumstance that has had, or could reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect. 

(g) Authorization of the Common Stock. The shares of Common Stock, if any, issuable upon conversion of the Notes have
been duly authorized and reserved for issuance upon such conversion by 

  
 -34- 

 
all necessary corporate action, and such shares, when issued upon such conversion, will be validly issued and will be fully paid and non-assessable and free and clear of all liens under the
Company’s certificate of incorporation and bylaws or under the Delaware General Corporation Law; and the issuance of such shares upon such conversion will not be subject to the preemptive or other similar rights of any securityholder of the
Company pursuant the Company’s certificate of incorporation or bylaws, the Delaware General Corporation Law or any Material Contract. 

(h) Public Filings, Etc. As of the Closing Date, none of the Company’s Annual Report on Form 10-K for the period
ended December 31, 2014, Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2015 or other public filings of the Company filed with the Commission since January 1, 2016 pursuant to the Exchange Act included or
includes an untrue statement of a material fact or omitted or omits to state a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading. 

(i) Solvency. Immediately after the issuance of the Initial Notes, (i) excluding contingent liabilities of the
Company to Baxalta Incorporated, Baxalta US Inc. and Baxalta GmbH pursuant to that certain Amended and Restated License Agreement by and among the Company, Baxter International Inc., Baxter Healthcare Corporation and Baxter Healthcare SA, dated
April 10, 2015, the fair value of the properties and assets of the Company and its Subsidiaries on a going concern basis will exceed its debts and liabilities, subordinated, contingent or otherwise; (ii) the present fair saleable value of
the property of the Company and its Subsidiaries on a going concern basis will be greater than the amount that will be required to pay the probable liability of its debts and other liabilities, subordinated, contingent or otherwise, as such debts
and other liabilities become absolute and matured; (iii) the Company and its Subsidiaries will be generally able to pay its debts and liabilities, subordinated, contingent or otherwise, as such debts and liabilities become absolute and matured;
and (iv) the Company and its Subsidiaries will not have unreasonably small capital with which to conduct its business, as now conducted. 

(j) Investment Company Act. Such Credit Party is not an “investment company,” as defined in the Investment
Company Act of 1940, as amended. 
 (k) Foreign Corrupt Practices Act. Neither the Company nor any of its Subsidiaries
nor, to the Company’s knowledge, any of its directors, officers, employees, Affiliates or agents has taken any action, directly or indirectly, that would result in a violation by such Persons of the FCPA, including making use of the mails or
any means or instrumentality of interstate commerce corruptly in furtherance of an offer, payment, promise to pay or authorization of the payment of any money, or other property, gift, promise to give, or authorization of the giving of anything of
value to any “foreign official” (as such term is defined in the FCPA) or any foreign political party or official thereof or any candidate for foreign political office, in contravention of the FCPA. The Company, its Subsidiaries and, to the
Company’s knowledge, its Affiliates have conducted their respective businesses in compliance in all material respects with the FCPA and have instituted and maintain policies and procedures designed to ensure, and which are reasonably expected
to continue to ensure, continued compliance therewith. 
 (l) Broker’s Fees. Except for any fees payable by the
Company to J. Wood Capital Advisors LLC, neither the Company nor any of its Subsidiaries has taken any action that would entitle any Person to any commission or broker’s, finder’s, placement or other similar fee in connection with the
transactions contemplated herein. 
 (m) Private Offering; No Integration or General Solicitation. 

(i) Assuming (i) the Initial Notes are issued, sold and delivered under the circumstances contemplated by this Agreement
and (ii) the accuracy of the representations and warranties of the Investors set forth in Section 8.01, and their compliance with the agreements set forth herein, it is not necessary in connection with the offer, sale and delivery of the
Initial Notes to the Investors in the manner contemplated by this Agreement to register the offer and sale of such Initial Notes to the Investors under the Securities Act. 

  
 -35- 

 (ii) The Company has not, directly or indirectly, offered, sold or solicited any
offer to buy, and the Company will not, directly or indirectly, offer, sell or solicit any offer to buy, any security of a type or in a manner which would be integrated with the sale of the Initial Notes and require the offer and sale of the Initial
Notes to the Investors to be registered under the Securities Act. Neither the Company nor any of its Affiliates or any Person acting on its behalf (other than the Holders, as to whom the Company makes no representation or warranty) has engaged or
will engage in any form of general solicitation or advertising (within the meaning of Rule 502(c) under the Securities Act) in connection with the offering and sale of the Initial Notes to the Investors pursuant to this Agreement. 

(n) Regulatory Disclosure. The Company has disclosed to HCR Investor and its representatives and consultants all
correspondence, notices, information and documents reasonably believed by the Company to be material to the Company’s business as of the Closing Date and received from the FDA or any similar Governmental Authority regarding any of the
Company’s products. 
 (o) Intellectual Property. To the knowledge of the Company, each Credit Party owns, or is
licensed to use, all trademarks, tradenames, copyrights, patents, and other intellectual property used in its business as currently conducted and the use thereof by such Credit Party does not infringe upon the rights of any other Person, except as
could not reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect. 
 (p) Tax Returns
and Payments. Except for any failure to file or pay, collect or remit that could not reasonably be expected, individually or in the aggregate, to result in a Material Adverse Effect, each Credit Party has (i) timely filed or caused to be
timely filed all Tax Returns required to have been filed by it and all such Tax Returns are true and correct in all material respects and (ii) duly and timely paid, collected or remitted or caused to be duly and timely paid, collected or
remitted all Taxes (whether or not shown on any Tax Return) due and payable, collectible or remittable by it (including in its capacity as a withholding agent), except Taxes that are being contested in good faith by appropriate proceedings and for
which the applicable Credit Party has set aside on its books adequate reserves in accordance with GAAP. 
 (q) Survival of
Representations and Warranties. All representations and warranties of the Company and the Guarantors contained in this Agreement shall survive the execution, delivery and acceptance thereof by the Investors and the issuance of the Initial Notes
for a period of two (2) years from the Closing Date. 
 Section 8.03 HSR Act Matters. Each of the Company and each Investor
agrees to cooperate with each other and use its commercially reasonable efforts to obtain or submit, as the case may be, the approvals and authorizations of, filings and registrations with, and notifications to, or expiration or termination of any
applicable waiting period, under the HSR Act, in each case with respect to any proposed conversion of the Notes, if applicable. Without limiting the foregoing, the Investors and the Company will prepare and file a Notification and Report Form
pursuant to the HSR Act in connection with any proposed conversion of the Notes, if applicable. 
 Section 8.04 Agreement Not to
Tender in Certain Fundamental Changes. If a Fundamental Change occurs pursuant to clause (a) of the definition of such term where the “person” or “group” referred to in such clause is, or includes, any Holder or
beneficial owner of Notes, or any Affiliate thereof, then such Holder or owner agrees not, and not to permit any of its Affiliates, to deliver any Fundamental Change Repurchase Notice with respect to, or otherwise tender, any such Notes in any offer
to repurchase Notes by the Company in connection with such Fundamental Change. 

  
 -36- 

 ARTICLE 9. 

EVENTS OF DEFAULT; REMEDIES 

Section 9.01 Events of Default. “Event of Default,” wherever used herein, means any one of the following events
(whatever the reason for such Event of Default and whether it shall be voluntary or involuntary or be effected by operation of law or pursuant to any judgment, decree or order of any court or any order, rule or regulation of any administrative or
Governmental Authority): 
 (a) default by the Company in any payment of principal, premium or interest on any Notes when due
and payable on an Interest Payment Date, the Maturity Date or any Redemption Date or Fundamental Change Repurchase Date, upon declaration of acceleration or otherwise and, in the case of any such default in the payment of interest, such default
continues for five (5) days; 
 (b) failure by the Company to comply with its obligation to convert the Notes in
accordance with this Agreement upon exercise of a Holder’s conversion right, and such failure continues for a period of five (5) Business Days; 

(c) failure by the Company to comply with its obligations under Article 10, hereof and such failure continues for a period of
ten (10) Business Days; 
 (d) any Guarantees cease to be in full force and effect (except as contemplated by the terms
of this Agreement), or are declared null and void in a judicial proceeding, or any Credit Party denies or disaffirms (in writing) their respective obligations under this Agreement or the applicable Guarantee; 

(e) failure by the Company in the performance of any other covenant or agreement of the Company in the Notes or in this
Agreement that continues for a period of thirty (30) days after the earlier of (i) actual knowledge by the Company of such failure and (ii) receipt by the Company from the Holders of at least twenty five percent (25%) of the
aggregate principal amount of Notes then outstanding of a Notice of Default with respect to such failure; 
 (f) failure by
the Company to issue a Fundamental Change Company Notice or notice of the effective date of a Make-Whole Fundamental Change, in each case, for a period of five (5) Business Days after the date the same is due; 

(g) a default by the Company or any of its Subsidiaries with respect to any one or more mortgages, agreements or other
instruments under which there is outstanding, or by which there is secured or evidenced, any Indebtedness for money borrowed of at least ten million dollars ($10,000,000) (or its foreign currency equivalent) in the aggregate of the Company or any of
its Subsidiaries, whether such Indebtedness exists as of the Closing Date or is thereafter created, where such default: 

(i) constitutes a failure to pay the principal of any of such indebtedness when due and payable at the stated maturity of such
Indebtedness, upon required repurchase, upon declaration of acceleration or otherwise, in each case after the expiration of any applicable grace period; and 

(ii) results in such indebtedness becoming or being declared due and payable before its stated maturity; 

(h) the entry by a court having jurisdiction in the premises of (i) a decree or order for relief in respect of the Company
or any Significant Subsidiary of the Company of a voluntary case or proceeding under any applicable federal, state or foreign bankruptcy, insolvency, reorganization or other similar law, (ii) a decree or order adjudging the Company or a
Significant Subsidiary of the Company as bankrupt or insolvent, or approving as properly filed a petition seeking reorganization, arrangement, adjustment or composition of or in respect of the Company or any Significant Subsidiary of the Company
under any applicable federal, state or foreign law or (iii) appointing a custodian, receiver, liquidator, assignee, trustee, sequestrator or other similar official of the Company or of a Significant Subsidiary of the Company of any substantial
part of its property, or ordering the winding up or liquidation of its affairs, and the continuance of any such decree or order for relief or any such other decree or order unstayed and in effect for a period of sixty (60) consecutive days;

 (i) the commencement by the Company or by a Significant Subsidiary of the Company of a voluntary case or proceeding under
any applicable federal, state or foreign bankruptcy, insolvency, reorganization or other similar law or of any other case or proceeding to be adjudicated a bankrupt or 

  
 -37- 

 
insolvent, or the consent by it to the entry of a decree or order for relief in respect of the Company or of a Significant Subsidiary of the Company in an involuntary case or proceeding under any
applicable federal, state or foreign bankruptcy, insolvency, reorganization or other similar law or to the commencement of any bankruptcy or insolvency case or proceeding against it, or the filing by it of a petition or answer or consent seeking
reorganization or relief under any applicable federal, state or foreign bankruptcy, insolvency, reorganization or other similar, or the consent by it to the filing of such petition or to the appointment of or taking possession by a custodian,
receiver, liquidator, assignee, trustee, sequestrator or other similar official of the Company or of a Significant Subsidiary of the Company or of any substantial part of such entity’s property, or the making by it of an assignment for the
benefit of creditors, or the admission by it in writing of its inability to pay its debts generally as they become due, or the taking of corporate action by the Company or by a Significant Subsidiary of the Company in furtherance of any such action;

 (j) any uninsured judgment, decree or order in excess of ten million dollars ($10,000,000) (excluding amounts subject to
indemnification from third parties for which the third party has acknowledged liability) shall be rendered against the Company and any of its Subsidiaries and either (i) enforcement proceedings shall have been commenced upon such judgment,
decree or order or (ii) such judgment, decree or order shall not have been settled, satisfied, stayed, vacated or discharged within thirty (30) days from entry; and 

(k) an Event of Default declared pursuant to Section 9.03(b). 

Section 9.02 Reporting Defaults. 

(a) Notwithstanding anything to the contrary, the Company may elect that the sole remedy for any Event of Default (a “Reporting Event
of Default”) pursuant to Section 9.01(e) arising from the Company’s failure to comply with Section 4.03 will, for each of the first one hundred and eighty (180) calendar days on which a Reporting Event of Default has
occurred and is continuing, consist exclusively of the accrual of Special Interest on the Notes. If the Company has made such an election, then the Notes will be subject to acceleration pursuant to Section 9.03 on account of the relevant
Reporting Event of Default from, and including, the one hundred and eighty first (181st) calendar day on which a Reporting Event of Default has occurred and is continuing or if the Company fails to pay any accrued and unpaid Special Interest
when due. 
 (b) Any Special Interest that accrues on a Note pursuant to Section 9.02(a) will be payable on the same dates and in the
same manner as the Stated Interest on such Note and will accrue at a rate per annum equal to (i) one quarter of one percent (0.25%) of the principal amount thereof for the first ninety (90) calendar days following the Reporting Event of
Default and (ii) one half of one percent (0.50%) thereafter until such Reporting Event of Default shall have been cured; provided, however, that in no event will Special Interest, together with any Additional Interest, accrue on
any day on a Note at a combined rate per annum that exceeds one-half of one percent (0.50%). For the avoidance of doubt, any Special Interest that accrues on a Note will be in addition to the Stated Interest that accrues on such Note and, subject to
the proviso of the immediately preceding sentence, in addition to any Additional Interest or Default Interest that accrues on such Note. 

(c) To make the election set forth in Section 9.02(a), the Company must send to the Holders, before the date on which each Reporting
Event of Default first occurs, a written notice that states that the Company is electing that the sole remedy for such Reporting Event of Default consist of the accrual of Special Interest. 

Section 9.03 Acceleration of Maturity; Waiver of Past Defaults and Rescission. 

(a) If an Event of Default (other than an event of default pursuant to Section 9.01(k), as to which the provisions of Section 9.03(b)
will apply, and other than an Event of Default specified in Section 9.01(h) or Section 9.01(i) with respect to the Company and not solely with respect to any Significant Subsidiaries of the Company) occurs and is continuing, then and in
every such case the Holders of at least a majority in the aggregate Principal Amount of the outstanding Notes may declare 100% of the Principal Amount plus the Repayment Premium plus accrued and unpaid interest on all the outstanding
Notes to be due and payable immediately, by a notice in writing to the Company (and to the other Holders if given by any Holder), and upon any such declaration, such Principal Amount, Repayment Premium and accrued and unpaid interest shall become
immediately due and payable. 

  
 -38- 

 Notwithstanding the foregoing, in the case of an Event of Default specified in
Section 9.01(h) or Section 9.01(i) with respect to the Company (and not solely with respect to any Significant Subsidiaries of the Company), 100% of the Principal Amount plus the Repayment Premium plus accrued and unpaid
interest on all outstanding Notes will automatically become due and payable without any declaration or other act on the part of any Holder. 

(b) If any representation or warranty of the Company or any of its Subsidiaries in any Note Document to which it is party or in any
certificate, financial statement or other document delivered by the Company or such Subsidiary in connection with this Agreement proves to have not been true and correct in any material respect at the time it was made (except that any representation
or warranty that is qualified as to “materiality” or “Material Adverse Effect” shall be true and correct in all respects), then Holders of a majority in aggregate Principal Amount of Notes then outstanding which are held by any
of the Investors (or their Affiliates) will have the right to designate such event to constitute an Event of Default and the right to declare 100% of the Principal Amount plus the Repayment Premium plus accrued and unpaid interest on
all the outstanding Notes to be due and payable immediately, in each case by a notice in writing to the Company (and to the other Holders if given by any Holder), and upon any such declaration, such Principal Amount, Repayment Premium and accrued
and unpaid interest shall become immediately due and payable. 
 (c) The Holders of a majority in aggregate Principal Amount of the
outstanding Notes, by written notice to the Company and each other Holder, may (x) waive any past Default and its consequences and (y) at any time after a declaration of acceleration has been made and before a judgment or decree for
payment of the money due has been obtained, rescind any such acceleration with respect to the Notes and its consequences, except, in each case, with respect to a Default described in Section 9.01(a), Section 9.01(b) or
Section 9.01(d), or in respect of a covenant or provision hereof which under Article 13 cannot be modified or amended without the consent of the Holder of each outstanding Note affected, if: 

(i) such rescission will not conflict with any judgment or decree of a court of competent jurisdiction; and 

(ii) all existing Events of Default (except the non-payment of Principal Amount, Repayment Premium and accrued and unpaid
interest that has become due solely because of such acceleration) have been cured or waived. 
 Upon any such waiver, the Default which has
been waived shall cease to exist and any Event of Default arising therefrom shall be deemed to have been cured, for every purpose of the Agreement; but no such waiver shall extend to any subsequent or other Default or impair any right consequent.

 No such rescission shall affect any subsequent default or impair any right consequent thereon. 

Section 9.04 Unconditional Right of Holders to Receive Payment and Convert. Notwithstanding any other provision of this Agreement,
the right of any Holder to receive payment of the Principal Amount (including interest in respect of the Notes held by such Holder, on or after the respective due dates expressed in the Notes or otherwise, as applicable), any accrued and unpaid
interest and to convert the Notes in accordance with Article 7, or to bring suit for the enforcement of any such payment on or after such respective dates or the right to convert, shall not be impaired or affected without the consent of such Holder.

 Section 9.05 Restoration of Rights and Remedies. If any Holder has instituted any proceeding to enforce any right or remedy
under this Agreement and such proceeding has been discontinued or abandoned for any reason, or has been determined adversely to such Holder, then and in every such case, subject to any determination in such proceeding, the Company and the Holders
shall be restored severally and respectively to their former positions hereunder and thereafter all rights and remedies of the Holders shall continue as though no such proceeding had been instituted. 

Section 9.06 Rights and Remedies Cumulative. Except as otherwise provided with respect to the replacement or payment of mutilated,
destroyed, lost or stolen Notes in the last paragraph of Section 3.07, no right or remedy herein conferred upon or reserved to the Holders is intended to be exclusive of any other right or remedy,

  
 -39- 

 
and every right and remedy shall, to the extent permitted by law, be cumulative and in addition to every other right and remedy given hereunder or now or hereafter existing at law or in equity or
otherwise. The assertion or employment of any right or remedy hereunder shall not prevent the concurrent assertion or employment of any other appropriate right or remedy. 

Section 9.07 Delay or Omission Not Waiver. No delay or omission of any Holder of any Note to exercise any right or remedy accruing
upon any Event of Default shall impair any such right or remedy or constitute a waiver of any such Event of Default or an acquiescence therein. Every right and remedy given by this Article or by law to the Holders may be exercised from time to time,
and as often as may be deemed expedient, by the Holders. 
 Section 9.08 Control by Holders. The Holders of a majority in
aggregate Principal Amount of the outstanding Notes may direct the time, method and place of conducting any proceeding for any remedy available to the Holders. 

Section 9.09 Undertaking for Costs. In any suit for the enforcement of any right or remedy under this Agreement in respect of the
Notes, a court may require any party litigant in such suit to file an undertaking to pay the costs of the suit, and the court may assess reasonable costs, including reasonable attorney’s fees and expenses, against any party litigant in the suit
having due regard to the merits and good faith of the claims or defenses made by the party litigant; but the provisions of this Section 9.09 shall not apply to any suit instituted by the Company or to any suit instituted by any Holder for the
enforcement of the payment of the Principal Amount on any Note on or after the Maturity Date of such Note. 
 ARTICLE 10. 

MERGER, CONSOLIDATION OR SALE OF ASSETS 

Section 10.01 Company May Consolidate, etc., only on Certain Terms. The Company shall not, in a single transaction or through a
series of related transactions, consolidate or merge with or into any other Person, or, directly or indirectly, sell, convey, transfer, lease or otherwise dispose of all or substantially all of the consolidated assets of the Company and its
Subsidiaries, taken as a whole, to another Person or group of affiliated Persons (in each case other than to one or more of its Wholly Owned Subsidiaries), except that the Company may consolidate or merge with or into, or sell, convey, transfer,
lease or otherwise dispose of all or substantially all of the consolidated assets of the Company and its Subsidiaries, taken as a whole, to another Person or group of affiliated Persons if: 

(a) the Company is the surviving Person or the resulting, surviving, transferee or successor Person (the “Successor Company”)
(if other than the Company) expressly assumes, by an agreement supplemental hereto, all obligations of the Company under this Agreement, including payment of the Principal Amount and interest on the Notes, and the performance and observance of all
of the covenants and conditions of this Agreement to be performed by the Company; and 
 (b) immediately after giving effect to such
transaction, no Default under this Agreement has occurred and is continuing. 
 Section 10.02 Successor Substituted. Upon any
consolidation of the Company with, or merger of the Company with or into, any other Person or any sale, conveyance, transfer, lease or other disposal of all or substantially all of the consolidated assets of the Company and its Subsidiaries, taken
as a whole, to another Person or group of affiliated Persons in accordance with Section 10.01, the Successor Company formed by such consolidation or with or into which the Company is merged or to which such sale, conveyance, transfer, lease or
other disposal is made shall succeed to, and may exercise every right and power of, the Company under this Agreement with the same effect as if such Successor Company had been named as the Company herein. If the predecessor is still in existence
after such transaction, it will be released from its obligations and covenants under this Agreement and the Notes, except in the case of a lease of all or substantially all of the consolidated assets of the Company and its Subsidiaries, taken as a
whole. 

  
 -40- 

 ARTICLE 11. 

REGISTRATION RIGHTS 

Section 11.01 Demand Registrations. 

(a) At any time after the Closing Date, any Holder or Holders (each, together with any Holder requesting registration pursuant to, and in
compliance with, Section 11.02, a “Requesting Holder”) may deliver a written request to the Company in accordance with Section 14.01 (a “Demand”) that the Company effect a registration with respect to the
Registrable Securities under the Securities Act to cover a registered sale of such Registrable Securities for cash by such Requesting Holder. Such Demand shall specify the number of Registrable Securities such Requesting Holder intends to include in
such registration and the methods by which such Requesting Holder intends to sell or dispose of such Registrable Securities (including whether such Requesting Holder intends to distribute the Registrable Securities by means of an underwritten
offering (an “Underwritten Offering”) or pursuant to sales from time to time without an underwriter (a “Shelf Offering”)); provided, however, that in no event may any Requesting Holder make a Demand
for an Underwritten Offering unless the Registrable Securities to be offered and sold by such Requesting Holder in such Underwritten Offering are reasonably expected to result in gross proceeds to such Requesting Holder of at least twenty million
dollars ($20,000,000). Upon receipt of such Demand, the Company shall, subject to the terms and conditions of this Article 11, use its commercially reasonably efforts (subject, for the avoidance of doubt, to Blackout Periods to the extent provided
in Section 11.04) to (i) file and cause to become effective under the Securities Act a Registration Statement covering the resale of such Registrable Securities by such Requesting Holder as soon as reasonably practicable; (ii) qualify
such Registrable Securities under applicable blue sky or other securities laws of any state of the United States of America to the extent set forth herein; and (iii) comply in all material respects with applicable regulations issued under the
Securities Act and any other governmental requirements or regulations, in each case in such a manner as would permit or facilitate the distribution in an underwritten offering or other sale of all or any portion of such Registrable Securities as
reasonably specified in such Demand. 
 (b) In connection with any Demand that requests an Underwritten Offering, the Requesting Holders
named as selling securityholders in the related Registration Statement shall be entitled to select (subject to the Company’s approval, with will not be unreasonably withheld or delayed) the lead managing underwriter thereof, and the Company
shall enter into any reasonable and customary agreement requested by such lead managing underwriter in connection with such Underwritten Offering, including, but not limited to, an underwriting agreement in customary form with such lead managing
underwriter; provided, however, that in no event shall the Company be required to include shares of Common Stock or any other securities for its own account in such offering. 

(c) Notwithstanding anything to the contrary: 

(i) upon the Company’s receipt of any Demand by a Requesting Holder pursuant to Section 11.01(a), the Company will
have the right to amend any Registration Statement theretofore filed pursuant to this Section 11.01 to add such Requesting Holder as a selling securityholder thereunder; and 

(ii) in no event will the Company be obligated to effect more than three (3) Underwritten Offerings pursuant to this
Section 11.01 (provided for this purpose, an offering shall not constitute an Underwritten Offering unless and until it is completed). 

Section 11.02 Piggyback Registration. 

(a) If the Company at any time determines to file a registration statement under the Securities Act to register the offer and sale, by the
Company, of Common Stock (other than (x) on Form S-4 or Form S-8 under the Securities Act or any successor forms thereto, (y) an at-the-market offering, or (z) a Registration of securities solely relating to an offering and sale to
employees or directors of the Company pursuant to any employee stock plan or other employee benefit plan arrangement) or a registration statement, or in connection with an Underwritten Offering, pursuant to Section 11.01, the Company shall, as
soon as reasonably practicable (but in no event will the Company be required to provide such notice before the time such Registration Statement is filed with the Commission and in no event will the Company be required to provide any information that
might be considered material non-public information), give written notice to each Holder of its intention to so register the offer and sale 

  
 -41- 

 
of Common Stock and, upon the written request, given within five (5) Business Days after delivery of any such notice by the Company, of any such Holder to include in such registration
Registrable Securities (which request shall specify the number of Registrable Securities proposed to be included in such registration), subject to Section 11.02(b), the Company shall cause all such Registrable Securities to be included in such
registration statement on the same terms and conditions as the Common Stock otherwise being sold pursuant to such registered offering. 

(b) In the event the registration statement referred to in Section 11.02(a) relates to an Underwritten Offering, if the managing
underwriter advises the Company that the inclusion of all such Registrable Securities proposed to be included in such registration pursuant to this Section 11.02 would interfere with the successful marketing (including pricing) of the Common
Stock to be offered thereby, then the number of shares of Common Stock proposed to be included in such registration shall be allocated among the Company and the selling Investors (i) first, to the Common Stock to be offered by the Company, if
any; and (ii) second, to the Registrable Securities to be offered by the Requesting Holders on a pro rata basis. 
 (c)
Notwithstanding anything to the contrary, (i) the Company retains the right, exercisable in its sole discretion, to abandon or delay the offering contemplated by any registration statement referred to in Section 11.02(a) and to withdraw
any such registration statement, in which event any offering of Registrable Securities contemplated therein will be similarly abandoned or delayed; and (ii) no Holder will have any right to receive any notice or to include any Registrable
Securities in any registration statement pursuant to this Section 11.02 to the extent that, at such time, a Registration Statement covering the resale of such Holders Registrable Securities has been filed and is effective in accordance with
Section 11.01. 
 Section 11.03 Obligations of the Company. At such time as the Company is obligated to file a Registration
Statement with the Commission pursuant to this Article 11, the Company shall also be obligated to use commercially reasonable efforts to take the following actions: 

(a) promptly prepare and file with the Commission such amendments and supplements to any Registration Statement filed and the
prospectus used in connection therewith as may be necessary to keep such Registration Statement effective, in the case of an Underwritten Offering, until the completion of such offering, and in the case of a Shelf Offering, until such time as the
Registrable Securities of the Holders subject to such registration shall have been sold pursuant thereto or such Registrable Securities have been, or could be without restriction, sold pursuant to Rule 144 or another available exemption from the
registration requirement of the Securities Act; 
 (b) a reasonable period of time before filing a Registration Statement or
prospectus or any amendments or supplements thereto (excluding documents to be incorporated by reference therein), furnish to one (1) legal counsel for the Holders participating in such offering and, if applicable, one (1) legal counsel
for the underwriters, if any, copies of all such documents in substantially the form proposed to be filed, to enable such counsel to review such documents prior to the filing thereof, and the Company shall make such reasonable changes thereto as may
be reasonably requested by such counsel; 
 (c) furnish or make available to each Holder participating in such offering, and
each underwriter, if any, without charge, such number of conformed copies of the Registration Statement and each post-effective amendment thereto, including financial statements (but excluding schedules, all documents incorporated or deemed to be
incorporated therein by reference, and all exhibits, unless requested in writing by such Holder or underwriter(s)), and such other documents, as such Holders or such underwriter(s) may reasonably request, and upon request a copy of any and all
transmittal letters or other correspondence to or received from, the Commission or any other relevant Governmental Authority relating to such offering; provided, however, that the Company will in no event be required to provide copies
of any documents that have been filed with the Commission on its EDGAR system (or any successor thereto); 
 (d) cooperate
with the Holders participating in such offering and the underwriter(s), if any, to facilitate the timely preparation and delivery of certificates (not bearing any legends) representing Registrable Securities to be sold after receiving written
representations and covenants from each such Holder in form reasonably satisfactory to the Company that the Registrable Securities represented by the 

  
 -42- 

 
certificates so delivered by such Holder have been sold, and will be transferred, in accordance with the Registration Statement, and enable such Registrable Securities to be in such denominations
and registered in such names as the underwriter(s), if any, or such Holders may request reasonably promptly following such sale; 

(e) register and qualify the securities covered by such Registration Statement under “blue sky” laws of such U.S.
jurisdictions as shall be reasonably requested by the underwriter(s), if any, and Holders (and to maintain such registrations and qualifications effective for the applicable period of time set forth in Section 11.03(a) above), and to do any and
all other acts and things that may be necessary or advisable to enable the underwriter(s), if any, and such Holders to consummate the disposition in such jurisdictions of such shares; provided, however, that the Company will not be
required to (i) qualify generally to do business in any jurisdiction where it would not be required but for this Section 11.03(e), (ii) subject itself to taxation in any such jurisdiction, or (iii) file any general consent to
service of process in any such jurisdiction; 
 (f) notify each Holder of Registrable Securities covered by such Registration
Statement at any time when a prospectus relating thereto is required to be delivered under the Securities Act of the happening of any event as a result of which the prospectus included in such Registration Statement, as then in effect, includes an
untrue statement of a material fact or omits to state a material fact necessary to make the statements therein, in the light of the circumstances under which they are made, not misleading. The Company will use all reasonable efforts to amend or
supplement such prospectus or Registration Statement or any document incorporated or deemed to be incorporated therein by reference, or file any other required document, as applicable, as soon as practicable in order to cause such prospectus to not
include any untrue statement of a material fact or omit to state a material fact necessary to make the statements therein, in the light of the circumstances under which they are made, not misleading; 

(g) notify each Holder of Registrable Securities covered by such Registration Statement and the underwriter(s), if any:
(i) when the prospectus or any prospectus supplement or post-effective amendment has been filed, and, with respect to the Registration Statement or any post-effective amendment, when the same has become effective; (ii) of any request by
the Commission for amendments or supplements to the Registration Statement or the prospectus or for additional information; (iii) of the issuance by the Commission of any stop order suspending the effectiveness of the Registration Statement or
the initiation of any proceedings for that purpose; and (iv) of the receipt by the Company of any notification with respect to the suspension of the qualification of the Registrable Securities for sale in any jurisdiction or the initiation or
threatening of any proceeding for such purpose; 
 (h) furnish, in the case of any Underwritten Offering of Registrable
Securities pursuant to this Article 11, at the request of the underwriter(s), on the date that such Registrable Securities are delivered to the underwriters, the letter (including any “bring-downs” related thereto) from the independent
registered accounting firm of the Company issued pursuant to the underwriting agreement relating to such Underwritten Offering; 

(i) cause all Registrable Securities sold pursuant to a Registration Statement to be listed on the stock exchange, if any, on
which the Company’s Common Stock is then listed; 
 (j) make such representations and warranties to the underwriter(s),
if any, in form, substance and scope as are customarily made by issuers to underwriters in underwritten offerings by selling stockholders of comparable size and confirm the accuracy of the same if and when reasonable and customarily requested by
such underwriters, and matters relating to the compliance of the Registration Statement and the prospectus with the Securities Act; 

(k) bear all expenses in connection with the procedures in this Article 11 and the registration of the offer and sale of the
Registrable Securities pursuant to the Registration Statement, including the reasonable fees and disbursements of a single counsel (together with no more than one local counsel) for the Requesting Holders designated in writing to the Company by
Requesting Holders holding a majority of the Registrable Securities (such counsel(s), the “Designated Counsel”); provided, however, that the 

  
 -43- 

 
Company will in no event bear, and each Holder shall instead bear, the cost of Selling Expenses with respect to such Holder’s Registrable Securities, if any, in connection with the offering
of the Registrable Securities pursuant to the Registration Statement, and each Holder and any other Person participating in such offering shall bear all such specified Selling Expenses pro rata among each other on the basis of the number of
Registrable Securities which have been registered; provided, further, the fees and disbursements of any Designated Counsel to be borne by the Company will in no event exceed, in the aggregate, fifty thousand dollars ($50,000) per
Underwritten Offering or, without duplication, per registration statement filed pursuant to Section 11.01 or Section 11.02 in which any Requesting Holder is named as a selling stockholder. 

(l) in the event of the issuance of any stop order suspending the effectiveness of a Registration Statement, or of any order
suspending or preventing the use of any related prospectus or suspending the qualification of any Registrable Securities included in such Registration Statement for sale in any jurisdiction, use all reasonable efforts to obtain the withdrawal of
such order as soon as practicable; and 
 (m) to the extent reasonably and customarily requested by any underwriter for
purposes of a disposition of Registrable Securities in an Underwritten Offering pursuant to this Article 11, provide such underwriter, its attorneys and agents the opportunity to conduct a reasonable due diligence investigation with respect to the
Company; provided, however, that such Persons will, at the Company’s request, first agree in writing with the Company that any information that is reasonably and in good faith designated by the Company as confidential will be kept
confidential by such persons and will be used solely for the purposes of contemplated by this Article 11, subject to customary exceptions. 

Section 11.04 Black-Out Periods. Notwithstanding anything to the contrary herein, the Company may delay the filing or
effectiveness of any Registration Statement pursuant to Section 11.01, or to suspend the effectiveness or availability thereof for the offer and sale of any Registrable Securities, for any reason determined in good faith by the Company
(including, without limitation, due to the entry of any stop order with respect to such Registration Statement or due to the occurrence or existence of any pending corporate development) (any such delay or suspension, a “Black-Out
Period”); provided, however, that the Company shall (i) promptly notify the Requesting Holders in writing of the commencement of such Blackout Period (provided that the Company will not be required to disclose any
information that might be considered material non-public information), stating the date on which such Black-Out Period will begin, and (ii) notify the Requesting Holders in writing of the date on which the Black-Out Period ends; and,
provided, further, that Black-Out Periods shall not exceed an aggregate of forty five (45) calendar days during any three hundred sixty five (365) day period (each, an “Allowable Black-Out Period”). For
purposes of determining the length of a Black-Out Period above, the Black-Out Period shall begin on and include the date the Requesting Holders receive the notice referred to in clause (i) and shall end on and include the later of the date the
Requesting Holders receive the notice referred to in clause (ii) and the date referred to in such notice. For the avoidance of doubt, the provisions of Section 11.03(l) hereof shall not be applicable during the period of any Allowable
Black-Out Period. Upon expiration of the Black-Out Period, the Company shall again be bound by Section 11.03(g). Notwithstanding anything to the contrary, the Company shall cause its transfer agent to deliver unlegended shares of Common Stock
to a transferee of any Holder in accordance with the terms of this Agreement in connection with any sale of Registrable Securities with respect to which a Holder has entered into a contract for sale, and delivered a copy of the prospectus included
as part of the applicable Registration Statement (unless an exemption from such prospectus delivery requirement exists), prior to the Holder’s receipt of the notice of a Black-Out Period and for which the Holder has not yet settled. 

Section 11.05 Effect of Failure to File and Obtain and Maintain Effectiveness of Registration Statement or Failure to Timely
Convert. Notwithstanding anything herein to the contrary, but subject to Section 11.04, if (a) a Registration Statement covering all of the Registrable Securities required to be covered thereby and required to be filed by the Company
pursuant to Section 11.01 is not effective under the Securities Act (an “Effectiveness Failure”) on or before on or before the ninetieth (90th) calendar day following receipt by the Company of the related Demand; or
(b) on any day after the Effective Date of a Registration Statement filed by the Company pursuant to Section 11.01, sales of all of the Registrable Securities required to be included on such Registration Statement cannot be made pursuant
to such Registration Statement (including, without limitation, because of a failure to keep such Registration Statement effective, to disclose such information as is necessary for sales to be 

  
 -44- 

 
made pursuant to such Registration Statement or to register a sufficient number of shares of Registrable Securities) (a “Maintenance Failure”), then, as relief for the damages to
any Holder by reason of any such Effectiveness Failure or Maintenance Failure, additional interest (“Additional Interest”) shall accrue on the principal amount of the Notes at a rate of one quarter of one percent (0.25%) per annum
until such Effectiveness Failure or Maintenance Failure, as the case may be, is cured; provided, however, that in no event will Additional Interest, together with any Special Interest, accrue on any day on a Note at a combined rate per
annum that exceeds one half of one percent (0.50%); provided, further, that no Effectiveness Failure or Maintenance Failure will be deemed to existing or be continuing at any time during any Allowable Black-Out Period. The payments to
which a Holder shall be entitled pursuant to this Section 11.05 are referred to herein as “Delay Payments.” Any Delay Payments will be payable in the same form, on the same dates and to the same persons as Stated
Interest; provided, that any Delay Payments shall be payable only to the affected Requesting Holder(s). For the avoidance of doubt, this Section 11.05 will not apply to any registration statements filed by the Company pursuant to
Section 11.02. The Delay Payment will constitute the exclusive and sole remedy available against the Company on account of any Effectiveness Failure or Maintenance Failure and will preclude (to the extent lawful) all other rights and remedies
with respect to any Effectiveness Failure or Maintenance Failure. 
 Section 11.06 Obligations of Holders. 

(a) Each Holder covenants and agrees that it will comply with the prospectus-delivery requirements of the Securities Act as applicable to it or
an exemption therefrom in connection with sale of Registrable Securities pursuant to the Registration Statement. 
 (b) Each Holder agrees
that upon receipt of any notice from the Company of the happening of any event of the kind described in Section 11.03(f) or Section 11.03(g)(ii), (iii) or (iv), such Holder will discontinue the disposition of Registrable Securities
pursuant to such Registration Statement or prospectus (or, with respect to a notice pursuant to Section 11.03(g)(iv), discontinue any such disposition in the applicable jurisdiction(s)) until such Holder’s receipt of the copies of the
supplemented or amended prospectus contemplated by Section 11.03(f), or until it is advised in writing by the Company that the use of the applicable prospectus may be resumed or that the applicable suspension of the qualification has been
lifted, and, if applicable, has received copies of any additional or supplemental filings that are incorporated or deemed to be incorporated by reference in such prospectus. 

(c) Each Holder shall furnish to the Company materially complete and accurate information regarding such Holder, the Registrable Securities
and other securities of the Company held by it and the distribution proposed by such Holder as shall be required by applicable law or requested by the underwriter(s) to effect the registration of their Registrable Securities. 

Section 11.07 Indemnification. 

(a) The Company will indemnify each Requesting Holder, each of its officers, directors, partners, employees and agents, and each Person
controlling such Holder (within the meaning of Section 15 of the Securities Act), with respect to any registration, qualification or sale which has been effected pursuant to this Article 11, against all expenses, claims, losses, damages or
liabilities (or actions in respect thereof), including any of the foregoing incurred in settlement of any litigation, commenced or threatened, arising out of or based on (i) any untrue statement (or alleged untrue statement) of a material fact
contained in any registration statement filed pursuant to this Article 11, or related prospectus, or any amendment or supplement thereto, incident to any such registration, qualification or sale, or based on any omission (or alleged omission) to
state therein a material fact required to be stated therein or necessary to make the statements therein (in the case of any such prospectus, in the light of the circumstances in which they were made) not misleading, or (ii) any violation (or
alleged violation) by the Company of the Securities Act, the Exchange Act or the securities or similar laws of any state or other jurisdiction in which Registrable Securities are sold, and the Company will reimburse or pay for the account of such
Requesting Holder, officer, director, partner, employee, agent or controlling person, for any legal and any other expenses reasonably incurred (as and when incurred) in connection with investigating, preparing the defense of or defending any such
claim, loss, damage, liability or action. 
 (b) To the extent permitted by law, each Requesting Holder, severally and not jointly, will, if
securities held by such Requesting Holder, are included in the securities as to which a registration, qualification or 

  
 -45- 

 
sale pursuant to this Article 11 is effected, indemnify the Company, each of its officers, directors, partners, employees and agents, each Person who controls the Company (within the meaning of
Section 15 of the Securities Act), and any other Person participating in such registration, each of its officers and directors and each Person controlling (within the meaning of Section 15 of the Securities Act) such Person participating
in such registration, against all expenses, claims, losses, damages or liabilities (or actions in respect thereof), including any of the foregoing incurred in settlement of any litigation, commenced or threatened, arising out of or based on any
untrue statement (or alleged untrue statement) of a material fact contained in any registration statement filed pursuant to this Article 11, or related prospectus, or any amendment or supplement thereto, incident to any such registration,
qualification or sale, or based on any omission (or alleged omission) to state therein a material fact required to be stated therein or necessary to make the statements therein (in the case of any such prospectus, in the light of the circumstances
in which they were made) not misleading, and the Company will reimburse or pay for the account of the Company or such Person, officer, director, partner, employee, agent or controlling person, for any legal and any other expenses reasonably incurred
(as and when incurred) in connection with investigating, preparing the defense of or defending any such claim, loss, damage, liability or action; provided, however, that in no event shall any Requesting Holder have any liability under
this Section 11.07(b) in any such case except to the extent that any such claim, loss, damage, liability or action arises out of or is based on any untrue statement or omission or alleged untrue statement or omission made in reliance upon and
in conformity with information furnished to the Company by such Requesting Holder. 
 (c) Each indemnified party under this
Section 11.07 shall give notice to the indemnifying party promptly after such indemnified party has actual knowledge of any claim as to which indemnity may be sought and shall permit the indemnifying party to assume the defense of any such
claim or any litigation resulting therefrom; provided, however, that counsel for the indemnifying party, who shall conduct the defense of such claim or litigation, shall be approved by the indemnified party (which approval shall not
unreasonably be withheld), and the indemnified party may participate in such defense at such indemnified party’s expense; provided, further, that the failure of any indemnified party to give notice as provided above shall not
relieve the indemnifying party of its obligations under this agreement except to the extent that the failure to give such notice is materially prejudicial to an indemnifying party’s ability to defend such action. No indemnifying party, in the
defense of any such claim or litigation, shall, except with the consent of each indemnified party, consent to entry of any judgment or enter into any settlement that does not include as an unconditional term thereof the giving by the claimant or
plaintiff to such indemnified party of a release from all liability in respect to such claim or litigation. 
 (d) The obligations of the
Company and the Requesting Holders under this Section 11.07 shall survive the completion of any offering of Registrable Securities in a Registration Statement pursuant to this Agreement. 

(e) If a claim for indemnification under Section 11.07(a) or Section 11.07(b) is available by its terms but is held by a court of
competent jurisdiction to be unavailable or insufficient to hold harmless an indemnified party, then each indemnifying party, in lieu of indemnifying such indemnified party, shall contribute to the amount paid or payable by such indemnified party as
a result of any such claim, loss, damage, liability or action that otherwise would have been indemnified under Section 11.07(a) or Section 11.07(b), as the case may be, in such proportion as is appropriate to reflect the relative fault of
the indemnifying party, on the one hand, and the indemnified party, on the other, in connection with the statements or omissions that resulted in such claim, loss, damage, liability or action, as well as any other relevant equitable considerations.
The relative fault of the indemnifying party and the indemnified party shall be determined by reference to, among other things, whether the untrue or alleged untrue statement of a material fact or the omission or alleged omission to state a material
fact relates to information supplied by the indemnifying party or the indemnified party and the parties’ relative intent, knowledge, access to information and opportunity to correct or prevent such statement or omission. The amount of such
claim, loss, damage, liability or action subject to this Section 11.07(e) shall be deemed to include any reasonable legal or other expenses incurred by such indemnified party in connection with investigating or defending any such claim, loss,
damage, liability or action (which shall be limited as provided in Section 11.07(c) if the indemnifying party has assumed the defense of any such action in accordance with the provisions thereof). Notwithstanding the foregoing in this
Section 11.07(e), no Person guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the Securities Act) shall be entitled to contribution from any Person who was not guilty of such fraudulent misrepresentation.
Promptly after receipt by an indemnified party of notice of the commencement or threatened commencement of any claims for which a claim for contribution may be made against an indemnifying party under this Section 11.07(e) and if a notice for
indemnification has not been otherwise given 

  
 -46- 

 
under this Section 11.07, such indemnified party shall give written notice thereof in the manner set forth hereunder for a claim for indemnification to the indemnifying party;
provided, however, that the failure to so notify the indemnifying party shall not relieve it of any obligation to provide contribution hereunder except to the extent that the indemnifying party’s ability to defend such action is
materially prejudiced by the failure to give such timely notice. The parties acknowledge that determining contribution pursuant to this Section 11.07(e) by pro rata allocation or by any other method of allocation that does not take account of
the equitable considerations referred to in this Section 11.07(e) would not be just or equitable. For the avoidance of doubt, if indemnification is available under Section 11.07(a) or Section 11.07(b), the indemnifying parties shall
indemnify each indemnified party to the fullest extent provided in Section 11.07(a) or Section 11.07(b) without regard to the relative fault of said indemnifying party or indemnified party or any other equitable consideration provided for
in this Section 11.07(e). 
 Section 11.08 Effectiveness; Termination; Survival. The provisions of Article 11 (other than
Section 11.07) shall survive the discharge or termination of this Agreement until the earlier of (a) the time when no Registrable Securities are outstanding; and (ii) four (4) years after the Maturity Date. The provisions of
Section 11.07 shall survive the discharge or termination of this Agreement indefinitely. 
 ARTICLE 12. 

GUARANTEES 
 Section 12.01
Guarantee. By its execution hereof, each Guarantor acknowledges and agrees that it receives substantial benefits from the Company and the issuance of the Notes and that the Guarantors are providing their Guarantee for good and valuable
consideration, including, without limitation, such substantial benefits. Accordingly, subject to the provisions of this Article 12, the Guarantors hereby jointly and severally unconditionally guarantee, as a primary obligor and not as a surety, to
each Holder and its successors and assigns that: (x) the principal of, and premium and interest on the Notes shall be duly and punctually paid in full or performed in accordance with the terms of this Agreement when due, whether at the Maturity
Date, upon declaration of acceleration, upon conversion or otherwise, together with interest on overdue principal, premium, interest and (to the extent permitted by law) interest on any overdue interest, if any, on the Notes; (y) in case of any
extension of time of payment or renewal of any Notes or any of such other obligations, the same shall be promptly paid in full when due or performed in accordance with the terms of the extension or renewal, whether at the Maturity Date, by
acceleration, conversion or otherwise; and (z) all other obligations of the Company to the Holders hereunder or under the Notes (including fees, expenses or other) shall be promptly paid in full or performed, all in accordance with the terms
hereof, subject, in the case of clauses (x), (y) and (z) above, to the limitations set forth in Section 12.03 hereof (the obligations set forth in this Section 12.01, collectively, the “Guarantee Obligations”).
The Guarantee constitutes a senior, unsecured, unsubordinated obligation of each Guarantor. 
 (a) Subject to the provisions of this Article
12, each Guarantor hereby jointly and severally agrees that its Guarantee hereunder shall be unconditional, irrespective of the validity, regularity or enforceability of the Notes or this Agreement, the absence of any action to enforce the same, any
waiver or consent by any Holder with respect to any thereof, the entry of any judgment against the Company, any action to enforce the same or any other circumstance which might otherwise constitute a legal or equitable discharge or defense of any
Guarantor. Each Guarantor hereby waives and relinquishes: (i) any right to require the Holders or the Company (each, a “Benefited Party”) to proceed against the Company or any other Person or to proceed against or exhaust any
security held by a Benefited Party at any time or to pursue any other remedy in any secured party’s power before proceeding against the Guarantor; (ii) any defense that may arise by reason of the incapacity, lack of authority, death or
disability of any other Person or Persons or the failure of a Benefited Party to file or enforce a claim against the estate (in administration, bankruptcy or any other proceeding) of any other Person or Persons; (iii) demand, protest and notice
of any kind (except as expressly required by this Agreement), including, but not limited to, notice of the existence, creation or incurring of any new or additional Indebtedness or obligation or of any action or non-action on the part of the
Guarantor, the Company, any Benefited Party, any creditor of the Guarantor or the Company or on the part of any other Person whomsoever in connection with any obligations the performance of which are hereby guaranteed; (iv) any defense based
upon an election of remedies by a Benefited Party, including, but not limited to, an election to proceed against the Guarantor for reimbursement; (v) any defense based upon any statute or rule of law which provides that the obligation of a
surety must be neither larger in amount nor in other respects more burdensome than that of the principal; (vi) any defense arising because of a Benefited Party’s election, in any proceeding instituted under bankruptcy law, of the
application of Section 1111(b)(2) of the Bankruptcy Code; and (vii) any defense based 

  
 -47- 

 
on any borrowing or grant of a security interest under Section 364 of the Bankruptcy Code. Each Guarantor hereby covenants that, except as otherwise provided therein, its Guarantee shall not
be discharged except by payment in full of all Guarantee Obligations, including the principal of, and premium and interest on, the Notes and all other costs provided for under this Agreement. 

(b) If any Holder is required by any court or otherwise to return to either the Company or any Guarantor, any amount paid by the Company or
such Guarantor to such Holder, then the Guarantees, to the extent theretofore discharged, shall be reinstated in full force and effect. The Guarantors jointly and severally agree that they shall not be entitled to any right of subrogation in
relation to the Holders in respect of any Guarantee Obligations hereby until payment in full of all such obligations guaranteed hereby. The Guarantors jointly and severally agree that, as between them, on the one hand, and the Holders, on the other
hand, (i) the maturity of the obligations guaranteed hereby may be accelerated as provided in Article 9 hereof for the purposes hereof, notwithstanding any stay, injunction or other prohibition preventing such acceleration in respect of the
Guarantee Obligations, and (ii) in the event of any acceleration of such obligations as provided in Article 9 hereof, such Guarantee Obligations (whether or not due and payable) shall forthwith become due and payable by the Guarantors for the
purpose of the Guarantee. 
 (c) If, at any time after the date of this Agreement, any Person that was not a Guarantor on the date hereof
becomes a directly owned Material Domestic Subsidiary of (x) the Company or (y) any Guarantor, then the Company will cause such Material Domestic Subsidiary to (i) execute an amendment or supplement to this Agreement and
(ii) otherwise comply with the provisions of this Article 12; provided, however, that, any Material Domestic Subsidiary of the Company that has no material assets other than equity in one or more Foreign Subsidiaries shall not be
required to become a Guarantor pursuant to this Section 12.01(c). 
 Section 12.02 Execution and Delivery of Guarantee. The
execution by each Guarantor of this Agreement (or an amendment or supplement to this Agreement pursuant to Section 12.01(c)) evidences the Guarantee of such Guarantor, and the delivery of any Note by the Company constitutes due delivery of each
Guarantee on behalf of each Guarantor. A Guarantee’s validity will not be affected by the failure of any officer of a Guarantor executing this Agreement or any such amendment or supplement on such Guarantor’s behalf to hold, at the time
any Note is issued and delivered, the same or any other office at such Guarantor, and each Guarantee will be valid and enforceable even if no notation, certificate or other instrument is set upon or attached to, or otherwise executed and delivered
to the Holder of, any Note. 
 Section 12.03 Limitation of Guarantors’ Liability; Certain Bankruptcy Events. Each
Guarantor, and, by its acceptance hereof, each Holder, hereby confirms that it is the intention of all such parties that the Guarantee Obligations of each Guarantor pursuant to its Guarantee not constitute a fraudulent transfer or conveyance for
purposes of any Bankruptcy Law, the Uniform Fraudulent Conveyance Act, the Uniform Fraudulent Transfer Act or any similar federal or state law. To effectuate the foregoing intention, the Holders and each Guarantor hereby irrevocably agree that the
Guarantee Obligations of the Guarantors under this Article 12 shall be limited to the maximum amount as shall, after giving effect to all other contingent and fixed liabilities of the Guarantors, result in the Guarantee Obligations of the Guarantors
under the Guarantee not constituting a fraudulent transfer or conveyance. 
 Section 12.04 Releases. If, in compliance with the
terms and provisions of the Note Documents, all of the Capital Stock of any Guarantor is sold or otherwise transferred to a Person or Persons, none of which is the Company or a Subsidiary, then such Guarantor shall, upon the consummation of such
sale or transfer, be released from its obligations under this Agreement. Without limiting the generality of the foregoing, the Company may, at its election, execute an amendment or supplement to this Agreement to memorialize any such release in
accordance with this Section 12.04. 

  
 -48- 

 ARTICLE 13. 

AMENDMENTS 
 Section 13.01
Amendments. 
 (a) Neither this Agreement nor any other Note Document or provision thereof may be waived, amended or modified except
by an agreement or agreements in writing executed by the Company, the Guarantors and the Holders of a majority in aggregate Principal Amount of the outstanding Notes, provided, however, that no such agreement shall do the following
without the written consent of each Holder affected thereby: (i) reduce the Principal Amount or Repayment Premium of any Note, (ii) reduce the rate of interest on any Note, (iii) change the Maturity Date of any Note, or extend the
time for the payment of any interest thereon or waive or excuse any such payment, (iv) make any change that impairs or adversely affects the conversion rights of any Note or reduces the Fundamental Change Repurchase Price of any Note,
(v) change any of the provisions of this Article 13 without the written consent of each Holder, or (vi) adversely affect the economic interests of any Holder hereunder disproportionately to other Holders without the written consent of such
Holder. Notwithstanding anything to the contrary in the immediately preceding sentence, this Agreement may be amended or supplemented without the consent of any Holder in order to comply with, and subject to the provisions of, Section 7.05,
Article 10, Section 12.01(c) or Section 12.04. 
 ARTICLE 14. 

MISCELLANEOUS 
 Section 14.01
Notices. Any notice or communication shall be in writing (including telecopy promptly confirmed in writing) and delivered in person, sent by electronic email or mailed by overnight mail addressed as follows: 

If to the Company or any Guarantor: 

Coherus BioSciences, Inc. 
 333
Twin Dolphin Drive, Suite 600 
 Redwood City, CA 94065 

Attention: Denny Lanfear, Jean-Frederic Viret and Keith Vendola 

Email: dlanfear@coherus.com, jviret@coherus.com and kvendola@coherus.com 

with copies (which shall not constitute notice) to each of: 

J. Wood Capital Advisors LLC 

1820 Calistoga Road 
 Santa Rosa,
CA 95404 
 Attention: Jason Wood 

Email: jason@jwoodcapital.com; 

and 
 Latham & Watkins
LLP 
 140 Scott Drive 
 Menlo
Park, CA 94025 
 Attention: Alan C. Mendelson and Benjamin A. Potter 

Email: alan.mendelson@lw.com and benjamin.potter@lw.com 

If to any Holder, to the address of such Holder set forth in the Register (except that any notice to a Holder pursuant to Article 11 will be
made to the address of such Holder set forth on the books of the Company or its transfer agent); 
 If to any Investor: 

HealthCare Royalty Partners III, L.P. 

300 Atlantic Street, Suite 600 

Stamford, CT 06901 
 Attention:
Todd C. Davis 
 E-mail: todd.davis@hcroyalty.com 

  
 -49- 

 with a copy (which shall not constitute notice) to each of: 

HealthCare Royalty Partners III, L.P. 

300 Atlantic Street, Suite 600 

Stamford, CT 06901 
 Attention:
Chief Legal Officer 
 E-mail: royalty@hcroyalty.com 

and 
 Morgan Lewis &
Bockius LLP 
 101 Park Avenue 

New York, NY 10178 
 Attn:
Patricia F. Brennan 
 E-mail: pbrennan@morganlewis.com 

MX II Associates LLC 
 5375
Medpace Way 
 Cincinnati, OH 45227 

and 
 KMG Capital Partners, LLC

 1225 Seventeenth Street 

Suite 2420 
 Denver, CO 80202 

and 
 KKR Biosimilar L.P. 

2800 Sand Hill Road 
 Suite 200

 Menlo Park, CA 94025 

(a) The Company or any Guarantor, by notice to each of the Holders, may designate additional or different addresses for
subsequent notices or communications. Any of the Holders, by notice to the Company, may designate additional or different addresses for subsequent notices or communications. 

(b) Any notice or communication sent to a registered Holder shall be e-mailed or mailed to the Holder at the Holder’s
e-mail or address, as the case may be, as it appears in the Register and shall be sufficiently given if so e-mailed or mailed within the time prescribed. 

(c) Failure to send a notice or communication to a Holder or any defect in it shall not affect its sufficiency with respect to
other Holders. If a notice or communication is sent in the manner provided above, it is duly given, whether or not the addressee receives it. 

(d) Where this Agreement provides for notice in any manner, such notice may be waived in writing by the Person entitled to
receive such notice, either before or after the event, and such waiver shall be the equivalent of such notice. 
 Section 14.02
Confidentiality. 
 (a) Except as expressly authorized in this Agreement or the other Note Documents or except with the prior written
consent of the Disclosing Party, the Recipient hereby agrees that (i) it will use the Confidential Information of the Disclosing Party solely for the purpose of the transactions contemplated by this Agreement and the other Note Documents and
exercising its rights and remedies and performing its obligations hereunder and thereunder; (ii) it will keep confidential the Confidential Information of the Disclosing Party; and (iii) it will not furnish or disclose to any Person any
Confidential Information of the Disclosing Party. 

  
 -50- 

 (b) Notwithstanding anything to the contrary in this Section 14.02, the Recipient may,
without the consent of the Disclosing Party, furnish or disclose Confidential Information of the Disclosing Party to (i) the Recipient’s Affiliates and their respective Representatives and actual or potential financing sources, in each
such case, who need to know such information to assist the Recipient in evaluating the transactions contemplated by this Agreement and the other Note Documents or in exercising its rights and remedies and performing its obligations hereunder and
thereunder and who are, prior to such furnishing or disclosure, informed of the confidentiality and non-use obligations contained in this Section 14.02 and who are bound by written or professional confidentiality and non-use obligations no less
stringent than those contained in this Section 14.02; and (ii) potential permitted assignees, purchasers, transferees or successors-in-interest under Section 3.09, in each such case, who need to know such information in connection
with such actual or potential assignment, sale or transfer, including, following any such assignment, sale or transfer, in order to exercise their rights and remedies and perform their obligations under this Agreement and the other Note Documents
and who are, prior to such furnishing or disclosure, informed of the confidentiality and non-use obligations contained in this Section 14.02 and who are bound by written or professional confidentiality and non-use obligations no less stringent
than those contained in this Section 14.02. 
 (c) In the event that the Recipient, its Affiliates or any of their respective
Representatives is required by applicable law, applicable stock exchange requirements or legal or judicial process (including by deposition, interrogatory, request for documents, subpoena, civil investigative demand or similar process) to furnish or
disclose any portion of the Confidential Information of the Disclosing Party, the Recipient shall, to the extent legally permitted, provide the Disclosing Party, as promptly as practicable, with written notice of the existence of, and terms and
circumstances relating to, such requirement, so that the Disclosing Party may seek, at its expense, a protective order or other appropriate remedy (and, if the Disclosing Party seeks such an order, the Recipient, such Affiliates or such
Representatives, as the case may be, shall provide, at their expense, such cooperation as such Disclosing Party shall reasonably require). Subject to the foregoing, the Recipient, such Affiliates or such Representatives, as the case may be, may
disclose that portion (and only that portion) of the Confidential Information of the Disclosing Party that is legally required to be disclosed; provided, however, that the Recipient, such Affiliates or such Representatives, as the case
may be, shall exercise reasonable efforts (at their expense) to preserve the confidentiality of the Confidential Information of the Disclosing Party, including by obtaining reliable assurance that confidential treatment will be accorded any such
Confidential Information disclosed. Notwithstanding anything to the contrary contained in this Section 14.02, in the event that the Recipient or any of its Affiliates receives a request from an authorized representative of a U.S. or foreign tax
authority for a copy of this Agreement or any of the other Note Documents, the Recipient or such Affiliate, as the case may be, may provide a copy hereof or thereof to such tax authority representative without advance notice to, or the consent of,
the Disclosing Party; provided, however, that the Recipient shall, to the extent legally permitted, provide the Disclosing Party with written notice of such disclosure as soon as practicable. 

(d) Notwithstanding anything to the contrary contained in Section 14.02, the Recipient may disclose the Confidential Information of the
Disclosing Party, including this Agreement, the other Note Documents and the terms and conditions hereof and thereof, to the extent necessary in connection with the enforcement of its rights and remedies hereunder or thereunder or as required to
perfect the Recipient’s rights hereunder or thereunder. 
 (e) Neither Party shall, and each Party shall cause its Affiliates not to,
without the prior written consent of the other Party (which consent shall not be unreasonably withheld or delayed), issue any press release or make any other public disclosure with respect to the transactions contemplated by this Agreement or any
other Note Document, except if and to the extent that any such release or disclosure is required by applicable law, by the rules and regulations of any applicable stock exchange or by any Governmental Authority of competent jurisdiction, in which
case, the Party proposing (or whose Affiliate proposes) to issue such press release or make such public disclosure shall use commercially reasonable efforts to consult in good faith with the other Party regarding the form and content thereof before
issuing such press release or making such public announcement. 
 (f) Except with respect to a Holder’s internal communications or
private communications with its Representatives, the Holders shall not, and shall cause its Representatives, its Affiliates and its Affiliates’ Representatives not to make use of the name, nickname, trademark, logo, service mark, trade dress or
other name, 

  
 -51- 

 
term, mark or symbol identifying or associated with the Company without the Company’s prior written consent to the specific use in question, provided that the consent of the Company
shall not be required with respect to publication of the Company’s name and logos in the a Holder’s promotional materials, including without limitation the websites for a Holder and its Affiliates consistent with its use of other similarly
situated Third Parties’ names and logos. 
 Section 14.03 When Notes Are Disregarded. In determining whether the Holders of
the required Principal Amount of Notes have concurred in any direction, waiver or consent, Notes owned by the Company or by any Affiliate of the Company shall be disregarded and deemed not to be outstanding. Also, subject to the foregoing, only
Notes outstanding at the time shall be considered in any such determination. 
 Section 14.04 Deferral of Payments When Payment Date
is Not a Business Day. If the due date for a payment on a Note as provided in this Agreement is not a Business Day, then, notwithstanding anything to the contrary in this Agreement or the Notes, payment shall be made on the next succeeding day
that is a Business Day, and no interest shall accrue for the intervening period. If a Regular Record Date is not a Business Day, the Regular Record Date shall not be affected. 

Section 14.05 Governing Law. THIS AGREEMENT AND THE NOTES, AND ANY CLAIM, CONTROVERSY OR DISPUTE ARISING UNDER OR RELATED TO THIS
AGREEMENT OR THE NOTES, SHALL BE GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH, THE LAWS OF THE STATE OF NEW YORK. 
 Section 14.06
No Recourse against Others. No incorporator, director, officer, employee, stockholder or Affiliate of the Company (other than the Guarantors, as such, to the extent provided in Article 12), or of any Guarantor, solely by reason of this
status, shall have any liability for any obligations of the Company or any Guarantor under the Notes or this Agreement or for any claim based on, in respect of or by reason of such obligations or their creation. By accepting a Note, each Holder will
be deemed to waive and release all such liability. The waiver and release shall be part of the consideration for the issue of the Notes. 

Section 14.07 Successors. All agreements of the Company, the Guarantors and each Investor and Holder, as applicable, in this
Agreement and the Notes shall bind their respective successors. 
 Section 14.08 Multiple Originals. The parties may sign any
number of copies of this Agreement. Each signed copy shall be an original, but all of them together represent the same agreement. One signed copy is enough to prove this Agreement. Delivery of an executed counterpart by facsimile or “.pdf”
shall be effective as delivery of a manually executed counterpart thereof. 
 Section 14.09 Indemnification. The Company agrees
to defend, indemnify, pay and hold harmless, each Indemnified Party from and against any and all Indemnified Liabilities, in all cases, arising, in whole or in part, out of or relating to any claim, notice, suit or proceeding commenced or threatened
by any Person (including any Governmental Authority); provided, however, that the Company shall not have any obligation to any Indemnified Party hereunder with respect to any Indemnified Liabilities to the extent such Indemnified
Liabilities arise from the gross negligence or willful misconduct of such Indemnified Party. To the extent that the undertakings to defend, indemnify, pay and hold harmless set forth in this Section 14.09 may be unenforceable in whole or in
part because they are violative of any law or public policy, the Company shall contribute the maximum portion that it is permitted to pay and satisfy under applicable law to the payment and satisfaction of all Indemnified Liabilities incurred by any
Indemnified Party. In addition, each Indemnified Party agrees that the Company shall not have any obligation to pay to or contribute on behalf of such Indemnified Party an amount in excess of an amount equal to the aggregate principal amount of the
Notes purchased by such Indemnified Party pursuant to this Agreement. 
 Section 14.10 Waiver of Consequential and Punitive
Damages. To the extent permitted by applicable law, no Party shall assert, and each Party hereby waives, any claim against each other Party and such Party’s Affiliates, directors, employees, attorneys or agents, on any theory of liability,
for special, indirect, consequential or punitive damages (as opposed to direct or actual damages) (whether or not the claim therefor is based on contract, tort or duty imposed by any applicable legal requirement) arising out of, in connection with,
as a result of, or in any way related to, this Agreement or any Note Documents or any agreement or instrument contemplated hereby or 

  
 -52- 

 
thereby or referred to herein or therein, the transactions contemplated hereby or thereby, the Notes or the use of the proceeds thereof or any act or omission or event occurring in connection
therewith, and each Party hereby waives, releases and agrees not to sue upon any such claim or any such damages, whether or not accrued and whether or not known or suspected to exist in its favor. 

Section 14.11 Table of Contents; Headings. The table of contents and headings of the Articles and Sections of this Agreement have
been inserted for convenience of reference only, are not intended to be considered a part hereof and shall not modify or restrict any of the terms or provisions hereof. 

Section 14.12 Severability Clause. In case any provision in this Agreement shall be invalid, illegal or unenforceable, the
validity, legality and enforceability of the remaining provisions shall not in any way be affected or impaired thereby and such provision shall be ineffective only to the extent of such invalidity, illegality or unenforceability. 

Section 14.13 Calculations. Except as otherwise provided herein, the Company (or its agents) will be responsible for making all
calculations called for under this Agreement or the Notes. The Company (or its agents) will make all such calculations in good faith, and, absent manifest error, its calculations will be final and binding on Holders. Upon written request of a
Holder, the Company (or its agents) will provide a detailed schedule of its calculations. 
 Section 14.14 Waiver of Jury Trial.
EACH OF THE COMPANY, THE GUARANTORS, THE INVESTORS AND THE HOLDERS HEREBY IRREVOCABLY WAIVES, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, ANY AND ALL RIGHT TO TRIAL BY JURY IN ANY LEGAL PROCEEDING ARISING OUT OF OR RELATING TO THIS AGREEMENT,
THE SECURITIES OR THE TRANSACTION CONTEMPLATED THEREBY. 
 Section 14.15 Consent to Jurisdiction. 

(a) Each of the Company, the Investors and the Holders hereby irrevocably and unconditionally submits, for itself and its property, to the
non-exclusive jurisdiction of any New York State court or federal court of the United States sitting in the State and City of New York, County and Borough of Manhattan, and any appellate court from any thereof, in any action or proceeding arising
out of or relating to this Agreement or the Notes, or for recognition or enforcement of any judgment, and each hereby irrevocably and unconditionally agrees that all claims in respect of any such action or proceeding may be heard and determined in
such state court sitting in the State and City of New York, County and Borough of Manhattan or, to the extent permitted by law, in such federal court sitting in the State and City of New York, County and Borough of Manhattan. 

(b) Each of the Company, the Investors and the Holders hereby irrevocably and unconditionally waives, to the fullest extent it may legally and
effectively do so, any objection which it may now or hereafter have to the laying of venue of any suit, action proceeding arising out of or relating to this Agreement or the Notes in any New York State or federal court, and each hereby irrevocably
waives, to the fullest extent permitted by law, the defense of an inconvenient forum to the maintenance of such action or proceeding in any such court. 

Section 14.16 Tax Forms. Each Holder, on or before the date it becomes a party to this Agreement and thereafter upon reasonable
request of the Company, shall furnish to the Company, to the extent such Holder is legally eligible to do so, either a completed and signed IRS Form W-9 or IRS Form W-8BEN or W-8BEN-E (or other applicable Form W-8, together with applicable
attachments), as may be applicable. 
 [Remainder of the page intentionally left blank] 

  
 -53- 

 IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be duly executed as of the
day and year first above written. 
  

			
	COHERUS BIOSCIENCES, INC.,
	as the Company
		
	By:	 	 /s/ Dennis M. Lanfear

	Name:	 	Dennis M. Lanfear
	Title:	 	President and Chief Executive Officer
	
	 INTEKRIN THERAPEUTICS INC.,
 as a
Guarantor

		
	By:	 	 /s/ Dennis M. Lanfear

	Name:	 	Dennis M. Lanfear
	Title:	 	President and Chief Executive Officer
	
	 COHERUS INTERMEDIATE CORP.,
 as a
Guarantor

		
	By:	 	 /s/ Dennis M. Lanfear

	Name:	 	Dennis M. Lanfear
	Title:	 	President and Chief Executive Officer

  
 [Signature Page to
Note Purchase Agreement] 

 
			
	HEALTHCARE ROYALTY PARTNERS III, L.P.
	as Holder
		
	By:	 	HEALTHCARE ROYALTY GP III, LLC,
		 	its General Partner
		
	By:	 	 /s/ Todd C. Davis

	Name:	 	Todd C. Davis
	Title:	 	Managing Partner

  
 [Signature Page to
Note Purchase Agreement] 

 
			
	MX II Associates LLC
	as Holder
		
	By:	 	 /s/ August J. Troendle

	Name:	 	August J. Troendle
	Title:	 	Managing Member

  
 [Signature Page to
Note Purchase Agreement] 

 
			
	KMG Capital Partners, LLC
	as Holder
		
	By:	 	 /s/ Mats Wahlström

	Name:	 	Mats Wahlström
	Title:	 	Executive Chairman

  
 [Signature Page to
Note Purchase Agreement] 

 
			
	KKR Biosimilar L.P.
	as Holder
		
	By:	 	 KKR Biosimilar GP LLC,
 its General
Partner

		
	By:	 	 /s/ Ali J. Satvat

	Name:	 	Ali J. Satvat
	Title:	 	Vice President

  
 [Signature Page to
Note Purchase Agreement] 

 EXHIBIT A 

[FORM OF NOTE] 
 THE
OFFER AND SALE OF NOTES REPRESENTED HEREBY OR ANY SHARES OF COMMON STOCK ISSUABLE UPON CONVERSION THEREOF HAVE NOT BEEN REGISTERED UNDER THE U.S. SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND SUCH NOTES AND SHARES MAY NOT
BE OFFERED, SOLD, PLEDGED, HEDGED OR OTHERWISE TRANSFERRED, EXCEPT (X) PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT AND A CURRENT PROSPECTUS, (Y) IN ACCORDANCE WITH RULE 144 UNDER THE SECURITIES ACT OR
(Z) PURSUANT TO ANOTHER APPLICABLE EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT. THE NOTES REPRESENTED HEREBY, AND ANY SHARES OF COMMON STOCK ISSUABLE UPON CONVERSION THEREOF, MAY NOT BE OFFERED, SOLD, PLEDGED, HEDGED OR OTHERWISE
TRANSFERRED WITHOUT THE HOLDER THERETOFORE PROVIDING THE COMPANY WITH SUCH CERTIFICATES OR OTHER DOCUMENTATION OR EVIDENCE AS A COMPANY MAY REASONABLY REQUEST TO DETERMINE THAT SUCH OFFER, SALE, PLEDGE, HEDGE OR OTHER TRANSFER COMPLIES WITH THE
FOREGOING RESTRICTION. 
 IN ADDITION, THE NOTES REPRESENTED HEREBY, AND ANY SHARES OF COMMON STOCK ISSUABLE UPON CONVERSION THEREOF,
MAY NOT BE OFFERED, SOLD, PLEDGED, HEDGED OR OTHERWISE TRANSFERRED WITHOUT THE PRIOR WRITTEN CONSENT OF THE COMPANY, WHICH CONSENT SHALL, FOR PURPOSES OF THIS SENTENCE, BE DEEMED TO HAVE BEEN GIVEN UPON THE REQUEST OF THE HOLDER. 

THE NOTES REPRESENTED HEREBY ARE GOVERNED BY THE PROVISIONS OF A SENIOR CONVERTIBLE NOTE PURCHASE AGREEMENT, DATED AS OF FEBRUARY 29, 2016
(THE “AGREEMENT”), AMONG THE COMPANY, THE GUARANTORS NAMED THEREIN AND THE INVESTORS NAMED THEREIN. BY ACCEPTING ANY NOTE REPRESENTED HEREBY, THE HOLDER THEREOF WILL BE DEEMED TO AGREE TO BE BOUND BY THE TERMS OF THE AGREEMENT. 

THE NOTES REPRESENTED HEREBY WERE ISSUED WITH ORIGINAL ISSUE DISCOUNT UNDER SECTIONS 1272, 1273 AND 1275 OF THE INTERNAL REVENUE CODE OF
1986, AS AMENDED. A HOLDER MAY OBTAIN THE ISSUE PRICE, AMOUNT OF ORIGINAL ISSUE DISCOUNT, ISSUE DATE AND YIELD TO MATURITY FOR SUCH NOTES BY SUBMITTING A REQUEST FOR SUCH INFORMATION TO THE COMPANY AT 333 TWIN DOLPHIN DRIVE, SUITE 600 REDWOOD CITY,
CA 94065. 
 8.2% Senior Convertible Notes due 2022 
  

					
	 No. [    ]
	  	U.S. $	[            	] 

 Coherus BioSciences, Inc., a Delaware corporation (herein called the “Company”), which term
includes any successor corporation under the Agreement referred to on the reverse hereof, for value received hereby promises to pay to
[                    ], or registered assigns, the principal sum of
[                    ] UNITED STATES DOLLARS (U.S. $[        ]) (which amount may from time to time be
increased or decreased by adjustments made on the records of the Company in accordance with the below-referred Agreement) on March 31, 2022. The Company will pay Principal Amount of any Note and interest and Repayment Premium thereon as
provided in the below-referred Agreement. 
 Reference is made to the further provisions of this Note set forth on the reverse hereof. Such
further provisions shall for all purposes have the same effect as though fully set forth at this place. Capitalized terms used but not defined herein shall have such meanings as are ascribed to such terms in the below-referred Agreement. In the case
of any conflict between this Note and such Agreement, the provisions of such Agreement shall control. 

  
 A-1 

 IN WITNESS WHEREOF, the Company has caused this instrument to be duly executed. 

 
  

									
		 		 		 	COHERUS BIOSCIENCES, INC.
					
	Dated:	 	  
	 		 	By:	 	  

		 		 		 	Name:	 	
		 		 		 	Title:	 	

  
 A-2 

 [FORM OF REVERSE OF NOTE] 

COHERUS BIOSCIENCES, INC. 

8.2% Senior Convertible Notes due 2022 

This Note is one of a duly authorized issue of Notes of the Company, designated as its 8.2% Senior Convertible Notes due 2022 (the
“Notes”), initially limited in aggregate principal amount to $100,000,000 all issued or to be issued under and pursuant to a Senior Convertible Note Purchase Agreement dated as of February 29, 2016 (the
“Agreement”) among the Company, the Guarantors named therein and the Investors named therein, to which Agreement and all agreements supplemental thereto reference is hereby made for a description of the rights, limitations of
rights, obligations, duties and immunities thereunder of the Company and the Holder of the Notes. 
 Except as provided for in the
Agreement, Principal Amount and Repayment Premium on this Note shall be payable, when and if due, only against surrender therefor, while payments of interest on this Note shall be made, in accordance with the Agreement. 

Interest. Stated Interest will accrue on this Note at a rate of 8.2% per annum, payable quarterly in arrears on each
March 31, June 30, September 30 and December 31 of each year, commencing on [        ]. Special Interest, Additional Interest and Default Interest may accrue on this Note in the
manner provided in the Agreement. 
 Ranking. The Notes constitute a general, senior unsubordinated and unsecured obligation of the
Company and are guaranteed by the Guarantors to the extent provided in Article 12 of the Agreement. 
 Conversion. The Notes are
convertible into shares of Common Stock (and, if applicable, cash in lieu of any fractional share of Common Stock) in the manner provided in the Agreement. 

Offers to Purchase Notes. The Agreement provides that, subject to certain conditions and limitations, upon a Fundamental Change, the
Company shall be required to make an offer to purchase all of the Notes as provided in the Agreement. 
 Redemption. The Notes will
be subject to Redemption as provided in Article 5 of the Agreement. 
 Acceleration of Maturity. Subject to certain exceptions in the
Agreement, if an Event of Default shall occur and be continuing, the Principal Amount, together with the Repayment Premium plus interest through such date on all the Notes, may in certain circumstances become due and payable. 

Denominations. The Notes are issuable only in registered form in denominations of $1,000 and any integral multiple of $1,000 in excess
thereof, as provided in the Agreement and subject to certain limitations therein set forth. 
 THIS NOTE, AND ANY CLAIM, CONTROVERSY OR
DISPUTE ARISING UNDER OR RELATED TO THIS NOTE, SHALL BE GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH, THE LAWS OF THE STATE OF NEW YORK. 

  
 A-3 

 CONVERSION NOTICE 

If you want to convert all or any portion (which must be $1,000 or in integral multiples of $1,000 in excess thereof) this Note, check the
box:  ̈ and specify the Principal Amount to be so converted: $        ,000. 
  

									
	Date:	 	  
	 		 	  

		 		 		 		 	(Legal Name of Holder)
					
		 		 		 	By:	 	  

		 		 		 	Name:	 	
		 		 		 	Title:	 	
				
		 		 		 	Signature Guaranteed:
				
		 		 		 	  

		 		 		 	Participant in a Recognized Signature
		 		 		 	Guarantee Medallion Program
					
		 		 		 	By:	 	  

		 		 		 		 	Authorized Signatory

 Note: Signatures must be guaranteed by an “eligible guarantor institution” meeting the requirements of the Company
or the transfer agent for the Company’s Common Stock, as applicable, which requirements include membership or participation in the Security Transfer Agent Medallion Program (“STAMP”) or such other “signature guarantee
program” as may be determined by the Company or the transfer agent for the Company’s Common Stock in addition to, or in substitution for, STAMP, all in accordance with the Securities Exchange Act of 1934, as amended. 

  
 A-4 

 OPTION OF HOLDER TO ELECT PURCHASE 

If you want to elect to have this Note repurchased in its entirety by the Company pursuant to Section 4.04 of the Agreement, check
the box:  ̈ 
 If you want to elect to have only a part of the principal amount of this Note
(which must be $1,000 or in integral multiples of $1,000 in excess thereof) repurchased by the Company pursuant to Section 4.04 of the Agreement, state the portion of such amount: $        ,000.

  

					
	Dated:                     	  	Your Signature:	  	  

		  		  	(Sign exactly as name appears on the other side of this Note)

  
 A-5 

 EXHIBIT B 

[FORM OF RESTRICTED STOCK LEGEND] 

THE OFFER AND SALE OF THE SHARES OF COMMON STOCK REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE U.S. SECURITIES ACT OF 1933, AS
AMENDED (THE “SECURITIES ACT”), AND MAY NOT BE OFFERED, SOLD, PLEDGED, HEDGED OR OTHERWISE TRANSFERRED, EXCEPT (1) PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT AND A CURRENT PROSPECTUS, (2) IN
ACCORDANCE WITH RULE 144 UNDER THE SECURITIES ACT, OR (3) PURSUANT TO ANOTHER APPLICABLE EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT. 

  
 B-1 

 EXHIBIT C 

Form of Closing Date Certificate 

  
 C-1

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00255-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00255-of-00352.parquet"}]]